Question,Answer
"What is the highest global development stage achieved by drugs targeting 5-HT2A receptor for schizophrenia up to April 2025, and which drugs are in this stage?",Approved; pipamperone
"What is the highest global development stage achieved by drugs targeting PDE2A for cognitive impairment in schizophrenia up to April 2025, and which drugs are in this stage?",Phase I; BI 474121
"What is the highest global development stage achieved by drugs targeting DCK for Crohn's disease up to April 2025, and which drugs are in this stage?",PreClinical; TRE-515
"What is the highest global development stage achieved by drugs targeting LANCL2 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",PreClinical; BT-111
"What is the highest global development stage achieved by drugs targeting CD3ε for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; foralumab
"What is the highest global development stage achieved by drugs targeting bacterial Top II for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase II; OPS-2071
"What is the highest global development stage achieved by drugs targeting RXR for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase I; ACT500
"What is the highest global development stage achieved by drugs targeting A3R for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?","Phase II; namodenoson, FM101"
"What is the highest global development stage achieved by drugs targeting CD40 for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase I; ravagalimab
"What is the highest global development stage achieved by drugs targeting bacterial DHPS for Crohn's disease up to April 2025, and which drugs are in this stage?",Approved; sulfasalazine
"What is the highest global development stage achieved by drugs targeting RANKL for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase I/II; denosumab
"What is the highest global development stage achieved by drugs targeting eotaxin-2 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; nebokitug
"What is the highest global development stage achieved by drugs targeting ERDR1 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",PreClinical; KINE-101
"What is the highest global development stage achieved by drugs targeting M1 receptor for schizophrenia up to April 2025, and which drugs are in this stage?",Phase I; 11C-LSN3172176
"What is the highest global development stage achieved by drugs targeting PPARα for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; pemafibrate
"What is the highest global development stage achieved by drugs targeting CB receptor for schizophrenia up to April 2025, and which drugs are in this stage?",Phase II; cannabidiol
"What is the highest global development stage achieved by drugs targeting GAT1 for schizophrenia up to April 2025, and which drugs are in this stage?",Phase III; tiagabine
"What is the highest global development stage achieved by drugs targeting HDAC for schizophrenia up to April 2025, and which drugs are in this stage?",Phase II; sulforaphane
"What is the highest global development stage achieved by drugs targeting KDM1A for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase I; baicalin
"What is the highest global development stage achieved by drugs targeting PAR2 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase I; PZ-235
"What is the highest global development stage achieved by drugs targeting KARS for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",PreClinical; ZMC001
"What is the highest global development stage achieved by drugs targeting α7 receptor for schizophrenia up to April 2025, and which drugs are in this stage?",Phase II; AQW051
"What is the highest global development stage achieved by drugs targeting CCR5 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; leronlimab
"What is the highest global development stage achieved by drugs targeting JAK1 for perianal fistulas in Crohn's disease up to April 2025, and which drugs are in this stage?",Phase I; upadacitinib
"What is the highest global development stage achieved by drugs targeting SCD1 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase III; Aramchol
"What is the highest global development stage achieved by drugs targeting PDE4 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; roflumilast
"What is the highest global development stage achieved by drugs targeting ROCK2 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?","Phase I; zelasudil, TDI01 (Tide Pharmaceutical)"
"What is the highest global development stage achieved by drugs targeting IL-36R for fibrostenosing crohn's disease  up to April 2025, and which drugs are in this stage?",Phase II; spesolimab
"What is the highest global development stage achieved by drugs targeting μ opioid receptor for schizophrenia up to April 2025, and which drugs are in this stage?",Approved; samidorphan
"What is the highest global development stage achieved by drugs targeting ACVR2B for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",PreClinical; LAE103
"What is the highest global development stage achieved by drugs targeting 17β-HSD13 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?","Phase II; rapirosiran, ARO-HSD, VSA006"
"What is the highest global development stage achieved by drugs targeting miR-124 for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase II/III; obefazimod
"What is the highest global development stage achieved by drugs targeting JNK1 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; CC-90001
"What is the highest global development stage achieved by drugs targeting SHC1 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; B-105
"What is the highest global development stage achieved by drugs targeting TGF-β1 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",PreClinical; NASH treatment ASO (Isarna Therapeutics)
"What is the highest global development stage achieved by drugs targeting dopamine receptor for schizophrenia up to April 2025, and which drugs are in this stage?","Approved; chlorpromazine, periciazine, mesoridazine, oxypertine, mosapramine, pipotiazine, zuclopenthixol decanoate?, zuclopenthixol, zuclopenthixol acetate?, acepromazine, pipotiazine palmitate, dixyrazine, clopenthixol"
"What is the highest global development stage achieved by drugs targeting ICAM-1 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase I; DNP007
"What is the highest global development stage achieved by drugs targeting FXR for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?","Phase II; cilofexor, EDP-305, vonafexor, TERN-101, MET409, omesdafexor, HEC96719, HPG1860, CS0159"
"What is the highest global development stage achieved by drugs targeting leptin for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; metreleptin
"What is the highest global development stage achieved by drugs targeting ACL for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase I/II; BGT-002
"What is the highest global development stage achieved by drugs targeting SIRT6 for schizophrenia up to April 2025, and which drugs are in this stage?",Phase I; SP-624
"What is the highest global development stage achieved by drugs targeting RXR for schizophrenia up to April 2025, and which drugs are in this stage?",Phase III; bexarotene
"What is the highest global development stage achieved by drugs targeting LANCL2 for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase II; omilancor
"What is the highest global development stage achieved by drugs targeting RORα for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase I; TB-840
"What is the highest global development stage achieved by drugs targeting SGLT2 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?","Phase III; dapagliflozin, empagliflozin"
"What is the highest global development stage achieved by drugs targeting DPP-4 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; sitagliptin
"What is the highest global development stage achieved by drugs targeting IL-12p40 for perianal fistulas in Crohn's disease up to April 2025, and which drugs are in this stage?",Phase I; ustekinumab
"What is the highest global development stage achieved by drugs targeting FGF21 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?","Phase III; pegozafermin, efruxifermin"
"What is the highest global development stage achieved by drugs targeting T-type calcium channel for schizophrenia up to April 2025, and which drugs are in this stage?",Phase II; suvecaltamide
"What is the highest global development stage achieved by drugs targeting FAS for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase III; denifanstat
"What is the highest development stage achieved in China for drugs targeting SCD1 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",IND; Aramchol
"What is the highest development stage achieved in China for drugs targeting SGLT2 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase III; dapagliflozin
"What is the highest development stage achieved in China for drugs targeting TNF-α for Crohn's disease up to April 2025, and which drugs are in this stage?","Approved; infliximab, adalimumab"
"What is the highest development stage achieved in China for drugs targeting PDE for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase III; ZSP1601
"What is the highest development stage achieved in China for drugs targeting α4β7 for Crohn's disease up to April 2025, and which drugs are in this stage?",Approved; vedolizumab
"What is the highest development stage achieved in China for drugs targeting VAP-1 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?","IND; TT-01025, TERN-201"
"What is the highest development stage achieved in China for drugs targeting HDAC for schizophrenia up to April 2025, and which drugs are in this stage?",Phase II; sulforaphane
"What is the highest development stage achieved in China for drugs targeting dopamine receptor for schizophrenia up to April 2025, and which drugs are in this stage?",Phase I; periciazine
"What is the highest development stage achieved in China for drugs targeting FXR for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; HEC96719
"What is the highest development stage achieved in China for drugs targeting KDM1A for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase I; baicalin
"What is the highest development stage achieved in China for drugs targeting IL-12p40 for perianal fistulas in Crohn's disease up to April 2025, and which drugs are in this stage?",Phase I; ustekinumab
"What is the highest development stage achieved in China for drugs targeting D2 receptor for schizophrenia up to April 2025, and which drugs are in this stage?","Approved; fluphenazine, fluphenazine decanoate"
"What is the highest development stage achieved in China for drugs targeting JAK1 for Crohn's disease up to April 2025, and which drugs are in this stage?",Approved; upadacitinib
"What is the highest development stage achieved in China for drugs targeting FAS for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; denifanstat
"What is the highest development stage achieved in China for drugs targeting IL-36R for fibrostenosing crohn's disease  up to April 2025, and which drugs are in this stage?",Phase II; spesolimab
"What is the highest development stage achieved in China for drugs targeting RORγ for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase I; RS1805
"What is the highest development stage achieved in China for drugs targeting IL-23p19 for Crohn's disease up to April 2025, and which drugs are in this stage?","Approved; guselkumab, risankizumab"
"What is the highest development stage achieved in China for drugs targeting FGF21 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; AP025
"What is the highest development stage achieved in China for drugs targeting DGAT2 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; ervogastat
"What is the highest development stage achieved in China for drugs targeting THR-β for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?","Phase II; ASC41, HSK31679"
"What is the highest development stage achieved in China for drugs targeting 17β-HSD13 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; VSA006
"What is the highest development stage achieved in China for drugs targeting CB1 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase III; rimonabant
"What is the highest development stage achieved in China for drugs targeting IL-36R for Crohn's disease up to April 2025, and which drugs are in this stage?",IND; spesolimab
"What is the highest development stage achieved in China for drugs targeting TYK2 for Crohn's disease up to April 2025, and which drugs are in this stage?","Phase II; deucravacitinib, zasocitinib"
"What is the highest development stage achieved in China for drugs targeting RXR for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase I; ACT500
"What is the highest development stage achieved in the United States for drugs targeting ANT for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; HU6
"What is the highest development stage achieved in the United States for drugs targeting GPR119 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; DA-1241
"What is the highest development stage achieved in the United States for drugs targeting M1 receptor for schizophrenia up to April 2025, and which drugs are in this stage?",Phase I; 11C-LSN3172176
"What is the highest development stage achieved in the United States for drugs targeting amylin for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; cagrilintide
"What is the highest development stage achieved in the United States for drugs targeting LTA4H for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; LYS006
"What is the highest development stage achieved in the United States for drugs targeting GM-CSF for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase III; sargramostim
"What is the highest development stage achieved in the United States for drugs targeting GABRA5 for cognitive impairment in schizophrenia up to April 2025, and which drugs are in this stage?",Phase II; basmisanil
"What is the highest development stage achieved in the United States for drugs targeting leptin for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; metreleptin
"What is the highest development stage achieved in the United States for drugs targeting IL-23p19 for Crohn's disease up to April 2025, and which drugs are in this stage?","Approved; guselkumab, risankizumab, mirikizumab-mrkz"
"What is the highest development stage achieved in the United States for drugs targeting BH4 for schizophrenia up to April 2025, and which drugs are in this stage?",Phase II; sapropterin
"What is the highest development stage achieved in the United States for drugs targeting α4β7 for Crohn's disease up to April 2025, and which drugs are in this stage?",Approved; vedolizumab
"What is the highest development stage achieved in the United States for drugs targeting MPC for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; azemiglitazone
"What is the highest development stage achieved in the United States for drugs targeting PDE10A for schizophrenia up to April 2025, and which drugs are in this stage?",Phase I; gemlapodect
"What is the highest development stage achieved in the United States for drugs targeting PPARγ for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; PXL065
"What is the highest development stage achieved in the United States for drugs targeting A1AT for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase I; BMN 349
"What is the highest development stage achieved in the United States for drugs targeting IL-6 for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase II; clazakizumab
"What is the highest development stage achieved in the United States for drugs targeting EAAT2 for schizophrenia up to April 2025, and which drugs are in this stage?",Phase I; riluzole
"What is the highest development stage achieved in the United States for drugs targeting Nav1.5 for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase II; ranolazine
"What is the highest development stage achieved in the United States for drugs targeting DGAT2 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?","Phase II; ISIS-DGAT2, ervogastat"
"What is the highest development stage achieved in the United States for drugs targeting GLP-2 for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase II; teduglutide
"What is the highest development stage achieved in the United States for drugs targeting PPARα for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; pemafibrate
"What is the highest development stage achieved in the United States for drugs targeting NMDA receptor for schizophrenia up to April 2025, and which drugs are in this stage?",Phase II; apimostinel
"What is the highest development stage achieved in the United States for drugs targeting FGF19 for metabolic dysfunction-associated steatohepatitis  up to April 2025, and which drugs are in this stage?",Phase II; aldafermin
"What is the highest development stage achieved in the United States for drugs targeting CD20 for schizophrenia up to April 2025, and which drugs are in this stage?",Phase I/II; ocrelizumab
"What is the highest development stage achieved in the United States for drugs targeting IL-21 for Crohn's disease up to April 2025, and which drugs are in this stage?",Phase II; NN8828/NN9828
"By April 2025, what drugs for metabolic dysfunction-associated steatohepatitis  are available on the market, and which institutions were responsible for their development?","saroglitazar, Zydus Lifesciences; resmetirom, Madrigal Pharmaceuticals;Roche;Via Pharmaceuticals; ursodiol+silymarin, Minapharm"
"By April 2025, what drugs for agitation associated with schizophrenia are available on the market, and which institutions were responsible for their development?","ziprasidone, Pfizer"
"By April 2025, what drugs for perianal fistulas in Crohn's disease are available on the market, and which institutions were responsible for their development?","darvadstrocel, TiGenix"
"What drugs for agitation associated with schizophrenia are in the clinical Phase I stage as of April 2025, and which development institutions are involved?","loxapine, Wander"
"What drugs for perianal fistulas in Crohn's disease are in the clinical Phase I stage as of April 2025, and which development institutions are involved?","ustekinumab, Mitsubishi Tanabe Pharma;Janssen Biotech;GenPharm International; upadacitinib, AbbVie; PF2020-CELL (human umbilical cord mesenchymal stem cells), University of Malaya; autologous bone marrow-derived mesenchymal stem cells (University of Oxford), University of Oxford"
"By April 2025, what drugs for perianal fistulas in Crohn's disease are in the clinical Phase II stage, and which institutions are responsible for their development?","AVB-114, Avobis Bio; human mesenchymal stem cell exosomes (The First Affiliated Hospital of Xiamen University), The First Affiliated Hospital of Xiamen University"
"By April 2025, what drugs for fibrostenosing crohn's disease  are in the clinical Phase II stage, and which institutions are responsible for their development?","spesolimab, Boehringer Ingelheim; AGMB-129, Origo Biopharma"
"What drugs for metabolic dysfunction-associated steatohepatitis  are in the clinical Phase III stage as of April 2025, and which development institutions are involved?","pioglitazone, Eli Lilly;Takeda Pharmaceuticals; rosuvastatin, Shionogi;AstraZeneca;Grünenthal; diosmin, Servier; metadoxine, Laboratori Baldacci; rimonabant, Sanofi; liraglutide, Novo Nordisk; dapagliflozin, AstraZeneca;Bristol-Myers Squibb; empagliflozin, Eli Lilly;Boehringer Ingelheim; semaglutide, Novo Nordisk; elafibranor, Ipsen;Genfit;Terns Pharmaceuticals; cenicriviroc, Dong-A Pharma;Tobira Therapeutics;Takeda Pharmaceuticals; azemiglitazone, Cirius Therapeutics;Metabolic Solutions Development; Aramchol, Galmed Pharmaceuticals; ZSP1601, Raynovent;WuXi AppTec; lanifibranor, Chia Tai Tianqing Pharmaceutical;Hepalys Pharma;Inventiva; denifanstat, Sagimet Biosciences;Ascletis; pegozafermin, 89Bio;Teva Pharmaceutical; survodutide, Boehringer Ingelheim;Zealand Pharma; efruxifermin, Akero Therapeutics;Amgen"
"What drugs for cognitive impairment in schizophrenia are in the clinical Phase III stage as of April 2025, and which development institutions are involved?","minocycline, Pfizer; varenicline, Pfizer"
"What drugs for Crohn's disease are in the clinical Phase III stage as of April 2025, and which development institutions are involved?","azathioprine, Prometheus Biosciences; thalidomide, Grünenthal;Celgene; mesalazine, MEDA; sargramostim, Partner Therapeutics;Genzyme; abatacept, Ono Pharmaceutical;Simcere;Bristol-Myers Squibb; remestemcel-L, JCR Pharmaceuticals;Mesoblast;Novartis;Osiris Therapeutics; ozanimod, Scripps Research;Receptos; filgotinib, Gilead Sciences;Galapagos;AbbVie; etrasimod, Everest Medicines;Arena Pharmaceuticals; masitinib, AB Science; clarithromycin+clofazimine+rifabutin, Redhill Biopharma; tulisokibart, Prometheus Biosciences; PF-06480605, Telavant;Pfizer;Chugai Pharmaceutical"
"What drugs for perianal fistulas in Crohn's disease are in the clinical Phase III stage as of April 2025, and which development institutions are involved?","infliximab, Mitsubishi Tanabe Pharma;Janssen Biotech; adalimumab, AbbVie;Eisai;Cambridge Antibody Technology;BASF; TH-SC01, Topcel-KH Pharmaceutical; allogeneic human adipose-derived mesenchymal stem cells (DK -001), Carephar Pharmaceutical"
"By April 2025, what drugs for metabolic dysfunction-associated steatohepatitis  are in the IND stage, and which institutions are responsible for their development?","benaglutide, Benemae Pharmaceutical; efsubaglutide alfa, InnoGen; GX-G6, CSPC PHARMA.;TJ Biopharma;Genexine;I-Mab;Tasly; RAY1225, Raynovent; TB001, Turier biotech; ZT002, QL Biopharm; ABP2111Na, Aibo New Medicine Research; HDM1005, Huadong Medicine; AP026, Chia Tai Tianqing Pharmaceutical;AMP Source; HZ012, Heze Pharma;Doer Biologics; BC0306, Buchang Pharmaceuticals; MWN109, Minwei Biotech; MWN105, Minwei Biotech; KL290052, Kelun Pharmaceutical; HEC138671, HEC Pharma; YH2000, Jinnuosai Medical Technology; HPG7233, Hepagene; KH629, Kanghong Pharmaceutical; HEC169584, Guangdong HEC; CVI-2742, CVI Pharmaceuticals; FNX010, FANXI Biopharma; SFA-001, SFA Therapeutics"
"By April 2025, what drugs for schizophrenia are in the IND stage, and which institutions are responsible for their development?","NH300094, Nhwa Pharmaceutical"
"By April 2025, what drugs for Crohn's disease are in the IND stage, and which institutions are responsible for their development?","golidocitinib, Dizal Pharma;AstraZeneca; ebdarokimab, Akeso Biopharma; mufemilast, Hailing Chempharma;Hemay Biological; picankibart, Innovent Biologics; allogeneic human adipose-derived mesenchymal stem cells (DK -001), Carephar Pharmaceutical; HS-10360, Hansoh Pharmaceutical; UA021, Usynova; HRS-7085, Hengrui Pharmaceuticals; GenSci120, GeneScience Pharmaceuticals; LD09163, Lidao Pharmaceutical; TNK05, Synnocare"
"By April 2025, what drugs for perianal fistulas in Crohn's disease are in the IND stage, and which institutions are responsible for their development?","VUM03, VCANBIO Cell and Gene Engineering"
"By April 2025, what preclinical pipelines for metabolic dysfunction-associated steatohepatitis  are under development, and which institutions are involved? Represent the pipelines using drug names or patent IDs.","belumosudil, Meiji Seika;Kadmon;Surface Logix;BioNova Pharmaceuticals; larazotide, Alba Therapeutics;University of Maryland, Baltimore;Innovate Biopharmaceuticals; pegipanermin, Inmune Bio; ALY688, Allysta Pharmaceuticals; VB-201, VBL Therapeutics; REVTx-99, Revelation Biosciences; INT-787, Intercept Pharmaceuticals;TES Pharma; TLC-3595, Shionogi;OrsoBio; GMA106, Gmax Biopharm;Sino Biopharmaceutical; ECC5004, AstraZeneca;Eccogene; KINE-101, KINE SCIENCES; STP707, Sirnaomics; KN056, Suzhou Alphamab; NP-011, NEXEL; XW014, Sciwind Biosciences; HZ010, Heze Pharma;Doer Biologics; SRN-001, siRNAgen; DA-1726, Dong-A ST;MetaVia; ZX2021, Zhongxin Pharmaceutical; KN069, Alphamab Oncology;Amoytop Biotech; GS-4571, Gilead Sciences; MNO-863, MoonBiotech; ZT003, QL Biopharm; AB004, AKSO; ACE-167, Acesis BioMed; AGTX-2003, Agentix; ALN-REGN-L2, Regeneron Pharmaceuticals;Alnylam Pharmaceuticals; ALN-REGN-L4, Regeneron Pharmaceuticals;Alnylam Pharmaceuticals; ALN-REGN-L5, Regeneron Pharmaceuticals;Alnylam Pharmaceuticals; ALN-REGN-L7, Regeneron Pharmaceuticals;Alnylam Pharmaceuticals; ATR-127, Atrogi; AX-2911, ProQR Therapeutics; BAR501, University of Perugia; BBH-010, Biobank Healing; BI-3231, Boehringer Ingelheim; BMS-986339, Bristol-Myers Squibb; BOS-467, Boston Pharmaceuticals;Novartis; BRE-NA01, Brexogen; BRL-191118, Beryl Therapeutics; BRL-201009, Beryl Therapeutics; BSC-1601, BiSiChem; BT-111, Landos Biopharma; BWL 200, Bioway; BXT-102, Bioxytran; C-192, Onegene Biotechnology; C455, AstraZeneca; CG-0416, CureGene; CIDEB RNAi (Argo Biopharma), Argo Biopharmaceutical; CN113831323, Humanwell Healthcare; CP701, Saipute Medicine; CR-P1, Curogen; CR-T5, Curogen; CR-T6, Curogen; CR-T7, Curogen; CR-T8, Curogen; CS271011, Chipscreen Biosciences; CVI-LM002, CVI Pharmaceuticals; CY-5, China Pharmaceutical University; DD03, D&D Pharmatech;Metsera; Dgat2-1473, UMass Chan Medical School; EME008, Epsilon Molecular Engineering; EPGN2154, Epigen Biosciences; ETX-312, e-Therapeutics; FY002, Foyou Pharma; GHB-004, Gatehouse Bio; GLP-1 program (Sino Biopharmaceutical), Sino Biopharmaceutical; GLP-1/FGF21 dual agonist (HEC), HEC Pharma; GM100, Glycomantra; GM60186, JD Bioscience; GMA10X, Gmax Biopharm; GS-834356, Gilead Sciences; GS300, Gelesis; GTI-334.1, GSNO Therapeutics; GTI-891.1, GSNO Therapeutics; GTX-11, GAT Therapeutics; GalNAc-Stk25 ASO, Ionis Pharmaceuticals; HDP-21079, Handing Medicine; HS-1120, Zizhi Biotechnology; HSD17B13 RNAi (Argo Biopharma), Argo Biopharmaceutical; HSD17β13 inhibitors (Metacrine), Metacrine; HT-201, Hepa Thera; HTB-C039, Humantech Biotechnology; Hx-001, HepaTx; IBI3012, Innovent Biologics; IM-102, Integral Molecular; IN-A004, inno.N; IOT022, Inorbit Therapeutics; JT001 (NLRP3 inhibitor), Jecure Therapeutics; KBLP-004, KoBioLabs; KLB program for NASH (Sino Biopharmaceutical), Sino Biopharmaceutical; KRIYA?497, Kriya Therapeutics; KRX-104130, KRICT; Kylo-01, Kylonova; LABthera-006, Atogen; LAE103, Laekna Therapeutics; LAE105, Laekna Therapeutics; LCB17A, LCB; LG203003, LG Chem; LH10, Guangdong Pharmaceutical University; MH008, MRM Health; MT-001, Mitotherapeutix; MTDX 401, Montdorex; MTDX 402, Montdorex; NASH oligonucleotides program (Aligos Therapeutics), Aligos Therapeutics; NASH program (ST Pharm), ST Pharm; NASH program (CK Regeon), CK Regeon; NASH treatment ASO (UGISense AG), UGISense; NASH treatment ASO (Isarna Therapeutics), Isarna Therapeutics; NASH treatment exosomes (Unicyte), Unicyte; NASH treatment small molecule (Viscient Bio), Viscient Bio; NASH treatment small molecule (Mito BioPharma), Mito BioPharma; NC-004, Nodcure; OGB21501, Onegene Biotechnology; OGB21502, Onegene Biotechnology; OXM-101, Nordic Bioscience; OXM-104, Nordic Bioscience; PM601, Pharvis Korea; PN-101-RS, Paean Biotechnology; PNPLA3 RNAi (Argo Biopharma), Argo Biopharmaceutical; PPAR agonist (Harbin Medisan Pharmaceutical), Harbin Medisan Pharmaceutical;China Pharmaceutical University; QPCTL inhibitor 2 (Vivoryon Therapeutics), Vivoryon Therapeutics; R0737072, Ribo Life Science; RAY0221, Raynovent; RBD1073, Ribo Life Science; RBD5083, Ribo Life Science; RBD9090, Ribo Life Science; RJ4348, Ruijie Pharma; RJ7183, Ruijie Pharma; SBI-102, Shiftbio; SCO-116, Scohia Pharma;Kuria Therapeutics;Takeda Pharmaceuticals; SL100, Senelix; SP-C01, Shenyang Pharmaceutical University; SPL-334.1, SAJE Pharma; SPL-891.1, SAJE Pharma; SR111, Boehringer Ingelheim;Ribo Life Science; SR112, Boehringer Ingelheim;Ribo Life Science; T3D-980, T3D Therapeutics; TAA08, PersonGen; TB-619R, Therasid Bioscience; TB-620R, Therasid Bioscience; TB-621R, Therasid Bioscience; TB-711, Therasid Bioscience; TB-901, Therasid Bioscience; TB-DK, Therasid Bioscience; TB-IH, Therasid Bioscience; TB-RB, Therasid Bioscience; THR-β program (Sino Biopharmaceutical), Sino Biopharmaceutical; TP-352, Thetis Pharmaceuticals; VNA-438, Vandria; WO2019072130, TargetRx; WO2019144835, TargetRx; WO2020073974, InventisBio; WO2020249064, Ruijie Pharma; WO2021057791, HEC Pharma; WO2021073643, Chia Tai Tianqing Pharmaceutical; WO2021121210, Hengrui Pharmaceuticals; WO2021129817, WuXi AppTec; WO2021129827, WuXi AppTec; WO2021139763, Hansoh Pharmaceutical; WO2021244582, Kanghong Pharmaceutical; WO2022002408A1, Sanofi; WO2022109030, Skyhawk Therapeutics; WO2022117044A1, Guangdong HEC; WO2022133797A1, Heze Pharma;Doer Biologics; WO2022143574, KPC Pharmaceuticals; WO2022147694, Erai Therapeutics; WO2022184177, Convalife; WO2022184849, Servier; WO2023046071A1, Hengrui Pharmaceuticals; WO2023069754A2, Amgen; WO2023091644A2, Wave Life Sciences; WO2023151473A1, Youngene Therapeutics; WO2023172132A1, Leiden University; WO2023177667A1, Brii Biosciences; WO2023208109, Foyou Pharma; WO2023212019, Enanta Pharmaceuticals; WO2023214772A1, KRICT; WO2023220561, Sanegene Bio; WO2023223257, X-Chem; WO2023226958, Guangdong HEC; WO2023247488, AstraZeneca; WO2023280144A1, Hansoh Pharmaceutical; WO2024061202, Foyou Pharma; WO2024075051, Pfizer; WO2024097576, Merck & Co.; WO2024102634, Bp Asset Ix; WO2024102884, Bristol-Myers Squibb; WO2024121183A1, Boehringer Ingelheim; WO2024125482A1, Hua Medicine; WO2024127297A1, Pfizer; WO2024146906A1, Kintsugi; WO2024175062A1, Rona Therapeutics; WO2024182446A2, Merck & Co.;Aligos Therapeutics; WO2024187038A1, Merck & Co.;Aligos Therapeutics; WO2024199481A1, Domirui Biotechnology; WO2024236595A1, CSIR, India; WO2024245151A1, Visirna Therapeutics; WO2024249901A2, NICO Therapeutics; WO2024252367A2, Sun Pharma; WO2024263005A1, SL BIGEN; WO2024263605A2, Bluejay Therapeutics; WO2025005151A1, Tokyo Institute of Technology; WO2025014332A1, KRICT; WO2025014844A1, Ionis Pharmaceuticals;Regents of the University of California; WO2025026266A1, Langlai Technology; WO2025031444A1, Foyou Pharma; WO2025034789A1, University of North Carolina at Chapel Hill; YG1805, Youngene Therapeutics; YH33619, Gilead Sciences;Yuhan; YHC1108, Gilead Sciences;Yuhan; YHC1131, Yuhan; ZLY16, Guangdong Pharmaceutical University; ZLY28, Guangdong Pharmaceutical University; ZMC001, Zymedi; fibrosis & inflammatory diseases treatment small molecule (Altay therapeutics), Altay Therapeutics; miR-22-3p antagomir (AptamiR), AptamiR Therapeutics; miR-515-3p agomir (AptamiR), AptamiR Therapeutics; dorzagliatin+pioglitazone, Hua Medicine; hepatic disease treatment siRNA (Rona Therapeutics), EnnovaBio;Rona Therapeutics; NASH treatment product (Stermirna), Stemirna Therapeutics"
"By April 2025, what preclinical pipelines for schizophrenia are under development, and which institutions are involved? Represent the pipelines using drug names or patent IDs.","YA-101, Yoda Pharmaceuticals; DPX-101, Damona Pharmaceuticals; AP163 (TAAR1 agonist), Accellena; AV115, AviMed Pharmaceuticals;Marquette University; CB-701, Cascade Biotechnology; CM-182, Curemark; COMT inhibitor (Boehringer Ingelheim), Boehringer Ingelheim;LIBD; CVL-047, Cerevel Therapeutics; CampbellCell, Therapeutic Solutions International; HTL0041178, Nxera Pharma; IHCH-7041, ShanghaiTech University;Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; KB-128, Küleon Bioscience; KS-133, Ichimaru Pharcos; LK00764, Saint Petersburg State University; LL-00066471, Lupin; LQFM215, Universidade Federal de Goiás; LTX-001, Leal Therapeutics; M4 PAM, Addex Therapeutics; M4 agonist (hepaitech), HEPAI-TECH; NMRA-M4R, Neumora Therapeutics; OAK-0011799, Exscientia;Blue Oak Pharmaceuticals; SND4, SyneuRx; WO2021022890, Xunhe Pharma; WO2021110574A1, Roche; WO2022029170A1, Boehringer Ingelheim; WO2023165262A1, ShanghaiTech University; WO2024091542, Neurocrine Biosciences; WO2024188143A1, Luye Pharma; WO2024222860A1, Hansoh Pharmaceutical; WO2024230794A1, China Pharmaceutical University;Nhwa Pharmaceutical; WO2024260386A1, Haisco Pharmaceutical; WO2024263563A1, Sanford Burnham Prebys Medical Discovery Institute; [18F]JNJ-46356479, Massachusetts General Hospital;Harvard Medical School; schizophrenia program (Exavir), Exavir Therapeutics"
"By April 2025, what preclinical pipelines for cognitive impairment in schizophrenia are under development, and which institutions are involved? Represent the pipelines using drug names or patent IDs.","INV-300, INVENT Pharmaceuticals; INV-331, INVENT Pharmaceuticals; SP14040, Spherium"
"By April 2025, what preclinical pipelines for Crohn's disease are under development, and which institutions are involved? Represent the pipelines using drug names or patent IDs.","BR55, Bracco; KPG-818, Kangpu; TRE-515, Trethera; TP-317, Thetis Pharmaceuticals; U-Factor solution, U-Factor; 2MW3311, Mabwell Bioscience; APPL-001, Celularity; BL-040, Bilayer Therapeutics; CAR-Treg therapy (Sangamo Therapeutics), Sangamo Therapeutics; Crohn's Disease program (TRACT Therapeutics), TRACT Therapeutics; FIN-525, Finch Therapeutics;Takeda Pharmaceuticals; GT-1908, Palisade Bio;Giiant Pharma; HP-1901, Huapont Life Sciences;Pregene Biotechnology; IMB1003, IMIDomics; INT-220, Intract Pharma; LQ081, Novamab; LQ082, Novamab; LQ083, Novamab; MAK11049, MAKScientific; MINI-007, Minicircle; NPD-1902, Nogra Pharma; NPD-1911, Nogra Pharma; NV-003, Novellus Therapeutics; ORYN 1051, Oryn Therapeutics; OTL-104, Orchard Therapeutics; PH00012, PwC Biomedical; PLM-301, PeLeMed; SPL-850, SAJE Pharma; SPL-891.1, SAJE Pharma; SVT-1A167, Servatus; SYD001, Synovo; V56B2, VHsquared; WO2021005586A1, Novartis; WO2022078305, Haisco Pharmaceutical; WO2022187738, New York University; WO2023150197A1, Nexys Therapeutics; WO2024026395, Cephalon; WO2024138042A1, XinThera; WO2024218059A1, Evotec; WO2024224086A1, Imhotex; WO2024227437A1, Haisco Pharmaceutical; WO2024246269A1, Zealand Pharma; Yso2, YSOPIA Bioscience; autoimmune disease program (TScan), Amgen;TScan Therapeutics; biologic cocktail IBD therapy program (Lumen), Lumen Bioscience; colitis/crohn's disease program (Ceria Therapeutics), Ceria Therapeutics"
"By April 2025, what preclinical pipelines for perianal fistulas in Crohn's disease are under development, and which institutions are involved? Represent the pipelines using drug names or patent IDs.","Allogeneic mesenchymal stem cells combines with biomaterial complex formulations (SNC stemcell), Huaxiayuan Cell; dental pulp mesenchymal stem cells (Affiliated Hospital of Nantong University), Affiliated Hospital of Nantong University"
What institution developed MWN103?,Minwei Biotech
What institution developed AP163 ?,Accellena
What institution developed tetrabenazine?,Lundbeck;Prestwick Pharmaceuticals;Cambridge Laboratories;Biovail
What institution developed loxapine?,Wander
What institution developed PBI-4547?,Liminal BioSciences
What institution developed xanomeline?,Karuna Therapeutics;Eli Lilly;Novo Nordisk
What institution developed WXFL10203614?,Fortune Pharmaceutical;WuXi AppTec
What institution developed leronlimab?,CytoDyn;Phoenixus;PDL BioPharma;Progenics Pharmaceuticals
What institution developed LL-00066471?,Lupin
What institution developed AGMB-129?,Origo Biopharma
What institution developed MTP-101S?,University of Minnesota
What institution developed BI 3006337?,Yuhan;Boehringer Ingelheim
What institution developed perospirone?,Sumitomo Pharma
What institution developed dexamethasone?,Ocular Therapeutix;Hikma Pharmaceuticals;Aspen Pharmacare;Alliance Pharma
What institution developed armodafinil?,Neuraxpharm;Cephalon
What institution developed NASH treatment ASO ?,Isarna Therapeutics
What institution developed SBI-102?,Shiftbio
What institution developed HEC96719?,HEC Pharma
What institution developed florilglutamic acid ?,Bayer;Life Molecular Imaging
What institution developed HEC88473?,Apollo Therapeutics;HEC Pharma
What institution developed KL290052?,Kelun Pharmaceutical
What institution developed risankizumab-800CW?,University Medical Center Groningen
What institution developed vonafexor?,Enyo Pharma;Poxel
What institution developed KBLP-004?,KoBioLabs
What institution developed LQ083?,Novamab
What institution developed amantadine?,Endo International
What institution developed DA-1241?,Dong-A ST;MetaVia
What institution developed droperidol?,Johnson & Johnson
What institution developed LMT503?,Lmito Therapeutics
What institution developed aripiprazole lauroxil?,Alkermes
What institution developed pentamidine?,Fresenius
What institution developed zuclopenthixol decanoate??,Lundbeck
What institution developed paliperidone palmitate?,Johnson & Johnson;élan;Alkermes
What institution developed andecaliximab?,Gilead Sciences;Ashibio
What institution developed minocycline?,Pfizer
What institution developed clesacostat+ervogastat?,Pfizer
What institution developed acepromazine?,Wyeth
What institution developed IHCH-7041?,"ShanghaiTech University;Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences"
What institution developed 2'-fucosyllactose?,Intrinsic Medicine
What institution developed GSK4528287?,GSK
What institution developed MAK11049?,MAKScientific
What institution developed fluphenazine?,Schering-Plough
What institution developed larsucosterol?,Virginia Commonwealth University;Durect
What institution developed amisulpride?,Sanofi
What institution developed NA-941?,Biomed Industries
What institution developed ondansetron?,GSK
What institution developed ecopipam?,Psyadon Pharmaceuticals;Schering-Plough
What institution developed emricasan?,Novartis;Histogen;Idun Pharmaceuticals;Amerimmune
What institution developed LPM787000048?,Luye Pharma
What institution developed lisdexamfetamine?,New River Pharmaceuticals;Shionogi
What institution developed CRB-A4?,Celros Biotech
What institution developed adalimumab-680LT?,University Medical Center Groningen
What institution developed RBD1073?,Ribo Life Science
What institution developed resmetirom?,Madrigal Pharmaceuticals;Roche;Via Pharmaceuticals
What institution developed KRX-104130?,KRICT
What institution developed RBD9090?,Ribo Life Science
What institution developed colitis/crohn's disease program ?,Ceria Therapeutics
What institution developed levosulpiride?,Ravizza Farmaceutici
What institution developed valbenazine?,Mitsubishi Tanabe Pharma;Neurocrine Biosciences
What institution developed rapirosiran?,Regeneron Pharmaceuticals;Alnylam Pharmaceuticals
What institution developed TB-901?,Therasid Bioscience
What institution developed U-Factor solution?,U-Factor
What institution developed BOS-467?,Boston Pharmaceuticals;Novartis
What institution developed ANAVEX 3-71?,Israel Institute?for?Biological Research;Anavex Life Sciences
What institution developed duvakitug?,Teva Pharmaceutical;Sanofi
What institution developed CS0159?,Cascade Pharma;Shanghai Institute of Materia Medica;Van Andel Institute
What institution developed GSK1070806?,GSK
What institution developed ETX-312?,e-Therapeutics
What institution developed carfloglitazar?,Chipscreen Biosciences
What institution developed R0737072?,Ribo Life Science
What institution developed NASH program ?,ST Pharm
What institution developed vidofludimus?,Immunic;4SC;Nycomed
What institution developed GH509?,1Globe Biomedical
What institution developed IN-A004?,inno.N
What institution developed dixyrazine?,UCB
What institution developed ARO-HSD?,GSK;Arrowhead Pharmaceuticals
What institution developed PM601?,Pharvis Korea
What institution developed FIN-525?,Finch Therapeutics;Takeda Pharmaceuticals
What institution developed trifluoperazine?,GSK
What institution developed REVTx-99?,Revelation Biosciences
What institution developed ECC5004?,AstraZeneca;Eccogene
What institution developed ZT003?,QL Biopharm
What institution developed B1344?,NEAU;Tasly
What institution developed HPG7233?,Hepagene
What institution developed thiothixene?,Pfizer
What institution developed ABBV-382?,AbbVie
What institution developed [18F]JNJ-46356479?,Massachusetts General Hospital;Harvard Medical School
What institution developed sitagliptin?,Merck & Co.;Ono Pharmaceutical
What institution developed methylprednisolone?,Pfizer
What institution developed Allogeneic mesenchymal stem cells combines with biomaterial complex formulations ?,Huaxiayuan Cell
What institution developed VNA-438?,Vandria
What institution developed survodutide?,Boehringer Ingelheim;Zealand Pharma
What institution developed N-methyl amisulpride?,LB Pharmaceuticals
What institution developed TERN-201?,Terns Pharmaceuticals;Eli Lilly
What institution developed vutiglabridin?,Glaceum
What institution developed VB-201?,VBL Therapeutics
What institution developed amphetamine?,GSK
What institution developed olanzapine+samidorphan?,Alkermes
What institution developed AZD2389?,AstraZeneca
What institution developed [18F]ASEM?,Johns Hopkins University
"What drug combinations for metabolic dysfunction-associated steatohepatitis  are under development as of April 2025, and what stages have they reached?","ursodiol+silymarin, Approved; clesacostat+ervogastat, Phase II; testosterone undecanoate+α-tocopherol, Phase II; cilofexor+firsocostat, Phase II; NNC0194-0499+semaglutide, Phase I; pemafibrate+tofogliflozin, Phase I; dorzagliatin+pioglitazone, PreClinical"
"What drug combinations for schizophrenia are under development as of April 2025, and what stages have they reached?","olanzapine+samidorphan, Approved; xanomeline+trospium chloride, Approved; dasatinib+quercetin, Phase II"
"What drug combinations for Crohn's disease are under development as of April 2025, and what stages have they reached?","clarithromycin+clofazimine+rifabutin, Phase III; guselkumab+golimumab, Phase II"
"What degraders for Crohn's disease are under development as of April 2025, and what stages have they reached?","thalidomide, Phase III; lenalidomide, Phase II"
"What peptide drugs for metabolic dysfunction-associated steatohepatitis  are under development as of April 2025, and what stages have they reached?","liraglutide, Phase III; dulaglutide, Phase II; benaglutide, IND; semaglutide, Phase III; PEGylated loxenatide, Phase I; tirzepatide, Phase II; mazdutide, Phase II; ecnoglutide, Phase I; cagrilintide, Phase II; survodutide, Phase III; RAY1225, IND; ALY688, PreClinical; cotadutide, Phase II/III; efinopegdutide, Phase II; pemvidutide, Phase II; VK2735, Phase I; TB001, IND; NNC0194-0499+semaglutide, Phase I; DD01, Phase II; ZT002, IND; HDM1005, IND; AZD9550, Phase I/II; utreglutide, Phase II; PB-718, Phase I; KINE-101, PreClinical; HZ010, PreClinical; PZ-235, Phase I; HZ012, IND; DA-1726, PreClinical; MWN109, IND; PB-722, Phase I; ACE-167, PreClinical; CY-5, PreClinical; DD03, PreClinical; HDP-21079, PreClinical; OXM-101, PreClinical; OXM-104, PreClinical; RAY0221, PreClinical"
"What peptide drugs for schizophrenia are under development as of April 2025, and what stages have they reached?","semaglutide, Phase I; KS-133, PreClinical"
"What peptide drugs for Crohn's disease are under development as of April 2025, and what stages have they reached?","tetracosactide, Approved; cyclosporine, Phase II; teduglutide, Phase II; [68Ga]CBP8, Phase I; adrenomedullin, Phase I; ORYN 1051, PreClinical"
"What RNAi therapies for metabolic dysfunction-associated steatohepatitis  are under development as of April 2025, and what stages have they reached?","rapirosiran, Phase II; ARO-HSD, Phase II; VSA006, Phase II; JNJ-75220795, Phase I; STP707, PreClinical; LY3849891, Phase I; NN6581, Phase I; NN6582, Phase I; ALN-PNP, Phase I; SRN-001, PreClinical; OLX702A, Phase I; ALN-CIDEB, Phase I; ALN-REGN-L2, PreClinical; ALN-REGN-L4, PreClinical; ALN-REGN-L5, PreClinical; ALN-REGN-L7, PreClinical; CIDEB RNAi (Argo Biopharma), PreClinical; ETX-312, PreClinical; GHB-004, PreClinical; HSD17B13 RNAi (Argo Biopharma), PreClinical; MT-001, PreClinical; PNPLA3 RNAi (Argo Biopharma), PreClinical; R0737072, PreClinical; RBD1073, PreClinical; RBD5083, PreClinical; RBD9090, PreClinical; SR111, PreClinical; SR112, PreClinical; hepatic disease treatment siRNA (Rona Therapeutics), PreClinical"
"What RNAi therapies for Crohn's disease are under development as of April 2025, and what stages have they reached?","MT-5745, Phase I"
"What gene therapies for metabolic dysfunction-associated steatohepatitis  are under development as of April 2025, and what stages have they reached?","AX-2911, PreClinical; CR-P1, PreClinical; KRIYA?497, PreClinical"
"What gene therapies for Crohn's disease are under development as of April 2025, and what stages have they reached?","MINI-007, PreClinical; OTL-104, PreClinical"
"What cell therapies for metabolic dysfunction-associated steatohepatitis  are under development as of April 2025, and what stages have they reached?","Hx-001, PreClinical; TAA08, PreClinical"
"What cell therapies for schizophrenia are under development as of April 2025, and what stages have they reached?","CampbellCell, PreClinical"
"What cell therapies for Crohn's disease are under development as of April 2025, and what stages have they reached?","remestemcel-L, Phase III; human umbilical cord mesenchymal stem cells (Shanghai East Hospital), Phase I; TH-SC01, Phase I; allogeneic human adipose-derived mesenchymal stem cells (DK -001), IND; bone-marrow derived autologous mesenchymal stem cells (Royan Institute), Phase I; adipose-derived adult mesenchymal stem cells (IIS-FJD), Phase I/II; Tolerogenic dendritic cells (Hospital Clinic of Barcelona), Phase I; donor-derived CD7 CAR T cells (Yake Bio), Phase I; AVB-114, Phase II; allogeneic human bone marrow derived mesenchymal stem cell (The Cleveland Clinic), Phase I/II; vertebral bone marrow derived mesenchymal stem cells (Ossium Health), Phase I/II; TRX103, Phase I/II; APPL-001, PreClinical; CAR-Treg therapy (Sangamo Therapeutics), PreClinical; Crohn's Disease program (TRACT Therapeutics), PreClinical; NV-003, PreClinical; OTL-104, PreClinical; PH00012, PreClinical; autoimmune disease program (TScan), PreClinical"
"What cell therapies for perianal fistulas in Crohn's disease are under development as of April 2025, and what stages have they reached?","darvadstrocel, Approved; TH-SC01, Phase III; allogeneic human adipose-derived mesenchymal stem cells (DK -001), Phase III; AVB-114, Phase II; allogeneic human bone marrow derived mesenchymal stem cell (The Cleveland Clinic), Phase I/II; vertebral bone marrow derived mesenchymal stem cells (Ossium Health), Phase I/II; PF2020-CELL (human umbilical cord mesenchymal stem cells), Phase I; autologous bone marrow-derived mesenchymal stem cells (University of Oxford), Phase I; VUM03, IND; Allogeneic mesenchymal stem cells combines with biomaterial complex formulations (SNC stemcell), PreClinical; dental pulp mesenchymal stem cells (Affiliated Hospital of Nantong University), PreClinical"
"What cell therapies for rectovaginal fistulas in Crohn's disease are under development as of April 2025, and what stages have they reached?","allogeneic human bone marrow derived mesenchymal stem cell (The Cleveland Clinic), Phase I/II"
"What antibodies for metabolic dysfunction-associated steatohepatitis  are under development up to April 2025, and what stages have they reached?","leronlimab, Phase II; PF-06480605, Phase I; foralumab, Phase II; nebokitug, Phase II; namacizumab, Phase I; fazpilodemab , Phase II; NGM313, Phase II; GMA106, PreClinical; BI 770371, Phase II; atrosimab, Phase I; DNP007, Phase I; KN069, PreClinical; CRB-A4, Phase I; BOS-467, PreClinical; EME008, PreClinical; GMA10X, PreClinical; IBI3012, PreClinical; IM-102, PreClinical; LAE103, PreClinical; LAE105, PreClinical"
"What antibodies for schizophrenia are under development up to April 2025, and what stages have they reached?","rituximab, Phase II; natalizumab, Phase I; tocilizumab, Phase I; siltuximab, Phase I/II; ocrelizumab, Phase I/II"
"What antibodies for Crohn's disease are under development up to April 2025, and what stages have they reached?","infliximab, Approved; adalimumab, Approved; natalizumab, Approved; tocilizumab, Phase I; certolizumab pegol, Approved; ustekinumab, Approved; golimumab, Phase II; denosumab, Phase I/II; vedolizumab, Approved; secukinumab, Phase II; brodalumab, Phase II; guselkumab, Approved; risankizumab, Approved; spesolimab, Phase II; mirikizumab-mrkz, Approved; ebdarokimab, IND; picankibart, IND; andecaliximab, Phase II; olokizumab, Phase II; clazakizumab, Phase II; tulisokibart, Phase III; lutikizumab, Phase II; PF-06480605, Phase III; QX004N, Phase I; ASP1002, Phase II; GSK1070806, Phase I/II; NN8828/NN9828, Phase II; foralumab, Phase II; ravagalimab, Phase I; quisovalimab, Phase I; duvakitug, Phase II; ABBV-154, Phase II; guselkumab+golimumab, Phase II; ABBV-382, Phase II; AZD7798, Phase II; adalimumab-680LT, Phase I/II; risankizumab-800CW, Phase I/II; [124I]IB PF 06687234, Phase I; GSK4528287, Phase I; BCD-261, Phase I; GenSci120, IND; 2MW3311, PreClinical; HP-1901, PreClinical; LQ081, PreClinical; LQ082, PreClinical; LQ083, PreClinical; MINI-007, PreClinical; V56B2, PreClinical"
"What antibodies for perianal fistulas in Crohn's disease are under development up to April 2025, and what stages have they reached?","infliximab, Phase III; adalimumab, Phase III; ustekinumab, Phase I"
"What antibodies for fibrostenosing crohn's disease  are under development up to April 2025, and what stages have they reached?","spesolimab, Phase II"
"What are the key drugs, targets, and indications being studied in clinical trial CTR20132464?","blonanserin, 5-HT2A receptor;D2 receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial jRCT2080223165?","vedolizumab, α4β7, ulcerative colitis ;Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial NCT00095524?","aripiprazole, 5-HT2A receptor;D2 receptor;5-HT1A receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial EudraCT2013-001029-17?","infliximab, TNF-α, Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial EudraCT2005-002979-33?","risperidone, 5-HT2A receptor;D2 receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial NCT02681055?","tipelukast, 5-LOX;LTR, metabolic dysfunction-associated steatohepatitis ;hypertriglyceridemia ;metabolic dysfunction associated fatty liver disease "
"What are the key drugs, targets, and indications being studied in clinical trial ChiCTR2400086371?","E. coli Nissle 1917, E. coli, ulcerative colitis ;Crohn's disease;inflammatory bowel disease "
"What are the key drugs, targets, and indications being studied in clinical trial NCT00711269?","lurasidone, α2C-AR;5-HT2A receptor;D2 receptor;5-HT7 receptor;5-HT1A receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial NCT00685334?","olanzapine, 5-HT3 receptor;5-HT2C receptor;5-HT2A receptor;D2 receptor, eating disorder;depressive disorder;obesity;osteoporosis;binge eating disorder ;heart failure;schizophrenia;anorexia nervosa;bulimia;anxiety disorder;psychiatry"
"What are the key drugs, targets, and indications being studied in clinical trial ISRCTN65243779?","visilizumab, CD3, Crohn's disease;perianal fistula"
"What are the key drugs, targets, and indications being studied in clinical trial NCT01516424?","blonanserin, 5-HT2A receptor;D2 receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial EudraCT2017-004294-14?","ozanimod, S1PR1;S1PR5, Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial NCT05182476?","luvadaxistat, DAAO, cognitive impairment in schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial NCT00704509?","bifeprunox, D2 receptor;5-HT1A receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial NCT04991324?","cholecalciferol, vitamin D3, ulcerative colitis ;Crohn's disease;inflammatory bowel disease "
"What are the key drugs, targets, and indications being studied in clinical trial UMIN000017047?","olanzapine
blonanserin
dopamine, 5-HT3 receptor;5-HT2C receptor;5-HT2A receptor;D2 receptor
5-HT2A receptor;D2 receptor
dopamine receptor, schizophrenia;psychiatry"
"What are the key drugs, targets, and indications being studied in clinical trial jRCT2031210380?","guanabenz, α2-adrenergic receptor;PPP1R15A, hypertension;metabolic dysfunction-associated steatohepatitis "
"What are the key drugs, targets, and indications being studied in clinical trial UMIN000022270?","adalimumab, TNF-α, Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial EudraCT2020-003760-11?","iclepertin, GlyT1, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial NCT01947803?","paliperidone palmitate, 5-HT2A receptor;D2 receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial EudraCT2017-000574-11?","ontamalimab, MAdCAM-1, ulcerative colitis ;Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial CTR20180670?","risperidone, 5-HT2A receptor;D2 receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial NCT01074073?","lurasidone, α2C-AR;5-HT2A receptor;D2 receptor;5-HT7 receptor;5-HT1A receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial NCT05552274?","ECC4703, THR-β, metabolic dysfunction-associated steatohepatitis "
"What are the key drugs, targets, and indications being studied in clinical trial CTR20160592?","blonanserin, 5-HT2A receptor;D2 receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial CTR20242491?","cariprazine, D2 receptor;D3 receptor;5-HT1A receptor, depressive disorder;schizophrenia;bipolar disorder;manic episode;bipolar depression"
"What are the key drugs, targets, and indications being studied in clinical trial NCT03783195?","fructose, carbohydrate, obesity;hepatocellular carcinoma ;metabolic dysfunction-associated steatohepatitis ;liver cirrhosis;liver disease;metabolic syndrome;fatty liver;metabolic dysfunction associated fatty liver disease "
"What are the key drugs, targets, and indications being studied in clinical trial NCT02781584?","firsocostat
cilofexor
fenofibrate
icosapent ethyl
selonsertib, ACC2;ACC1
FXR
PPARα
PPARα;EPA
ASK1, metabolic dysfunction-associated steatohepatitis ;metabolic dysfunction associated fatty liver disease "
"What are the key drugs, targets, and indications being studied in clinical trial EudraCT2009-018054-33?","vitamin E, vitamin E, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial NCT02970292?","pimavanserin, 5-HT2A receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial CTR20250525?","DR10624, FGF21;GLP-1R;GCGR, metabolic dysfunction-associated steatohepatitis ;hepatic fibrosis;metabolic dysfunction associated fatty liver disease "
"What are the key drugs, targets, and indications being studied in clinical trial NCT00329537?","sargramostim, GM-CSF, Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial jRCT2080225223?","clesacostat
ervogastat, ACC
DGAT2, metabolic dysfunction-associated steatohepatitis "
"What are the key drugs, targets, and indications being studied in clinical trial NCT03440372?","ozanimod, S1PR1;S1PR5, Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial NCT01300364?","citalopram
reboxetine, SERT
NET, schizophrenia;psychiatry"
"What are the key drugs, targets, and indications being studied in clinical trial NCT00255515?","quetiapine, 5-HT2A receptor;D2 receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial UMIN000010293?","infliximab, TNF-α, Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial NCT00234377?","quetiapine, 5-HT2A receptor;D2 receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial ACTRN12616000098437?","aripiprazole
quetiapine
omega-3-carboxylic acids
fluoxetine, 5-HT2A receptor;D2 receptor;5-HT1A receptor
5-HT2A receptor;D2 receptor
PPARα;EPA;DHA
NLRP3;SERT, schizophrenia;psychiatry"
"What are the key drugs, targets, and indications being studied in clinical trial NCT02413372?","pegbelfermin, FGF21, metabolic dysfunction-associated steatohepatitis "
"What are the key drugs, targets, and indications being studied in clinical trial EudraCT2014-003509-13?","vedolizumab, α4β7, Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial CTR20211529?","SIPI6398, 5-HT2A receptor;D2 receptor;D3 receptor;5-HT1A receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial CTR20244338?","upadacitinib, JAK1, ulcerative colitis ;Crohn's disease;atopic dermatitis;psoriatic arthritis ;rheumatoid arthritis "
"What are the key drugs, targets, and indications being studied in clinical trial NCT02260830?","Lu AF11167, PDE, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial CTR20244661?","upadacitinib, JAK1, Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial NCT00152490?","certolizumab pegol, TNF-α, Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial NCT02501291?","thalidomide, CRBN;IKZF3;IKZF1, Crohn's disease"
"What are the key drugs, targets, and indications being studied in clinical trial CTR20211514?","brexpiprazole, 5-HT2A receptor;D2 receptor;5-HT1A receptor, major depressive disorder ;schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial jRCT2080221591?","brexpiprazole, 5-HT2A receptor;D2 receptor;5-HT1A receptor, schizophrenia"
"What are the key drugs, targets, and indications being studied in clinical trial EudraCT2021-002068-30?","lumateperone, 5-HT2A receptor;D2 receptor, schizophrenia"
Which entity originally sponsored clinical trial NCT02288845?,"Intra-Cellular Therapies, Inc."
Which entity originally sponsored clinical trial NCT04822181?,Novo Nordisk A/S
Which entity originally sponsored clinical trial NCT06548542?,AbbVie
Which entity originally sponsored clinical trial NCT04975035?,"Second Affiliated Hospital, School of Medicine, Zhejiang University"
Which entity originally sponsored clinical trial EudraCT2007-004857-27?,"Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich"
Which entity originally sponsored clinical trial C000000301?,"Zeria Pharmaceutical Co.,LTD."
Which entity originally sponsored clinical trial NCT00209027?,Emory University
Which entity originally sponsored clinical trial NCT05499156?,Tehran University of Medical Sciences
Which entity originally sponsored clinical trial CTRI/2020/02/023099?,Newron Pharmaceuticals SpA
Which entity originally sponsored clinical trial NCT00633048?,Wyeth is now a wholly owned subsidiary of Pfizer
Which entity originally sponsored clinical trial NCT00230828?,Solvay Pharmaceuticals
Which entity originally sponsored clinical trial NCT00609973?,"University of North Carolina, Chapel Hill"
Which entity originally sponsored clinical trial NCT05624801?,"University Hospital, Basel, Switzerland"
Which entity originally sponsored clinical trial EudraCT2017-000497-11?,Alkermes Inc
Which entity originally sponsored clinical trial EudraCT2006-006967-22?,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium"
Which entity originally sponsored clinical trial NCT05837897?,Takeda
Which entity originally sponsored clinical trial NCT00757978?,Hospital de Clinicas de Porto Alegre
Which entity originally sponsored clinical trial NCT03329209?,Takeda
Which entity originally sponsored clinical trial EudraCT2006-002078-23?,Abbott GmbH & Co. KG (Abbott)
Which entity originally sponsored clinical trial NCT05145413?,Karuna Therapeutics
Which entity originally sponsored clinical trial NCT01192867?,Hoffmann-La Roche
Which entity originally sponsored clinical trial CTRI/2024/06/069258?,Torrent Pharmaceuticals Ltd.
Which entity originally sponsored clinical trial NCT01787591?,Ohio State University
Which entity originally sponsored clinical trial NCT00488319?,"Janssen Research & Development, LLC"
Which entity originally sponsored clinical trial ChiCTR2200063225?,Xiamen Xianyue Hospital
Which entity originally sponsored clinical trial EudraCT2010-018911-13?,"Otsuka Pharmaceutical Development & Commercialization, Inc."
Which entity originally sponsored clinical trial NCT00774982?,Teva GTC
Which entity originally sponsored clinical trial jRCT2080221450?,"Chugai Pharmaceutical Co., Ltd."
Which entity originally sponsored clinical trial NCT00193713?,Solvay Pharmaceuticals
Which entity originally sponsored clinical trial jRCT2080224899?,"Otsuka Pharmaceutical Co., LTD."
Which entity originally sponsored clinical trial JapicCTI-111627?,"Chugai Pharmaceutical Co., Ltd."
Which entity originally sponsored clinical trial NCT03187496?,"Enanta Pharmaceuticals, Inc"
Which entity originally sponsored clinical trial NCT00686140?,Beijing HuiLongGuan Hospital
Which entity originally sponsored clinical trial NCT00159757?,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Which entity originally sponsored clinical trial EudraCT2006-005734-20?,Janssen L.P.
Which entity originally sponsored clinical trial NCT06613334?,Centre Hospitalier St Anne
Which entity originally sponsored clinical trial NCT04521868?,Central South University
Which entity originally sponsored clinical trial NCT01263080?,Capital Medical University
Which entity originally sponsored clinical trial JapicCTI-060325?,"Otsuka Pharmaceutical Co., Ltd."
Which entity originally sponsored clinical trial NCT05731596?,Tanta University
Which entity originally sponsored clinical trial NCT05415722?,"Terns, Inc."
Which entity originally sponsored clinical trial NCT03745820?,Biogen
Which entity originally sponsored clinical trial UMIN000004931?,"Department of Neuropsychiatry 
Keio University School of Medicine"
Which entity originally sponsored clinical trial EudraCT2014-003824-36?,F. Hoffmann-La Roche Ltd
Which entity originally sponsored clinical trial NCT02420015?,Duke University
Which entity originally sponsored clinical trial NCT00560937?,Durham VA Medical Center
Which entity originally sponsored clinical trial NCT04761952?,"Sixth Affiliated Hospital, Sun Yat-sen University"
Which entity originally sponsored clinical trial NCT00215904?,Herzog Hospital
Which entity originally sponsored clinical trial jRCT2080223209?,"Sunovion Pharmaceuticals Inc.,"
Which entity originally sponsored clinical trial EudraCT2015-001925-18?,Celgene Corporation
What completed Phase I clinical trials for metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs .,"NCT06365580, NCT06308861, NCT06308874, NCT06188026, NCT06105060, CTR20233135, NCT05874336, NCT05848440, NCT05835180, NCT05766709, CTR20230472, NCT05737433, NCT05727644, CTR20230074, KCT0008007, NCT05552274, NCT05553470, NCT05441904, CTR20221600, jRCT2031210703, CTR20220073, CTR20213238, ISRCTN47896018, CTR20212697, NCT05117489, CTR20212812, NCT05090111, NCT04972396, NCT04932252, NCT04897594, NCT04887038, NCT04829123, NCT04808154, jRCT2071200100, NCT04722653, NCT04709913, CTR20202354, NCT04643795, NCT04559126, NCT04546984, KCT0005295, CTR20201303, NCT04483947, NCT04463017, CTR20201054, NCT04408937, ACTRN12620000104954, NCT04202354, NCT04194242, CTR20192517, CTR20192326, CTR20192073, CTR20191375, NCT04152473, NCT04146805, NCT04142424, NCT04137055, NCT03976687, ACTRN12619000655145, NCT03783897, NCT03748628, NCT03610945, NCT03392779, CTR20171627, ACTRN12617001444370, NCT03213145, NCT03187496, NCT02891408, NCT02696941, NCT02654002, ACTRN12615001355561, NCT02571192, NCT02287779, NCT02235233"
What completed Phase I clinical trials for schizophrenia exist up to April 2025? Provide the trial IDs .,"NCT03093064, EudraCT2016-003529-41, NCT02978599, EudraCT2016-002327-29, NCT02943213, NCT02935725, NCT02919774, NCT02901587, CTR20160323, NCT02831231, NCT02824666, NCT02824055, NCT02804568, NCT02769936, NCT02768649, NCT02765555, NCT02748694, NCT02720263, ChiCTR-IIR-16008071, NCT02687984, NCT02636842, NCT02589262, NCT02577575, NCT02568709, NCT02567370, NCT02567032, NCT02504476, NCT02501109, NCT02418819, NCT02411526, NCT02411695, NCT02389881, NCT02332798, NCT02333487, NCT02331433, NCT02320032, NCT02260830, CTR20131451, CTR20140616, NCT02232529, NCT02220712, CTR20132389, NCT02202213, NCT02202226, NCT02181803, NCT02176044, NCT02174510, NCT02174523, CTR20130409, CTR20130411, NCT02074319, NCT02051387, JapicCTI-142423, jRCT2080222373, NCT02037074, NCT02019329, NCT01994473, NCT01972711, NCT01964404, ACTRN12613001133729, ACTRN12613001134718, ACTRN12613001131741, NCT01955564, NCT01942382, NCT01940159, ACTRN12613000955718, NCT01923025, NCT01892384, NCT01879722, ACTRN12613000650796, NCT01870999, NCT01854944, NCT01829048, NCT01774435, JapicCTI-122010, jRCT2080221964, NCT01696929, NCT01654601, NCT01634373, NCT01606436, NCT01592110, NCT01566487, NCT01556763, NCT01545310, NCT01519557, NCT01518894, NCT01511510, NCT01506765, NCT01493726, NCT01457339, NCT01429740, NCT01423916, NCT01394471, NCT01381419, NCT01376076, NCT01354353, NCT01299454, NCT01289080, NCT01268124, NCT01165294, NCT01150448, NCT01116830, NCT01110317, NCT01101659, NCT01090440, NCT01082250, NCT01082263, NCT01082289, NCT01074073, NCT01074632, NCT01043458, NCT00986531, NCT00946348, NCT00945503, NCT00934466, NCT00919607, NCT00892320, NCT00892489, NCT00892541, NCT00888693, NCT00876304, NCT00838669, NCT00821600, NCT00805454, NCT00796029, NCT00796081, NCT00796185, NCT00796276, NCT00796432, NCT00796471, NCT00796640, NCT00796835, NCT00790777, NCT00791167, NCT00791193, NCT00791232, NCT00791284, NCT00791349, NCT00791401, NCT00791622, NCT00791713, NCT00758030, NCT00645502, NCT00633048, NCT00628420, NCT00611741, NCT00567034, NCT00541996, NCT00527020, NCT00505973, NCT00500201, NCT00463372, NCT00458107, NCT00456976, NCT00448890, NCT00447941, NCT00411866, EudraCT2005-005343-26, NCT00269035, NCT00255918, NCT00197093, NCT00174889, NCT06906224, NCT06880328, CTR20242908, NCT06319170, CTR20233666, NCT06107803, NCT05893862, NCT05848700, CTR20230273, CTR20222422, NCT05542264, NCT05463770, CTR20221720, NCT05406440, NCT05402111, CTR20220711, NCT05245539, ISRCTN10534853, NCT05106309, ACTRN12621001490864, CTR20212631, NCT04972227, CTR20211529, NCT04865835, NCT04849026, NCT04787302, NCT04779177, CTR20210165, NCT04712734, NCT04709224, CTR20202206, NCT04588129, NCT04510298, NCT04506905, CTR20201016, NCT04369391, NCT04325737, NCT04306146, jRCT2080225100, JapicCTI-205195, NCT04187560, NCT04158453, NCT04136873, CTR20192086, jRCT2080224899, NCT04038957, CTR20190614, NCT03817346, NCT03669250, NCT03627195, NCT03565068, jRCT2080223873, NCT03370640, NCT03356639, JapicCTI-173787, jRCT2080223731, NCT03321617, NCT03181841, NCT03164876, NCT03150771"
What completed Phase I clinical trials for cognitive impairment in schizophrenia exist up to April 2025? Provide the trial IDs .,"NCT02079844, NCT01346163, NCT01186471, NCT01181934, NCT00567203, NCT05136690"
What completed Phase I clinical trials for Crohn's disease exist up to April 2025? Provide the trial IDs .,"NCT06053424, CTR20223375, NCT05567029, CTR20221643, NCT05452304, CTR20200850, NCT03962998, NCT03709628, ChiCTR1800018107, ACTRN12617001426370, NCT02998190, NCT02968108, EudraCT2016-001956-22, EudraCT2014-005666-29, ChiCTR-IPR-15006904, NCT02367183, NCT02148185, NCT01915927, NCT01827631, NCT01769755, NCT01611805, NCT01258205, NCT01114607, NCT00950105, NCT00838149, NCT00774969, NCT00774982, NCT00245947, NCT00025805, NCT00007163"
What completed Phase I clinical trials for perianal fistulas in Crohn's disease exist up to April 2025? Provide the trial IDs .,NCT02589119
What completed Phase I clinical trials for Crohn's fistula exist up to April 2025? Provide the trial IDs .,"NCT03449069, NCT03220243, NCT00992485"
What completed Phase II clinical trials for metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs .,"NCT06677788, NCT06342947, NCT06054815, NCT05824156, NCT05638737, NCT05591079, NCT05461105, NCT05415722, NCT05397379, NCT05364931, NCT05254626, ISRCTN27793187, CTR20213202, NCT05016882, CTR20211428, NCT04944992, NCT04932512, NCT04929483, jRCT2051210037, NCT04906421, NCT04874233, NCT04773964, CTR20210074, jRCT2051200083, EudraCT2019-003048-63, NCT04521114, NCT04480710, jRCT2080225223, NCT04399538, CTR20192369, NCT04328077, NCT04321343, EudraCT2019-001550-26, NCT04173065, NCT04166773, EudraCT2019-001897-27, NCT04052516, NCT03987074, NCT03976401, NCT03969719, NCT03938246, NCT03912532, NCT03863574, EudraCT2018-003119-22, NCT03812029, NCT03656068, EudraCT2017-004365-27, NCT03449446, NCT03421431, NCT03400163, jRCT2080223679, JapicCTI-173735, NCT03248882, EudraCT2016-000499-83, NCT03008070, EudraCT2016-002496-10, NCT02970942, NCT02923154, EudraCT2016-001979-70, EudraCT2016-000685-39, NCT02856555, NCT02854605, NCT02784444, NCT02686762, NCT02633956, NCT02510599, NCT02466516, NCT02443116, NCT02413372, NCT02316717, NCT02279524, NCT01919294, NCT01766713, jRCT2080221948, JapicCTI-121993, NCT01694849, NCT01571063, NCT01265498, NCT01154985, NCT01068444, NCT01066364, NCT00740610, EudraCT2008-002361-31, NCT00680407, NCT00668070, NCT00666016, NCT00596934, NCT00590161, NCT00586911, EudraCT2007-002114-19, NCT00470171, NCT00323414, NCT00063232, NCT00062764"
What completed Phase II clinical trials for schizophrenia exist up to April 2025? Provide the trial IDs .,"EudraCT2016-003436-20, NCT03055338, NCT02970305, NCT02970929, NCT02969382, NCT02928965, CTR20160592, NCT02880462, EudraCT2016-001556-21, NCT02832037, NCT02810964, EudraCT2016-000285-28, NCT02624167, NCT02524899, NCT02477670, NCT02477020, UMIN000017295, EudraCT2014-001968-35, EudraCT2014-004878-42, ISRCTN14760638, NCT02288845, NCT02281773, NCT02237235, NCT02164981, NCT02695589, NCT02156908, NCT02151656, CTR20140090, EudraCT2013-005451-32, CTR20140154, CTR20140091, CTR20140089, NCT02062190, NCT02019459, NCT02008773, EudraCT2013-002193-45, NCT01952132, NCT01934023, NCT01903837, EudraCT2012-004504-35, EudraCT2013-000121-31, NCT01812642, NCT01779700, NCT01716858, NCT01677377, CTRI/2012/08/002944, JapicCTI-121914, jRCT2080221869, NCT01649557, NCT01623713, NCT01606254, EudraCT2011-005138-21, EudraCT2011-004844-23, NCT01548612, JapicCTI-121755, jRCT2080221713, NCT01503359, NCT01499563, NCT01490086, NCT01488929, NCT01400477, NCT01390376, NCT01377233, NCT01364792, NCT01354132, NCT01323205, EudraCT2010-023369-23, NCT01234779, EudraCT2010-020764-38, NCT01175135, NCT01163227, NCT01111149, NCT01101464, NCT01093365, NCT01086748, EudraCT2009-017852-28, NCT01052103, NCT01047592, CTRI/2009/091/000952, EudraCT2009-016245-26, EudraCT2009-012567-33, EudraCT2009-012568-14, NCT01009060, NCT00960219, CTRI/2009/091/000395, NCT00922272, NCT00921804, NCT00905307, NCT00862992, NCT00861796, NCT00845026, NCT00839852, NCT00827918, NCT00772005, NCT00770744, NCT00768326, EudraCT2008-001441-26, EudraCT2007-007083-22, NCT00639886, NCT00728728, NCT00728195, NCT00725075, NCT00722176, NCT00694707, NCT00892528, NCT00690274, NCT00686998, EudraCT2007-001611-32, EudraCT2006-006184-23, NCT00639483, EudraCT2007-007669-20, NCT00628290, NCT00616798, NCT00580125, NCT00567710, NCT00563706, NCT00520923, NCT00509067, NCT00505765, NCT00491569, NCT00490516, NCT00480571, EudraCT2007-001541-18, NCT00404573, NCT00374244, NCT00361166, EudraCT2005-006048-42, NCT00316238, NCT00309413, NCT00300963, NCT00268749, NCT00265551, NCT00259870, NCT00257023, NCT00254787, JapicCTI-050150, NCT00235274, EudraCT2005-002883-27, NCT00206570, NCT00202007, JapicCTI-050092, jRCT2080220090, NCT00154258, NCT00149292, NCT00141479, NCT00139906, NCT00129441, EudraCT2005-000016-27, NCT00105326, NCT00103727, EudraCT2004-003776-10, NCT00100165, NCT00097942, EudraCT2004-001041-15, NCT00088621, NCT00088634, NCT00074477, NCT00073164, NCT00049946, NCT00044005, NCT00044044, EudraCT2022-000580-52, NCT05545111, EudraCT2022-000581-17, NCT05278156, NCT05227690, NCT05227703, EudraCT2020-004752-16, jRCT2071200096, jRCT2031200287, jRCT2031200288, EudraCT2020-000094-24, NCT04624243, EudraCT2020-000437-41, EudraCT2020-000439-32, NCT04521868, NCT04512066, NCT04461119, EudraCT2020-002316-51, NCT04158687, NCT03983018, jRCTs031180371, NCT03859973, EudraCT2018-004618-17, EudraCT2018-002708-15, NCT03697252, EudraCT2018-001581-42, jRCT2080223908, NCT03510741, JapicCTI-183893, EudraCT2017-003471-54, NCT03382639, NCT03359785, NCT03319953, EudraCT2017-000788-34"
What completed Phase II clinical trials for cognitive impairment in schizophrenia exist up to April 2025? Provide the trial IDs .,"NCT02953639, NCT01911676, NCT01730768, NCT01678755, NCT01655680, EudraCT2012-000418-13, NCT01266174, NCT01095562, NCT01077700, NCT01003379, NCT00968851, NCT00963846, NCT00848484, NCT00810667, NCT00615511, NCT00588731, NCT00528905, NCT00506077, NCT00505076, NCT00487942, NCT00482430, NCT04822883, EudraCT2018-003825-27, JapicCTI-195032, NCT03745820, NCT03557931"
What completed Phase II clinical trials for Crohn's disease exist up to April 2025? Provide the trial IDs .,"NCT05940558, EudraCT2021-002869-18, ISRCTN10684113, EudraCT2021-000092-37, jRCT2031200406, NCT04321941, EudraCT2019-004219-29, EudraCT2019-002895-14, NCT04186247, NCT04056442, EudraCT2019-000886-19, jRCTs041180126, NCT03854305, EudraCT2018-003303-19, CTR20182464, jRCT2080224183, NCT03752970, NCT03733314, EudraCT2017-003090-34, jRCT2080224078, NCT03677648, EudraCT2018-001272-37, EudraCT2017-001976-48, jRCT2080223890, EudraCT2017-003359-43, NCT03476317, NCT03395184, EudraCT2017-003017-25, EudraCT2017-002258-36, EudraCT2016-003153-15, NCT03077412, EudraCT2016-003179-23, NCT03046056, EudraCT2016-002204-84, NCT02891226, NCT02877134, EudraCT2016-000634-21, NCT02765256, EudraCT2015-000609-38, EudraCT2015-002025-19, EudraCT2015-001678-17, NCT02531113, EudraCT2015-001249-10, NCT02513459, NCT02501291, EudraCT2015-001834-15, EudraCT2014-003240-12, NCT02389790, NCT02378688, NCT02365649, EudraCT2014-001295-65, EudraCT2014-002556-77, EudraCT2014-002557-19, EudraCT2014-001892-30, CTR20130986, NCT02048618, NCT02031276, NCT02015793, EudraCT2013-002857-32, EudraCT2013-002902-29, JapicCTI-132108, jRCT2080222062, NCT01783106, EudraCT2012-004098-26, JapicCTI-122033, JapicCTI-122029, JapicCTI-122031, JapicCTI-122027, JapicCTI-122026, NCT01751152, UMIN000009284, NCT01714726, NCT01696396, NCT01692808, EudraCT2012-000529-31, EudraCT2012-002432-93, EudraCT2011-005886-19, EudraCT2011-004763-72, UMIN000007514, EudraCT2011-003622-27, EudraCT2011-002981-19, NCT01470599, NCT01466374, EudraCT2011-001733-16, EudraCT2011-001754-28, NCT01393626, NCT01393899, NCT01355614, EudraCT2011-000722-30, EudraCT2010-023437-30, EudraCT2010-024638-48, NCT01345318, NCT01345799, EudraCT2010-023034-23, EudraCT2011-000854-44, NCT01298492, NCT01291810, NCT01287897, EudraCT2010-024528-12, NCT01276509, NCT01233570, EudraCT2010-019996-32, NCT01203631, EudraCT2010-020836-21, NCT01190410, EudraCT2010-019544-39, NCT01155362, EudraCT2009-010225-39, EudraCT2009-011621-14, UMIN000002074, EudraCT2009-011763-37, ISRCTN77283008, EudraCT2008-008359-40, EudraCT2008-007445-31, EudraCT2008-001137-99, EudraCT2008-004919-36, NCT00771667, EudraCT2008-000649-77, NCT00741910, NCT00739986, NCT00740103, NCT00737932, EudraCT2008-004276-49, NCT00715117, EudraCT2008-003571-45, JapicCTI-080566, NCT00655135, NCT00615199, NCT00609973, NCT00528073, EudraCT2007-000189-19, EudraCT2007-001014-17, NCT00454545, NCT00446433, NCT00417391, JapicCTI-060251, JapicCTI-060252, NCT00329420, NCT00329550, JapicCTI-060230, NCT00308438, NCT00306215, ISRCTN16473514, NCT00294112, NCT00291668, NCT00267722, NCT00265122, NCT00250198, EudraCT2005-002319-26, NCT00234741, NCT00105261, NCT00221026, NCT00206596, NCT00138840, EudraCT2005-001148-22, NCT00109473, EudraCT2004-004854-19, NCT00102921, NCT00101946, EudraCT2004-004388-31, EudraCT2004-002693-37, NCT00072943, NCT00072839, NCT00055523, NCT00055536, NCT00055367, NCT00042055, NCT00040521"
What completed Phase II clinical trials for perianal fistulas in Crohn's disease exist up to April 2025? Provide the trial IDs .,"NCT01316601, NCT00267709, EudraCT2004-004387-72"
What completed Phase II clinical trials for Crohn's fistula exist up to April 2025? Provide the trial IDs .,NCT01011244
What completed Phase II clinical trials for fibrostenosing crohn's disease  exist up to April 2025? Provide the trial IDs .,EudraCT2020-005770-99
What completed Phase III clinical trials for metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs .,"NCT05284448, NCT03723252, NCT03439254, EudraCT2016-004374-18, NCT01934777, EudraCT2012-000975-18, EudraCT2009-015166-62, NCT01051219, ISRCTN57849521, UMIN000001258, EudraCT2007-003012-61, NCT00108589, NCT00063622"
What completed Phase III clinical trials for schizophrenia exist up to April 2025? Provide the trial IDs .,"EudraCT2016-003434-24, NCT03043820, NCT02970292, EudraCT2006-006434-17, NCT02892422, NCT02873208, EudraCT2015-003284-11, EudraCT2016-000060-42, EudraCT2016-000061-23, jRCT2080223209, JapicCTI-163264, jRCT2080223187, NCT02717195, EudraCT2014-003569-12, NCT02772393, NCT02694328, EudraCT2015-003880-13, EudraCT2015-004835-10, NCT02669758, NCT02634346, NCT02469155, NCT02431702, JapicCTI-152765, NCT02335658, jRCT2080222713, NCT02287584, NCT02282761, JapicCTI-142688, jRCT2080222637, CTR20131380, CTR20131465, CTR20140617, NCT02194933, NCT02142556, CTR20130412, NCT02054702, NCT02013622, NCT02002832, NCT01999309, EudraCT2013-001695-38, NCT01979679, JapicCTI-132324, JapicCTI-132325, NCT01942148, NCT01911429, NCT01895452, EudraCT2010-018408-96, EudraCT2010-018407-28, NCT01821378, NCT01810783, NCT01810380, EudraCT2012-005485-36, EudraCT2012-002252-17, EudraCT2012-002705-21, EudraCT2011-005766-38, EudraCT2012-003996-20, EudraCT2012-003445-15, NCT01716975, KCT0000544, NCT01668797, NCT01662310, NCT01662648, EudraCT2011-004790-90, NCT01626456, NCT01617187, NCT01617200, JapicCTI-121859, JapicCTI-121860, NCT01614899, NCT01614912, jRCT2080221816, jRCT2080221817, NCT01606228, NCT01573637, NCT01566162, NCT01561898, EudraCT2004-002185-38, EudraCT2011-001711-31, NCT01541371, EudraCT2011-000245-20, NCT01516424, jRCT2080221682, jRCT2080221683, JapicCTI-111724, JapicCTI-111725, EudraCT2011-004327-13, NCT01469039, EudraCT2011-002513-11, EudraCT2011-002048-29, NCT01456897, NCT01452919, NCT01448720, JapicCTI-111632, EudraCT2011-002292-41, jRCT2080221592, JapicCTI-111627, jRCT2080221587, NCT01435928, EudraCT2011-002514-37, EudraCT2011-002538-38, NCT01412060, NCT01397786, NCT01396421, NCT01393613, JapicCTI-111526, jRCT2080221487, EudraCT2010-023550-36, JapicCTI-111430, NCT01299389, NCT01295372, NCT01291511, CTRI/2011/091/000140, NCT01281527, EudraCT2009-018038-12, JapicCTI-111384, EudraCT2009-017971-10, EudraCT2010-022181-28, NCT01258920, NCT01244828, EudraCT2010-021143-41, NCT01235520, NCT01235559, NCT01235585, CTRI/2010/091/001068, CTRI/2010/091/001400, NCT01192867, NCT01192880, NCT01192906, NCT01190254, NCT01190267, jRCT2080221140, NCT01149655, NCT01143077, NCT01143090, NCT01142596, JapicCTI-101156, JapicCTI-101146, JapicCTI-101147, CTRI/2010/091/000502, jRCT2080221112, jRCT2080221113, NCT01129882, NCT01121042, NCT01104766, NCT01104779, NCT01104792, NCT01098110, NCT01081769, NCT01359293, NCT01051531, NCT01009047, EudraCT2009-014811-11, NCT01001702, ACTRN12609000528257, ISRCTN44297014, NCT00882518, NCT00864045, NCT00856583, NCT00843687, NCT00789698, NCT00790192, NCT00759421, NCT00759460, NCT00712686, NCT00711269, JapicCTI-080585, jRCT2080220563, NCT00668837, ISRCTN97049967, NCT00654706, NCT00650793, NCT00649844, NCT00645099, NCT00645307, NCT00645372, NCT00641745, NCT00640562, NCT00640601, NCT00615433, EudraCT2007-005773-63, NCT00604279, NCT00600756, NCT00589914, NCT00590577, EudraCT2007-004246-32, NCT00566631, NCT00558298, NCT00549718, NCT00535574, NCT00523445, NCT00518323, NCT00495118, EudraCT2006-006967-22, NCT00488319, NCT00485901, NCT00473434, EudraCT2006-006642-34, EudraCT2007-000577-38, NCT00460512, EudraCT2006-005734-20, NCT00435370, EudraCT2006-004265-34, NCT00412373, NCT00403546, NCT00397033, NCT00396565, EudraCT2006-003560-62, NCT00380224, NCT00372151, NCT00366171, NCT00350467, NCT00347425, NCT00334126, NCT00328978, NCT00305422, EudraCT2005-000497-50, NCT00304473, NCT00297388, NCT00292409, EudraCT2004-000750-22, NCT00283179, NCT00265343, JapicCTI-050178, NCT00254813, NCT00254202, NCT00250575, NCT00249119, NCT00249132, NCT00246272, NCT00246285, EudraCT2005-002169-35, NCT00239356, NCT00237913, NCT00237939, NCT00236353, NCT00236587, NCT00237809, NCT00237848, NCT00234377, NCT00230828, EudraCT2004-003340-22, NCT00228462, EudraCT2005-002979-33, NCT00216580, NCT00147173, NCT00206115, NCT00206128, NCT00210548, NCT00210691, NCT00210717, NCT00210769, NCT00212771, NCT00212784, NCT00212836, NCT00193687, NCT00193713, NCT00174265, NCT00174447, JapicCTI-050100, jRCT2080220098, ACTRN12605000363684, NCT00156065, NCT00156091, NCT00156104, NCT00156117, NCT00159770, NCT00161018, NCT00151424, NCT00148447, NCT00149734, NCT00150176, NCT00148083, NCT00145444, NCT00145496, NCT00143351, NCT00139737, NCT00119756, EudraCT2004-000707-18, EudraCT2005-001845-40, NCT00111189, EudraCT2004-000830-35, NCT00102063, NCT00101569, NCT00101634, EudraCT2004-002560-17, EudraCT2004-002694-22, NCT00095524, EudraCT2004-001376-39, EudraCT2004-000986-37, EudraCT2004-001181-41, NCT00090324, EudraCT2004-000913-21, EudraCT2004-000912-13, NCT00088465, NCT00088075, NCT00086593, NCT00086320, EudraCT2004-000326-70, NCT00085891, NCT00085748, NCT00083668, NCT00078039, NCT00077714, NCT00073320, NCT00071747, NCT00051298, NCT00036361, NCT00034749, NCT00034775, NCT00034892, NCT00000371, NCT06572449, CTR20240938, NCT05628103, CTR20222759, jRCT2031220096, EudraCT2021-004193-64, jRCT2031220039, EudraCT2021-002572-39, NCT05145413, EudraCT2021-002068-30, NCT04959032, NCT04860830, NCT04846868, NCT04846881, EudraCT2020-003744-84, NCT04820309, NCT04738123, EudraCT2020-003726-23, EudraCT2020-003760-11, NCT04659161, NCT04659174, NCT04531982, NCT04327843, NCT04115319, EudraCT2019-003343-29, NCT04092686, NCT04072354, NCT04072575, EudraCT2017-000818-34, EudraCT2019-000696-16, NCT03874494, ISRCTN16522451, NCT03848234, EudraCT2017-001447-12, NCT03510325, NCT03465787, NCT03397134, EudraCT2017-003333-29, NCT03345979, NCT03198078, EudraCT2016-003437-18"
What completed Phase III clinical trials for cognitive impairment in schizophrenia exist up to April 2025? Provide the trial IDs .,"NCT01714661, NCT01714713, NCT00733057, NCT00077727"
What completed Phase III clinical trials for agitation associated with schizophrenia exist up to April 2025? Provide the trial IDs .,"NCT00970281, NCT00797277, NCT00723606, NCT00640510"
What completed Phase III clinical trials for Crohn's disease exist up to April 2025? Provide the trial IDs .,"EudraCT2022-002389-33, CTR20211103, EudraCT2020-004301-31, CTR20190772, CTRI/2020/10/028507, EudraCT2019-001866-14, jRCTs021200013, CTR20200092, NCT04245215, CTR20190773, EudraCT2018-004614-18, NCT03926130, NCT03782376, CTR20181735, CTR20181733, EudraCT2017-004209-41, EudraCT2017-000575-88, EudraCT2017-000576-29, EudraCT2017-000617-23, NCT03464136, NCT03440385, EudraCT2017-004293-33, NCT03345836, NCT03345849, EudraCT2017-001226-18, EudraCT2017-001240-35, CTRI/2017/08/009477, NCT03234907, CTR20170820, EudraCT2016-003190-17, EudraCT2016-003123-32, NCT03107793, NCT03104413, NCT03105128, EudraCT2016-002918-43, EudraCT2015-001924-40, NCT03009396, EudraCT2016-001367-36, EudraCT2016-002763-34, NCT02914561, NCT02772965, EudraCT2015-001963-37, EudraCT2015-001925-18, CTR20150507, NCT02499783, EudraCT2015-001179-36, NCT02425111, EudraCT2014-003509-13, NCT02394028, EudraCT2014-003824-36, EudraCT2014-003855-76, NCT02255370, EudraCT2013-004034-15, NCT02186275, NCT02185014, EudraCT2013-001746-33, NCT02065570, JapicCTI-142426, jRCT2080222376, NCT02038920, jRCT2080222352, NCT01958827, NCT01951326, EudraCT2013-002838-20, EudraCT2013-000971-34, NCT01661257, NCT01580670, NCT01564823, JapicCTI-121765, NCT01514240, EudraCT2011-002817-12, EudraCT2011-000885-36, NCT01369329, NCT01369342, NCT01369355, EudraCT2010-022758-18, EudraCT2010-022759-42, EudraCT2010-022760-12, NCT01277666, EudraCT2010-022384-35, NCT01235689, NCT01233960, EudraCT2010-022383-12, EudraCT2009-016488-12, EudraCT2010-022382-10, NCT01224171, EudraCT2010-020137-10, EudraCT2010-018431-18, NCT01086553, NCT01070303, NCT00976690, EudraCT2008-006957-42, NCT00946946, EudraCT2008-005688-32, JapicCTI-080663, NCT00805766, NCT00783692, EudraCT2008-002783-33, EudraCT2007-006494-90, EudraCT2008-002100-26, NCT00686374, NCT00613197, NCT00571337, NCT00552058, NCT00552344, EudraCT2007-001913-41, EudraCT2007-002716-26, NCT00543374, NCT00509639, NCT00482092, NCT00609232, EudraCT2006-004814-41, NCT00427921, EudraCT2006-003371-13, EudraCT2005-003977-25, NCT00409617, NCT00409682, EudraCT2006-003871-11, EudraCT2006-003870-88, EudraCT2006-002027-16, EudraCT2006-001729-24, EudraCT2006-002078-23, NCT00356408, NCT00348283, NCT00338650, NCT00333788, EudraCT2005-005291-32, NCT00308581, NCT00300118, NCT00297648, EudraCT2005-004104-37, NCT00269841, NCT00269386, NCT00185497, NCT00206674, NCT00207662, NCT00207675, NCT00207766, NCT00195715, NCT00160524, NCT00160706, NCT00152425, NCT00152490, NCT00132899, EudraCT2004-002934-20, EudraCT2004-003839-31, EudraCT2004-002815-10, NCT00105300, EudraCT2004-004083-77, EudraCT2004-001109-81, EudraCT2004-001213-34, NCT00094458, EudraCT2004-002163-24, NCT00078611, NCT00077779, NCT00074542, NCT00055497, NCT00048295, NCT00048113, NCT00032786, NCT00032799, NCT00004941"
What completed Phase III clinical trials for perianal fistulas in Crohn's disease exist up to April 2025? Provide the trial IDs .,"NCT06441526, NCT04075825, NCT03706456, NCT03279081, NCT01541579, NCT00736983"
What completed Phase III clinical trials for Crohn's fistula exist up to April 2025? Provide the trial IDs .,EudraCT2005-005363-28
What completed clinical trials related to target CD3ε and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT00630643, Phase I/II; EudraCT2005-004313-15, Phase I/II"
What completed clinical trials related to target NPY5R and disease cognitive impairment in schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT00482430, Phase II"
What completed clinical trials related to target GPR139 and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02748694, Phase I; NCT03319953, Phase II"
What completed clinical trials related to target MAO-B and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT00456976, Phase I"
What completed clinical trials related to target DHFR and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02074319, Phase I"
What completed clinical trials related to target IL-18 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT03681067, Phase I/II"
What completed clinical trials related to target PDE and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02260830, Phase I; EudraCT2018-002708-15, Phase II; EudraCT2018-001581-42, Phase II"
What completed clinical trials related to target H3 receptor and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT01009060, Phase II; NCT00888693, Phase I; NCT00690274, Phase II"
What completed clinical trials related to target IL-12p40 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"ChiCTR2400084547, Phase IV; NCT04245215, Phase III; EudraCT2018-004269-14, Phase IV; EudraCT2019-002038-35, Phase IV; NCT03782376, Phase III; EudraCT2017-005151-83, Phase IV; EudraCT2017-004209-41, Phase III; NCT03464136, Phase III; NCT03107793, Phase III; EudraCT2016-002918-43, Phase III; NCT02968108, Phase I; EudraCT2016-001956-22, Phase I; NCT01369329, Phase III; NCT01369342, Phase III; NCT01369355, Phase III; EudraCT2010-022758-18, Phase III; EudraCT2010-022759-42, Phase III; EudraCT2010-022760-12, Phase III; EudraCT2008-004919-36, Phase II; NCT00771667, Phase II; EudraCT2008-000649-77, Phase II; NCT00265122, Phase II; NCT00007163, Phase I"
What completed clinical trials related to target LOXL2 and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"ACTRN12617001444370, Phase I"
What completed clinical trials related to target COX and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT01578486, Phase IV; ISRCTN27745631, Other"
What completed clinical trials related to target GPR84 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"EudraCT2014-001892-30, Phase II"
What completed clinical trials related to target 30S subunit and disease cognitive impairment in schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT00733057, Phase III"
What completed clinical trials related to target 5-HT3 receptor and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02389881, Phase I; NCT01121042, Phase III; NCT03669250, Phase I"
What completed clinical trials related to target ACL and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT06491576, Phase I/II; CTR20230344, Phase I/II"
What completed clinical trials related to target GlyT1 and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02832037, Phase II; EudraCT2016-000285-28, Phase II; JapicCTI-122010, Phase I; jRCT2080221964, Phase I; EudraCT2011-004844-23, Phase II; NCT01503359, Phase II; JapicCTI-111627, Phase III; jRCT2080221587, Phase III; EudraCT2010-021984-33, Phase II/III; NCT01235520, Phase III; NCT01235559, Phase III; NCT01235585, Phase III; NCT01234779, Phase II; NCT01192867, Phase III; NCT01192880, Phase III; NCT01192906, Phase III; NCT01116830, Phase I; NCT00934466, Phase I; NCT00725075, Phase II; NCT00616798, Phase II; NCT04860830, Phase III; NCT04846868, Phase III; NCT04846881, Phase III; EudraCT2020-003744-84, Phase III; EudraCT2020-003726-23, Phase III; EudraCT2020-003760-11, Phase III; NCT03859973, Phase II; jRCT2080223908, Phase II"
What completed clinical trials related to target CXCL10 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"EudraCT2011-002981-19, Phase II; NCT01466374, Phase II"
What completed clinical trials related to target ERβ and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT00245947, Phase I"
What completed clinical trials related to target PDE2A and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT01429740, Phase I"
What completed clinical trials related to target ISBT and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT02571192, Phase I; NCT02287779, Phase I"
What completed clinical trials related to target viral polymerase and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02008773, Phase II; NCT01794897, Phase IV; NCT01364792, Phase II"
What completed clinical trials related to target α7 receptor and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02978599, Phase I; NCT02331433, Phase I; NCT02205099, Phase I/II; NCT01716975, Phase III; EudraCT2011-005138-21, Phase II; NCT01556763, Phase I; NCT01488929, Phase II; NCT01400477, Phase II; NCT01163227, Phase II; NCT01043458, Phase I; NCT00825539, Phase I/II; NCT00255918, Phase I; NCT00100165, Phase II; NCT03356639, Phase I"
What completed clinical trials related to target RANKL and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT02321280, Phase I/II"
What completed clinical trials related to target IL-23R and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"ACTRN12617001426370, Phase I"
What completed clinical trials related to target α7 receptor and disease cognitive impairment in schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT01730768, Phase II; NCT01714661, Phase III; NCT01714713, Phase III; NCT01678755, Phase II; NCT01655680, Phase II; EudraCT2012-000418-13, Phase II; NCT01095562, Phase II; NCT01003379, Phase II; NCT00968851, Phase II"
What completed clinical trials related to target IL-6 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"EudraCT2011-004763-72, Phase II; EudraCT2011-000722-30, Phase II; NCT01345318, Phase II; EudraCT2010-023034-23, Phase II; NCT01287897, Phase II"
What completed clinical trials related to target AMPA receptor and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02332798, Phase I; NCT01518894, Phase I; NCT01511510, Phase I; EudraCT2007-001611-32, Phase II; NCT00448890, Phase I; NCT00235352, Phase II/III"
What completed clinical trials related to target amino acid and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT00838149, Phase I"
What completed clinical trials related to target TYK2 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"jRCT2080224183, Phase II; EudraCT2017-001976-48, Phase II; TWCT00002043, Phase II"
What completed clinical trials related to target ICAM-1 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT00048295, Phase III; NCT00048113, Phase III"
What completed clinical trials related to target D2 receptor and disease agitation associated with schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT00866645, Phase II/III"
What completed clinical trials related to target D1 receptor and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02720263, Phase I"
What completed clinical trials related to target GLP-1R and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02417142, Phase IV; EudraCT2013-000121-31, Phase II"
What completed clinical trials related to target estrogen and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT00206570, Phase II; NCT03848234, Phase III"
What completed clinical trials related to target VAP-1 and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT04897594, Phase I; EudraCT2016-000499-83, Phase II"
What completed clinical trials related to target IL-21 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT01751152, Phase II; EudraCT2012-002432-93, Phase II"
What completed clinical trials related to target glucocorticoid and disease cognitive impairment in schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT00615511, Phase II"
What completed clinical trials related to target HDAC and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02880462, Phase II; NCT02810964, Phase II; NCT01716858, Phase II; NCT04521868, Phase II"
What completed clinical trials related to target PDE and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"CTR20200207, Phase I/II; NCT04140123, Phase I/II; NCT03392779, Phase I; CTR20171627, Phase I"
What completed clinical trials related to target THR-β and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT06342947, Phase II; NCT05552274, Phase I; NCT05090111, Phase I; NCT04643795, Phase I; NCT04173065, Phase II"
What completed clinical trials related to target vitamin E and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"EudraCT2009-018054-33, Phase IV"
What completed clinical trials related to target ADM and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"jRCT2080223890, Phase II"
What completed clinical trials related to target sodium channel and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT02624167, Phase II; NCT01955564, Phase I; NCT00637234, Phase II/III; NCT00086593, Phase III; NCT00071747, Phase III; EudraCT2020-006062-36, Phase II/III; EudraCT2020-000437-41, Phase II; EudraCT2020-000439-32, Phase II; NCT04461119, Phase II"
What completed clinical trials related to target μ opioid receptor and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"EudraCT2013-002193-45, Phase II; NCT01903837, Phase II"
What completed clinical trials related to target folic acid and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT00249288, Phase IV"
What completed clinical trials related to target glucocorticoid and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"CTR20221643, Phase I; NCT01086553, Phase III; EudraCT2008-006957-42, Phase III; JapicCTI-080566, Phase II; NCT00300118, Phase III; EudraCT2004-001109-81, Phase III; EudraCT2004-001213-34, Phase III"
What completed clinical trials related to target S1PR1 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT02389790, Phase II; NCT02378688, Phase II; EudraCT2014-002556-77, Phase II; EudraCT2014-002557-19, Phase II; NCT02148185, Phase I; JapicCTI-132108, Phase II; jRCT2080222062, Phase II"
What completed clinical trials related to target BH4 and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT01706965, Phase I/II"
What completed clinical trials related to target DGAT2 and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT04932512, Phase II"
What completed clinical trials related to target CD49d and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT03093064, Phase I"
What completed clinical trials related to target CCR9 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT05452304, Phase I; NCT01827631, Phase I; NCT01611805, Phase I; EudraCT2011-002817-12, Phase III; JapicCTI-111457, Other; NCT01277666, Phase III; EudraCT2010-022384-35, Phase III; EudraCT2010-022383-12, Phase III; EudraCT2010-022382-10, Phase III; NCT01114607, Phase I; NCT00306215, Phase II; ISRCTN58248439, Other; NCT00102921, Phase II"
What completed clinical trials related to target DNMT1 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT02255370, Phase III"
What completed clinical trials related to target PDE4 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT00989573, Phase II/III; jRCT2080220884, Phase II/III"
What completed clinical trials related to target NOP and disease cognitive impairment in schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT00848484, Phase II"
What completed clinical trials related to target Cyp and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT05737433, Phase I; NCT05461105, Phase II; NCT04480710, Phase II"
What completed clinical trials related to target TNF-α and disease perianal fistulas in Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT01624376, Phase I/II"
What completed clinical trials related to target KHK and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT03969719, Phase II"
What completed clinical trials related to target IL-13 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT01355614, Phase II"
What completed clinical trials related to target bile acid and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT01066364, Phase II; NCT00470171, Phase II"
What completed clinical trials related to target GLP-2 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT00308438, Phase II; NCT00072839, Phase II"
What completed clinical trials related to target GM-CSF and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT00185497, Phase III; NCT00206596, Phase II; NCT00206674, Phase III"
What completed clinical trials related to target SERT and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT01041274, Phase IV; NCT00456937, Phase IV; NCT00148447, Phase III; ChiCTR-INR-17011986, Other"
What completed clinical trials related to target G-CSF and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT00025805, Phase I"
What completed clinical trials related to target DNMT1 and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"ISRCTN27793187, Phase II"
What completed clinical trials related to target CysLT1 and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT04080947, Phase I/II"
What completed clinical trials related to target IL-11 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"NCT00040521, Phase II"
What completed clinical trials related to target sGC and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT04972227, Phase I"
What completed clinical trials related to target FAS and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT05835180, Phase I; NCT04906421, Phase II; CTR20192369, Phase II; CTR20192517, Phase I; NCT03938246, Phase II"
What completed clinical trials related to target FGF19 and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT03912532, Phase II; NCT02443116, Phase II"
What completed clinical trials related to target IL-23p19 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"CTR20223375, Phase I; EudraCT2022-002389-33, Phase III; NCT05567029, Phase I; CTR20190772, Phase III; CTRI/2020/10/028507, Phase III; EudraCT2019-001866-14, Phase III; CTR20200092, Phase III; CTR20190773, Phase III; EudraCT2018-004346-42, Phase II/III; EudraCT2018-004614-18, Phase III; NCT03926130, Phase III; EudraCT2016-003190-17, Phase III; EudraCT2016-003123-32, Phase III; NCT03104413, Phase III; NCT03105128, Phase III; EudraCT2016-002204-84, Phase II; NCT02891226, Phase II; EudraCT2015-000609-38, Phase II; NCT02513459, Phase II; EudraCT2015-001834-15, Phase II; NCT02031276, Phase II; EudraCT2013-002902-29, Phase II; EudraCT2012-004098-26, Phase II; NCT01714726, Phase II; NCT01258205, Phase I; TWCT00002239, Phase III"
What completed clinical trials related to target Fe and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT01278056, Phase I/II"
What completed clinical trials related to target androgen and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT01919294, Phase II"
What completed clinical trials related to target AChE and disease cognitive impairment in schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT00963846, Phase II"
What completed clinical trials related to target 50S subunit and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT02510599, Phase II"
What completed clinical trials related to target SCD1 and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT05874336, Phase I; NCT02279524, Phase II"
What completed clinical trials related to target T-type calcium channel and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT00827918, Phase II"
What completed clinical trials related to target MMP9 and disease Crohn's disease exist up to April 2025? Provide the trial IDs and stages.,"EudraCT2015-001249-10, Phase II"
What completed clinical trials related to target eotaxin-2 and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT05824156, Phase II"
What completed clinical trials related to target GCCR and disease metabolic dysfunction-associated steatohepatitis  exist up to April 2025? Provide the trial IDs and stages.,"NCT05553470, Phase I; NCT05117489, Phase I"
What completed clinical trials related to target D2 receptor and disease schizophrenia exist up to April 2025? Provide the trial IDs and stages.,"NCT01812642, Phase II; EudraCT2007-007083-22, Phase II; NCT00728195, Phase II; NCT00722176, Phase II; EudraCT2007-007669-20, Phase II; NCT00580125, Phase II; NCT00567710, Phase II; NCT00480571, Phase II"
What caused the termination of clinical trial NCT02769091?,Business decision
What caused the termination of clinical trial NCT00577148?,Company decision taken in light of demands by certain national health authorities
What caused the termination of clinical trial NCT04583423?,Business reasons
What caused the termination of clinical trial ISRCTN44563171?,Participant recruitment issue
What caused the termination of clinical trial NCT02605616?,Astra Zeneca notified Dr. Rita Basu that they will not manufacture new drug due to business reasons and study was stopped.
What caused the termination of clinical trial NCT00406653?,Sponsor Decision
What caused the termination of clinical trial NCT02144155?,Break in funding
What caused the termination of clinical trial NCT01570348?,Annual accrual goal not met
What caused the termination of clinical trial NCT03059446?,This study was terminated early due to lack of efficacy based on the results of Part I of the AURORA study.
What caused the termination of clinical trial NCT04456517?,Low accrual and subject engagement
What caused the termination of clinical trial NCT00929370?,Study has now been terminated due to changes in project strategy. Current available data will be analysed and reported in a synoptic study report.
What caused the termination of clinical trial NCT01900522?,Business Decision; No Safety or Efficacy Concerns
What caused the termination of clinical trial NCT04151225?,Internal sponsor decision to terminate project in Crohn's disease due to potential narrow therapeutic window. No subjects were enrolled
What caused the termination of clinical trial NCT00916201?,Lack of funding
What caused the termination of clinical trial NCT05890768?,PI was unable to meet 1 year recruitment goal
What caused the termination of clinical trial NCT03467958?,Business objectives have changed
What caused the termination of clinical trial NCT03010865?,sponsor withdrew the funds because the smell of sodium butyrate made blinding impossible
What caused the termination of clinical trial ACTRN12613000970741?,Participant recruitment difficulties
What caused the termination of clinical trial NCT05688852?,Sponsor Decision
What caused the termination of clinical trial NCT01880307?,Not enough study subjects
What caused the termination of clinical trial NCT02914600?,development program for filgotinib for participants with Crohn's disease has been stopped
What caused the termination of clinical trial NCT01696942?,Lack of accrual
What caused the termination of clinical trial NCT00307931?,Study was terminated early because of slow recruitment
What caused the termination of clinical trial NCT00857818?,Slow Accrual
What caused the termination of clinical trial NCT05359081?,Due to company business strategy
What caused the termination of clinical trial ACTRN12616001638426?,Other reasons/comments: We will have adequate 6 month outcome measures with the final collection date on the 30/09/2020 to have a meaningful statistical analysis.
What caused the termination of clinical trial NCT01487083?,The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.
What caused the termination of clinical trial NCT03053063?,This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.
What caused the termination of clinical trial NCT01545050?,due to sponsor decision
What caused the termination of clinical trial NCT04643483?,Sponsor decision
What caused the termination of clinical trial NCT04216693?,Administrative decision to terminate.
What caused the termination of clinical trial NCT04395950?,Poor enrollment
What caused the termination of clinical trial NCT01465074?,Limited staff and operating resources
What caused the termination of clinical trial NCT04340102?,Study was not funded.
What caused the termination of clinical trial NCT04530877?,no funding
What caused the termination of clinical trial NCT02021201?,No suitable patients could be recruited in the available time period
What caused the termination of clinical trial NCT02435095?,"slow patient recruitment, low patient-commpliance, high dropout rates,"
What caused the termination of clinical trial NCT00936585?,Study halted by the sponsor
What caused the termination of clinical trial NCT03291249?,Due to MOH request.
What caused the termination of clinical trial NCT00712270?,Study terminated due to failure to meet sufficient enrollment for valid analysis
What caused the termination of clinical trial NCT05013385?,Sponsor decision
What caused the termination of clinical trial NCT03416569?,Unanticipated staff changes are preventing completion within funding period.
What caused the termination of clinical trial NCT01674413?,Unable to recruit; all patients interested simply wanted to stop medication
What caused the termination of clinical trial NCT01433432?,Sponsor withdrew support for study due to reorganization and project prioritization
What caused the termination of clinical trial NCT05836883?,Enrollment challenges.
What caused the termination of clinical trial NCT02234752?,Funding no longer available and PI no longer working at the institution
What caused the termination of clinical trial NCT02974322?,Sponsor decision not to start trial
What caused the termination of clinical trial NCT01122927?,The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational Plan was met and provided 2 years of safety data.
What caused the termination of clinical trial NCT01813955?,Patient recruitment insufficient
What caused the termination of clinical trial NCT02677350?,Study is permanently closed to enrollment
What caused the termination of the clinical trial for mongersen developed by Celgene?,Study terminated by Sponsor following a recommendation from external DMC to terminate the ongoing Phase 3 CD studies; there were no new emergent safety findings
What caused the termination of the clinical trial for OPS-2071 developed by Otsuka?,Sponsor Decision
What caused the termination of the clinical trial for tetomilast developed by Otsuka?,Efficacy was not cleared at US study
What caused the termination of the clinical trial for zotepine developed by Astellas Pharma?,Study was stopped due to difficulty in patient enrollment
What caused the termination of the clinical trial for vitamin E developed by Indiana University School of Medicine?,lack of coordinator resources and lack of access to study resources during and due to the COVID pandemic
"What caused the termination of the clinical trial for dexamethasone
dexamethasone phosphate developed by Quince Therapeutics?",due to the difficulty to enroll suitable patients
What caused the termination of the clinical trial for izencitinib developed by Theravance Biopharma?,The study was terminated by the sponsor on 16 November 2021 after a planned review by the Independent Data Monitoring Committee.
What caused the termination of the clinical trial for vedolizumab developed by Takeda Pharmaceuticals?,Early Completed - Alternative Source of Drug Available
What caused the termination of the clinical trial for sertindole developed by University of Zurich?,Not enough subjects have been recruited in the expected period.
What caused the termination of the clinical trial for Aramchol developed by Galmed Pharmaceuticals?,Interim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.
What caused the termination of the clinical trial for brodalumab developed by Amgen?,The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups
What caused the termination of the clinical trial for aripiprazole developed by Louisiana State University?,Enrollment too difficult
"What caused the termination of the clinical trial for caffeine
warfarin
ustekinumab
phytonadione
omeprazole
midazolam
dextromethorphan developed by Johnson & Johnson?",The study was stopped as all post-marketing commitments had been fulfilled or released
What caused the termination of the clinical trial for rifaximin developed by Imperial College London?,Primary endpoint data review concluded no further patients required.
What caused the termination of the clinical trial for deudextromethorphan+quinidine developed by Otsuka?,"Based on the Interim Analysis outcome and recommendation by the DMC, Otsuka approved termination of the study based on futility."
What caused the termination of the clinical trial for rimonabant developed by Sanofi?,Company decision taken in light of demands by certain national health authorities
What caused the termination of the clinical trial for infliximab developed by Janssen Biotech?,Study is terminated as per Sponsor's Decision.
What caused the termination of the clinical trial for selonsertib developed by Gilead Sciences?,This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.
What caused the termination of the clinical trial for brazikumab developed by AstraZeneca?,Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
What caused the termination of the clinical trial for ustekinumab developed by Hospices Civils de Lyon?,No inclusion
"What caused the termination of the clinical trial for vedolizumab
W10 developed by CHU Centre Hospitalier Universitaire de Saint?",The study was stopped due to lack of inclusions
What caused the termination of the clinical trial for mifepristone developed by Stanford University?,Lack of funding.
What caused the termination of the clinical trial for paliperidone palmitate developed by Johnson & Johnson?,This study was stopped due to an internal reconsideration of priorities of the product portfolio.
What caused the termination of the clinical trial for AZD0328 developed by AstraZeneca?,"Since AZD0328 is unlikely to meet the current Target Product Profile, Astrazeneca decided to stop further development of AZD0328"
"What caused the termination of the clinical trial for amino acids
dextrose
fat emulsion  developed by University of Miami?",Difficulty in recruiting patients
What caused the termination of the clinical trial for brexpiprazole developed by Lundbeck?,This study was withdrawn for administrative reasons. There were no safety concerns.
What caused the termination of the clinical trial for cholecalciferol developed by University of Saskatchewan?,We couldn't recruit the sample the we required
What caused the termination of the clinical trial for APN1125 developed by CoMentis?,Study halted by sponsor for business reasons
What caused the termination of the clinical trial for cyclophosphamide developed by Johns Hopkins University?,Too difficult to recruit given new Crohn's medications approved
What caused the termination of the clinical trial for certolizumab pegol developed by UCB?,Study was terminated early because of slow recruitment
What caused the termination of the clinical trial for PF-06412562 developed by Pfizer?,Study recruitment was terminated on 14 June 2016 due to a Pfizer business decision. This study was not terminated for reasons of safety.
What caused the termination of the clinical trial for bifeprunox developed by Lundbeck?,Interim analysis showed inadequate efficacy of bifeprunox
What caused the termination of the clinical trial for spesolimab developed by Boehringer Ingelheim?,Sponsor decision
What caused the termination of the clinical trial for bifeprunox developed by Lundbeck?,Interim analysis showed inadequate efficacy of bifeprunox
What caused the termination of the clinical trial for valbenazine developed by Neurocrine Biosciences?,Study ATS3020 was closed due to business reasons. Neurocrine Biosciences will continue to conduct study ATS3019 (NCT05110157). There were no unexpected safety findings for this compound that motivated the decision.
"What caused the termination of the clinical trial for glycerin
mesalazine developed by The First Affiliated Hospital of PLA Air Force Military Medical University?",Lack of funds
What caused the termination of the clinical trial for foralumab developed by Tiziana Life Sciences?,Due to MOH request.
What caused the termination of the clinical trial for risperidone developed by University of Illinois at Chicago?,Study was terminated due to low accrual.
What caused the termination of the clinical trial for infliximab developed by Cincinnati Children's Hospital Medical Center?,"This was the Pilot study. The larger, confirmatory study has started"
What caused the termination of the clinical trial for rifaximin developed by Bausch Health?,The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.
What caused the termination of the clinical trial for nicotine developed by Vanderbilt University Medical Center?,Recruitment challenges due to Covid19.
What caused the termination of the clinical trial for melatonin developed by University of Western Australia?,Participant recruitment difficulties
What caused the termination of the clinical trial for secukinumab developed by Novartis?,The study was terminated prematurely after futility criterion was met at planned interim analysis of 41 patients.
What caused the termination of the clinical trial for guselkumab developed by Johnson & Johnson?,Janssen made an internal business decision to discontinue the PROGRESS study. This decision is not related to any efficacy or safety concerns.
What caused the termination of the clinical trial for apimostinel developed by NYU Langone Health?,The study was withdrawn by the sponsor.
What caused the termination of the clinical trial for semapimod developed by Ferring Pharmaceuticals?,Unable to enroll into study.
What caused the termination of the clinical trial for somatropin developed by Nationwide Children's Hospital?,PI left the institution
"What caused the termination of the clinical trial for cyclophosphamide
tacrolimus
mycophenolic acid
mycophenolate mofetil
fludarabine phosphate developed by Fred Hutchinson?",Annual accrual goal not met
What caused the termination of the clinical trial for lisdexamfetamine developed by Shire?,Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.
"What caused the termination of the clinical trial for farampator
benfluorex developed by University of California, Los Angeles?",Study terminated at Sponsor's request.
What molecular targets and specific diseases are associated with the invention described in WO2022224195A1?,"VAP-1; Metabolic Syndrome, Diabetes Mellitus, Type 2, Liver Cirrhosis, Alcoholic, Hepatitis B, Colonic Cancer, Psoriasis, Dyslipidemias, Lipid Metabolism Disorders, Cholestasis, Extrahepatic, Inflammatory Bowel Diseases, Diabetes Mellitus, Obesity, liver function failure, Thrombosis, Fibrosis, Liver, Nonalcoholic Steatohepatitis, Osteoarthritis, Atherosclerosis, Rheumatoid Arthritis, Chronic liver disease, Hepatocellular Carcinoma, Hepatitis A, Stroke, Cholestasis, Intrahepatic, Persistent Infection, Brain Infarction, Fatty Liver, Hepatitis C, Acute myocardial infarction"
What molecular targets and specific diseases are associated with the invention described in WO2016109492A1?,"Aldosterone; Scleroderma, Collagen Diseases, Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Canavan Disease, Diabetes Mellitus, Phenylketonurias, Polycystic Kidney Diseases, Pancreatitis, Fibrosis, Liver, Urinary tract obstruction, Nonalcoholic Steatohepatitis, Cholangitis, Sclerosing, Hepatolenticular Degeneration, Hemochromatosis, Alcoholism, Alpha 1-Antitrypsin Deficiency, Muscular Dystrophies, Leukodystrophy NOS, Refsum Disease, Brain Infarction, Multiple Sclerosis, Liver Diseases, Hepatitis C, Cerebrovascular Disorders, occlusions, Reperfusion Injury, Pulmonary Disease, Chronic Obstructive, Hepatitis B, Renal Insufficiency, Wounds and Injuries, Hypertension, Myocardial Ischemia, Gallstones, Leukodystrophy, Metachromatic, Myocardial Infarction, Leukodystrophy, Globoid Cell, Hepatitis D, Primary Biliary Cholangitis, Alexander Disease, Emphysema, Idiopathic Pulmonary Fibrosis, Fibrosis, Atherosclerosis, Pelizaeus-Merzbacher Disease, Adrenoleukodystrophy, Chronic Kidney Diseases, Kidney Diseases, Stroke, Central nervous system injury, Renal fibrosis, Pulmonary Fibrosis"
What molecular targets and specific diseases are associated with the invention described in WO2025016351A1?,CRBN; Neoplasms
What molecular targets and specific diseases are associated with the invention described in WO2024169773A1?,"GLP-1R; Nonalcoholic Steatohepatitis, Diabetes Complications, Hyperglycemia, Dementia, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Stroke, Insulin Resistance, Glucose Intolerance, Diabetes Mellitus, Hyperlipidemias, Brain Infarction, Obesity, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2022040293A1?,"TLR9; Fibrosis, Liver, Nonalcoholic Steatohepatitis, Idiopathic Pulmonary Fibrosis, Cholangitis, Sclerosing, Fibrosis, Collagen Diseases, Fibrosis of pancreas, Chronic Kidney Diseases, Renal fibrosis, Diabetic Nephropathies, Metabolic dysfunction-associated steatotic liver disease, Primary Biliary Cholangitis, Gallbladder Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2021086816A1?,"galectin-3; Thrombosis, Acute Myeloid Leukemia, Myocardial fibrosis, Nonalcoholic Steatohepatitis, Acute Lymphoblastic Leukemia, Solid tumor, Fibrosis, Neoplasms, Atherosclerosis, Nerve Degeneration, Pancreatic Cancer, Graft vs Host Disease, Bone Cancer, Cardiovascular Diseases, Myocardial Infarction, Multiple Myeloma, Neovascularization, Pathologic, Colorectal Cancer, Liver Diseases, Pulmonary Fibrosis, Epileptic Syndromes, Chronic Myelogenous Leukemia, Synucleinopathies"
What molecular targets and specific diseases are associated with the invention described in WO2017182433A1?,"MEP1B; Alzheimer Disease, Kidney Tubular Necrosis, Acute, Fibrosis, Neoplasms, Acute Kidney Injury, Inflammation, Cystitis, Colitis, Keloid, Hypertension, Inflammatory Bowel Diseases, Colitis, Ulcerative, Nephritis, Lung Diseases, Interstitial, Crohn Disease, Hypertension, Pulmonary, Colorectal Cancer, Renal injury"
What molecular targets and specific diseases are associated with the invention described in WO2019089667A1?,"FXR; Fibrosis, Liver, Nonalcoholic Steatohepatitis, Idiopathic Pulmonary Fibrosis, Fibrosis, Cholangitis, Sclerosing, Neoplasms, Fibrosis of pancreas, Cholestatic liver disease, Chronic Kidney Diseases, Renal fibrosis, Diabetic Nephropathies, Graft Rejection, Osteoporosis, Metabolic dysfunction-associated steatotic liver disease, Primary Biliary Cholangitis, Gallbladder Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2020249669A1?,"NLRP3; Alzheimer Disease, Gout, Pulmonary Disease, Chronic Obstructive, Squamous Cell Carcinoma of Head and Neck, Autoimmune Diseases, Neoplasms, Neuroinflammation, Neonatal-Onset Multisystem Inflammatory Disease, Neurodegenerative Diseases, Familial Mediterranean Fever, Diabetes Mellitus, Skin Diseases, Skin Neoplasms, Obesity, Metabolic dysfunction-associated steatotic liver disease, Acne Vulgaris, Brain Cancer, Proteostasis Deficiencies, Nonalcoholic Steatohepatitis, Autoinflammatory disease, Osteoarthritis, Fibrosis, Muckle-Wells Syndrome, Rheumatoid Arthritis, Familial cold urticaria, Chronic Kidney Diseases, Carbamoyl-Phosphate Synthase I Deficiency Disease, Non-Small Cell Lung Cancer, Multiple Sclerosis, Colorectal Cancer, Prion Diseases, Carcinoma, Gastrointestinal Neoplasms"
What molecular targets and specific diseases are associated with the invention described in WO2022063876A1?,"NLRP3; Gout, Diabetes Mellitus, Type 2, Colonic Cancer, Arthritis, Inflammation, Joint Diseases, Neuroinflammation, Wounds and Injuries, Hypertension, Metabolic Diseases, Immune System Diseases, Retinal Diseases, Acute decompensated heart failure, Lung Cancer, Asthma, inflammatory dermatosis, Neurodegenerative Diseases, Age Related Macular Degeneration, Liver Diseases, Alcoholic, Lupus Nephritis, Hyperoxaluria, Acne Vulgaris, Cryopyrin-Associated Periodic Syndromes, Nonalcoholic Steatohepatitis, Osteoarthritis, Chondrocalcinosis, Atherosclerosis, Rheumatoid Arthritis, Myeloproliferative Disorders, Brain Abscess, Chronic liver disease, Sarcoidosis, Peripheral Arterial Disease, Kidney Diseases, Cardiovascular Diseases, Cicatrix, Multiple Sclerosis, Myelofibrosis, Leukemia, Hypertensive Nephropathy, Juvenile Gout, Myelodysplastic Syndromes"
What molecular targets and specific diseases are associated with the invention described in WO2021026479A1?,"S1PR2; Chronic Traumatic Encephalopathy, Sarcoma, Multiple Organ Failure, Acute Lung Injury, Hyperemia, Coronavirus Infections, Neoplasms, Inflammation, Neuroblastoma, Coma, Pancreatic Cancer, Systemic Inflammatory Response Syndrome, Cytokine Release Syndrome, Hypertensive Encephalopathy, Neurodegenerative Diseases, Vascular Neoplasms, Diabetes Mellitus, Age Related Macular Degeneration, Neovascularization, Pathologic, Metabolic dysfunction-associated steatotic liver disease, Capillary Leak Syndrome, Nonalcoholic Steatohepatitis, Glioblastoma, Digestive System Disorders, Hypoxia, Atherosclerosis, Brain Injuries, Filoviridae Infections, Diabetic Retinopathy, Diabetic Angiopathies, Hemorrhagic Fever, Ebola, Flaviviridae Infections, Blood brain barrier defect, COVID-19, Functional disorder, Stroke, Disseminated Intravascular Coagulation, Renal Cell Carcinoma, Multiple Sclerosis, Sepsis, Marburg Virus Disease, Ischemia, Dementia, Vascular, Pulmonary Fibrosis, Shock, Brain Injuries, Traumatic"
What molecular targets and specific diseases are associated with the invention described in WO2022150362A1?,"PSD95; Nerve injury, Retinal Degeneration, Depressive Disorder, Pain, Autistic Disorder, Neurolytic Block, Epilepsy, Inflammation, Schizophrenia, Amyotrophic Lateral Sclerosis, Stroke, Neurodegenerative Diseases, Nervous System Diseases, Brain Injuries, Traumatic"
What molecular targets and specific diseases are associated with the invention described in WO2024141535A1?,"NLRP3; Gout, Pulmonary Disease, Chronic Obstructive, Coronary Artery Disease, Autoimmune Diseases, Cardiomyopathies, Neonatal-Onset Multisystem Inflammatory Disease, Inflammatory Bowel Diseases, Colitis, Ulcerative, inflammatory dermatosis, Asthma, Myocardial Infarction, Diabetic Nephropathies, Metabolic dysfunction-associated steatotic liver disease, Systemic Lupus Erythematosus, Acne Vulgaris, Cryopyrin-Associated Periodic Syndromes, Celiac Disease, Chemical and Drug Induced Liver Injury, Nonalcoholic Steatohepatitis, Cardiomegaly, Autoinflammatory disease, Idiopathic Pulmonary Fibrosis, Chondrocalcinosis, Acute Kidney Injury, Muckle-Wells Syndrome, Rheumatoid Arthritis, Familial cold urticaria, Chronic Kidney Diseases, Hidradenitis Suppurativa, Kidney Diseases, Cardiovascular Diseases, Chronic lung disease, Multiple Sclerosis, Vitiligo, Liver Diseases, Respiratory Diseases, Hepatitis C, Chronic, Reperfusion Injury"
What molecular targets and specific diseases are associated with the invention described in WO2024104317A1?,"15-PGDH; Scleroderma, Pain, Pulmonary Arterial Hypertension, Psoriasis, Autoimmune Diseases, Neoplasms, Inflammation, Muscle injury, Nonalcoholic fatty liver, Equilibration disorder, Xerophthalmia, Neurodegenerative Diseases, Diabetes Mellitus, Glaucoma, Eye Diseases, Peptic Ulcer, Fibrosis, Liver, Myocardial fibrosis, Cystitis, Interstitial, Autoinflammatory disease, Acute Kidney Injury, Rheumatoid Arthritis, Angina Pectoris, Cardiovascular Diseases, Muscular Dystrophies, Crohn Disease, Vasculitis, Chronic pelvic pain syndrome, Multiple Sclerosis, Myelofibrosis, Osteoporosis, Otitis, Acute Lung Injury, Vertigo, Burns, Pulmonary Disease, Chronic Obstructive, Ulcer, Urinary Bladder, Underactive, Renal Insufficiency, Neuritis, Chronic prostatitis, Colitis, Ulcerative, Inflammatory Bowel Diseases, Dermatitis, Atopic, Asthma, Myocardial Infarction, Hearing Loss, Nephrosis, Chronic nephritis, Psychotic Disorders, Idiopathic Pulmonary Fibrosis, Fibrosis, Heart Failure, Liver Injury, Muscular Disorders, Atrophic, Heart Diseases, Graft vs Host Disease, Uterine Cervicitis, Stroke, Tinnitus, Renal fibrosis, Leukopenia, Prostatitis, Sepsis, Pressure Ulcer, Pulmonary Fibrosis"
What molecular targets and specific diseases are associated with the invention described in WO2016109220A1?,"BTK; Eczema, Allograft Rejection, Psoriasis, Sinusitis, Purpura, Thrombocytopenic, Idiopathic, Arthritis, Cachexia, Graves Disease, Spondylitis, Anemia, Arthritis, Infectious, Uveitis, Diabetes Mellitus, Thyroiditis, Chronic, Arthritis, Psoriatic, Pancreatitis, Dermatitis, Contact, Celiac Disease, Rheumatoid Arthritis, Arthritis, Reactive, Nephrotic Syndrome, Sarcoidosis, Chronic lung disease, Conjunctivitis, Crohn Disease, Vasculitis, Multiple Sclerosis, Pulmonary Emphysema, Inflammatory pain, Behcet Syndrome, Periodontal Diseases, Pulmonary Disease, Chronic Obstructive, Inflammatory Bowel Diseases, Glomerulonephritis, Colitis, Ulcerative, Rhinitis, Dermatitis, Atopic, Asthma, Stevens-Johnson Syndrome, Sunburn, Systemic Lupus Erythematosus, Primary Biliary Cholangitis, Otitis Media, Pneumoconiosis, Silicosis, Osteoarthritis, Neutropenia, Pulmonary Valve Insufficiency, Synovitis, Chronic arthritis, Arthritis, Gouty, Bronchitis, Chronic Kidney Diseases, Graft vs Host Disease, Hematologic Diseases, Hamman-Rich Syndrome, Guillain-Barre Syndrome, Anemia, Hemolytic, Myasthenia Gravis, Pulmonary Fibrosis, Gastritis"
What molecular targets and specific diseases are associated with the invention described in WO2021092500A1?,"IAP; Scleroderma, Hodgkin's Lymphoma, Hashimoto Disease, Hemarthrosis, Liver Cancer, Psoriasis, Autoimmune Diseases, Purpura, Thrombocytopenic, Idiopathic, Neoplasms, Small Cell Lung Cancer, Graves Disease, Retinopathy of Prematurity, Cicatrix, Hypertrophic, Pancreatic Cancer, Rheumatic Fever, Sjogren's Syndrome, Lung Cancer, Neovascularization, Pathologic, Uterine Neoplasms, Celiac Disease, Tissue Adhesions, Glioblastoma, Prostatic Cancer, Rheumatoid Arthritis, Esophageal Squamous Cell Carcinoma, Diabetic Retinopathy, Lymphoma, Diabetes Mellitus, Type 1, Hepatitis, Autoimmune, Dermatomyositis, Renal Cell Carcinoma, Crohn Disease, Multiple Sclerosis, Angiofibroma, Colorectal Cancer, Telangiectasis, Leukemia, Fibromyalgia, Chronic Myelogenous Leukemia, Carcinoma, Sarcoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Cardiomyopathies, Breast Cancer, Wounds and Injuries, Lichen Planus, Colitis, Ulcerative, Glaucoma, Neovascular, Fatigue Syndrome, Chronic, Multiple Myeloma, Skin Neoplasms, Systemic Lupus Erythematosus, Uterine Cervical Cancer, Crouzon Syndrome With Acanthosis Nigricans, Keratoplasty rejection, Acute Myeloid Leukemia, Atherosclerosis, Stomach Cancer, Graft vs Host Disease, Ovarian Cancer, Non-Small Cell Lung Cancer, Dystrophy, Macular, Anemia, Hemolytic, Myasthenia Gravis, Glomerulonephritis, IGA, Vitiligo, Non-Hodgkin Lymphoma"
What molecular targets and specific diseases are associated with the invention described in WO2018214796A1?,"GABARAPL2; Liver Cancer, Endometrial Carcinoma, Autoimmune Diseases, Neoplasms, Breast Cancer, Pancreatic Cancer, Hypertension, Intestinal Neoplasms, Retinal Diseases, Amyotrophic Lateral Sclerosis, Lung Cancer, Asthma, Neurodegenerative Diseases, Multiple Myeloma, Bone Marrow Neoplasms, Uterine Cervical Cancer, Acute Kidney Injury, Prostatic Cancer, Lymphoma, Stomach Cancer, Cardiovascular Diseases, Ovarian Cancer, Crohn Disease, Absent Corpus Callosum Cataract Immunodeficiency, Nasopharyngeal Carcinoma, Leukemia, Brain Ischemia, Infectious Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2022109741A1?,"CD73; Eczema, Sarcoma, Alzheimer Disease, Psoriasis, Colonic Cancer, Basal Cell Carcinoma, Mesothelioma, Neoplasms, Renal Insufficiency, Scleroderma, Systemic, Breast Cancer, Pancreatic Cancer, Hypercholesterolemia, Colitis, Ulcerative, Lung Cancer, Asthma, Hypersensitivity, Pancreatitis, Melanoma, Arteriosclerosis, Dermatitis, Allergic Contact, Brain Cancer, Glioblastoma, Fibrosis, Heart Failure, Rheumatoid Arthritis, Prostatic Cancer, Colitis, Lupus Erythematosus, Lymphoma, Stomach Cancer, Aortic Valve Stenosis, Stroke, Ovarian Cancer, Seminoma, Crohn Disease, Renal Cell Carcinoma, Choriocarcinoma, Multiple Sclerosis, Kaposi Sarcoma, Leukemia, Osteoporosis, Fibromyalgia, Infectious Diseases, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2024105021A1?,"mGluR7; Inflammatory pain, Hearing Loss, Sudden, Pain, Vestibular Diseases, Central Nervous System Diseases, Schizoaffective disorder, Anxiety Disorders, Labyrinth Diseases, Pain, Postoperative, Cancer Pain, Hearing Loss, Language Development Disorders, Ototoxicity, Paranoid Schizophrenia, Pain, Intractable, Stress Disorders, Post-Traumatic, Visceral Pain, Pain Disorder, Chronic Pain, Psychotic Disorders, Otitis Media, Generalized anxiety disorder, Acute Pain, Schizophrenia, Panic Disorder, Neuralgia, Agoraphobia, Functional disorder, Tinnitus, Post-traumatic pain, Nervous System Diseases, Hearing Loss, Noise-Induced, Obsessive-Compulsive Disorder, Presbycusis, Hearing Loss, Sensorineural, Headache"
What molecular targets and specific diseases are associated with the invention described in WO2021133924A1?,"galectin-3; Acute Myeloid Leukemia, Thrombosis, Myocardial fibrosis, Nonalcoholic Steatohepatitis, Acute Lymphoblastic Leukemia, Solid tumor, Fibrosis, Neoplasms, Atherosclerosis, Nerve Degeneration, Pancreatic Cancer, Graft vs Host Disease, Bone Cancer, Cardiovascular Diseases, Myocardial Infarction, Multiple Myeloma, Neovascularization, Pathologic, Colorectal Cancer, Liver Diseases, Pulmonary Fibrosis, Chronic Myelogenous Leukemia, Epileptic Syndromes, Synucleinopathies"
What molecular targets and specific diseases are associated with the invention described in WO2016109215A1?,"BTK; Eczema, Allograft Rejection, Psoriasis, Sinusitis, Purpura, Thrombocytopenic, Idiopathic, Cachexia, Arthritis, Graves Disease, Spondylitis, Anemia, Arthritis, Infectious, Uveitis, Thyroiditis, Chronic, Diabetes Mellitus, Arthritis, Psoriatic, Pancreatitis, Dermatitis, Contact, Celiac Disease, Rheumatoid Arthritis, Arthritis, Reactive, Sarcoidosis, Nephrotic Syndrome, Chronic lung disease, Conjunctivitis, Crohn Disease, Multiple Sclerosis, Vasculitis, Pulmonary Emphysema, Inflammatory pain, Behcet Syndrome, Periodontal Diseases, Pulmonary Disease, Chronic Obstructive, Colitis, Ulcerative, Glomerulonephritis, Inflammatory Bowel Diseases, Rhinitis, Dermatitis, Atopic, Asthma, Stevens-Johnson Syndrome, Sunburn, Systemic Lupus Erythematosus, Primary Biliary Cholangitis, Otitis Media, Pneumoconiosis, Silicosis, Osteoarthritis, Neutropenia, Pulmonary Valve Insufficiency, Synovitis, Arthritis, Gouty, Chronic arthritis, Bronchitis, Chronic Kidney Diseases, Graft vs Host Disease, Hematologic Diseases, Hamman-Rich Syndrome, Guillain-Barre Syndrome, Anemia, Hemolytic, Myasthenia Gravis, Pulmonary Fibrosis, Gastritis"
What molecular targets and specific diseases are associated with the invention described in WO2017095722A1?,"LTB4R; Diabetes Mellitus, Type 2, Metabolic Syndrome, Insulin Resistance, Nonalcoholic Steatohepatitis, Dyslipidemias, Neoplasms, Atherosclerosis, Lipid Metabolism Disorders, Hyperglycemia, Obesity, Metabolic dysfunction-associated steatotic liver disease, Hypertension"
What molecular targets and specific diseases are associated with the invention described in WO2016022521A1?,"LXR; Alzheimer Disease, Eczema, Niemann-Pick Disease, Type C, Psoriasis, Dyslipidemias, Autoimmune Diseases, Neoplasms, Inflammation, Lipid Metabolism Disorders, Diabetic Neuropathies, Hypercholesterolemia, Microvascular Angina, inflammatory dermatosis, Neurodegenerative Diseases, Diabetes Mellitus, Glomerulosclerosis, Focal Segmental, Obesity, Acne Vulgaris, Dermatitis, Contact, Nonalcoholic Steatohepatitis, Peripheral Nervous System Diseases, Cardiovascular Diseases, Acute Coronary Syndrome, Proteinuria, Hyperlipidemias, Multiple Sclerosis, Skin aging, Hypertensive Nephropathy, Metabolic Syndrome, Amnesia, Lipodystrophy, Wounds and Injuries, Immune System Diseases, Dermatitis, Atopic, Hyperphosphatemia, Diabetic Nephropathies, Melanoma, Skin Diseases, Metabolic dysfunction-associated steatotic liver disease, Hyperlipoproteinemias, Hypertriglyceridemia, Optic Nerve Diseases, Peripheral arterial occlusive disease, Atherosclerosis, Cholelithiasis, Hyperglycemia, Wrinkling of skin, Kidney Diseases, Stroke, Central nervous system injury, Insulin Resistance, Fatty Liver, Glomerulonephritis, IGA, Dermatitis, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2023067322A1?,"GPR65; Sarcoma, Scleroderma, Adenocarcinoma of large intestine, Pulmonary Disease, Chronic Obstructive, Hashimoto Disease, Psoriasis, Neoplasms, Scleroderma, Systemic, Blood Platelet Disorders, Graves Disease, Respiratory Distress Syndrome, Acute, Colitis, Ulcerative, Immune System Diseases, Head and Neck Neoplasms, Sjogren's Syndrome, Lung Cancer, Asthma, Uveitis, Arthritis, Psoriatic, Triple Negative Breast Cancer, Polyendocrinopathies, Autoimmune, Melanoma, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Pancreatic adenocarcinoma, Systemic Vasculitis, Acute Myeloid Leukemia, Solid tumor, Rheumatoid Arthritis, Sarcoidosis, Autoimmune Haemolytic Anaemias, Uveitis, Intermediate, Stomach Cancer, Glioblastoma Multiforme, Ovarian Cancer, Dermatomyositis, Glioma, Crohn Disease, Renal Cell Carcinoma, Multiple Sclerosis, Thyroiditis, Autoimmune, Colorectal Cancer, Spondylarthropathies"
What molecular targets and specific diseases are associated with the invention described in WO2024028601A1?,"EP4; Pulmonary Disease, Chronic Obstructive, Chemotherapy oral mucositis, Colitis, Ulcerative, Inflammatory Bowel Diseases, Chronic cough, Postoperative ileus, Gastrointestinal motility disorder, Asthma, Intestinal Diseases, Gastrointestinal Diseases, Waterborne Diseases, Drug-induced diarrhea, Constipation, Duodenogastric Reflux, Celiac Disease, Food Hypersensitivity, Emphysema, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchitis, Chronic, Signs and Symptoms, Digestive, Lung Diseases, Colitis, Ischemic, Chronic idiopathic constipation, Crohn Disease, Gastroesophageal Reflux, Irritable Bowel Syndrome"
What molecular targets and specific diseases are associated with the invention described in WO2023114822A1?,"RXFP1; Nonalcoholic Steatohepatitis, Angina, Unstable, Idiopathic Pulmonary Fibrosis, Fibrosis, Heart Failure, Hypertension, Portal, Chronic heart failure, Chronic Kidney Diseases, Acute decompensated heart failure, Kidney Diseases, Lung Diseases, Angina Pectoris, Acute Coronary Syndrome, Myocardial Infarction, Liver Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2023033679A4?,"TAAR1; Dyslipidemias, Epilepsy, Hypertension, Metabolic Diseases, Cognition Disorders, Cognitive Dysfunction, Stress-related problem, Sleep Disorders, Circadian Rhythm, Neurodegenerative Diseases, Diabetes Mellitus, Behavioural disorders, Substance Abuse, Obesity, Nicotine Dependence, Psychotic Disorders, Bipolar Disorder, Depressive Disorder, Migraine Disorders, Diabetes Complications, Schizophrenia, Attention Deficit Disorder With Hyperactivity, Cardiovascular Diseases, Nervous System Diseases, Obsessive-Compulsive Disorder, Temperature disorder"
What molecular targets and specific diseases are associated with the invention described in WO2018109607A1?,"GLP-1R; Peripheral Vascular Diseases, Alzheimer Disease, Cataract, Diabetes Mellitus, Type 2, Coronary Artery Disease, Psoriasis, Dyslipidemias, Hypertrophy, Left Ventricular, Arthritis, Short Bowel Syndrome, Ischemic stroke, Diabetic Neuropathies, Skin and Connective Tissue Diseases, Hyperinsulinism, Microvascular Angina, Vascular restenosis, Cognitive Dysfunction, Diabetes Mellitus, Foot Ulcer, Hypertension, Pulmonary, Obesity, psychological symptoms behavior compulsive behavior addiction, Nonalcoholic Steatohepatitis, Schizophrenia, Diabetic Retinopathy, Peripheral Arterial Disease, Cardiovascular Diseases, Angina Pectoris, Sleep Apnea Syndromes, Crohn Disease, Hyperlipidemias, Osteoporosis, Hyperlipoproteinemia Type II, Glomerulosclerosis (disorder), Gout, Metabolic Syndrome, Endothelial dysfunction, Hemorrhagic stroke, Hypertension, Inflammatory Bowel Diseases, Colitis, Ulcerative, Hyperuricemia, Myocardial Infarction, Glucose Intolerance, Diabetic Nephropathies, Premenstrual Syndrome, Intermittent Claudication, Metabolic dysfunction-associated steatotic liver disease, Weight Gain, Glucose Metabolism Disorders, Ketosis, Thrombosis, Diabetes, Gestational, Fibrosis, Heart Failure, Atherosclerosis, Hyperglycemia, Colitis, Erectile Dysfunction, Kidney Diseases, Hepatocellular Carcinoma, Functional disorder, Stroke, Insulin Resistance, Ischemic Attack, Transient, Prediabetic State, Kidney Failure, Chronic, Polycystic Ovary Syndrome, Dystrophy, Macular, Brain Injuries, Traumatic, Irritable Bowel Syndrome, Acidosis, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2017089458A1?,"5-HT2C receptor; Alzheimer Disease, Diabetes Mellitus, Type 2, Pain, Bulimia, Psoriasis, Central Nervous System Diseases, Tobacco Use Disorder, Dementia, Mutism, Ocular Hypertension, Urinary Incontinence, Diabetes Insipidus, Adjustment disorders, Cognitive Dysfunction, Meningitis, Diabetes Mellitus, Behavioural disorders, Gastrointestinal Diseases, Neurocognitive Disorders, Obesity, Borderline Personality Disorder, Phobia, Social, disorder of aging, Attention Deficit and Disruptive Behavior Disorders, Migraine Disorders, Spinal Cord Injuries, Schizophrenia, Alcoholism, Diabetes Mellitus, Type 1, Cardiovascular Diseases, Neuropsychiatric syndrome, Intracranial Hypertension, Sleep Apnea Syndromes, Sexual Dysfunction, Obsessive-Compulsive Disorder, Autistic Disorder, Epilepsy, Amnesia, Pancreatic Diseases, Wounds and Injuries, Lewy Body Disease, Fatigue Syndrome, Chronic, Substance-Related Disorders, Premenstrual Syndrome, Anorexia Nervosa, Psychotic Disorders, Post-Concussion Syndrome, Bladder dysfunction, Bipolar Disorder, Depressive Disorder, Diabetes Complications, Panic Disorder, Hyperglycemia, Attention Deficit Disorder With Hyperactivity, Erectile Dysfunction, Cocaine-Related Disorders, Stroke, Central nervous system injury, Insulin Resistance, Weight Loss, Disruptive, Impulse Control, and Conduct Disorders, Encephalitis, Mood Disorders, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2023169436A1?,"GLP-1R; Alzheimer Disease, Cataract, Metabolic Syndrome, Liver Cancer, Dyslipidemias, Epilepsy, Diabetic Neuropathies, Hypertension, Hyperuricemia, Diabetes Mellitus, Nephrosis, Liver Cirrhosis, Metabolic dysfunction-associated steatotic liver disease, Obesity, Ketosis, Nonalcoholic Steatohepatitis, Fibrosis, Atherosclerosis, Diabetic Retinopathy, Hyperglycemia, Heart Diseases, Stroke, Diabetes Mellitus, Type 1, Insulin Resistance, Latent Autoimmune Diabetes in Adults, Osteoporosis, Cerebrovascular Disorders, Acidosis, Infectious Diseases, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2022224212A1?,"GPR35; Pulmonary Disease, Chronic Obstructive, Pain, Neoplasms, Dysentery, Cystitis, Systemic Mastocytosis, Hepatitis, Pelvic Pain, Colitis, Ulcerative, Inflammatory Bowel Diseases, Chronic cough, Gastrointestinal motility disorder, Endometriosis, Asthma, Hypersensitivity, Gastrointestinal Diseases, Visceral Pain, Pancreatitis, Waterborne Diseases, Eosinophilic Enteropathy, Duodenogastric Reflux, Colitis, Microscopic, Celiac Disease, Food Hypersensitivity, Fibrosis, Liver, Emphysema, Cystitis, Interstitial, Idiopathic Pulmonary Fibrosis, Fibrosis, Digestive System Disorders, Cystic Fibrosis, Mucositis, Colitis, Anaphylaxis, Mast Cell Activation Disorders, Bronchitis, Chronic, Lung Diseases, Signs and Symptoms, Digestive, Crohn Disease, Prostatitis, Radiation Colitis, Gastroesophageal Reflux, Eosinophilic Esophagitis, Irritable Bowel Syndrome"
What molecular targets and specific diseases are associated with the invention described in WO2021214472A1?,"Nrf2; Cerebral Hemorrhage, Polycystic Kidney, Autosomal Dominant, Pulmonary Arterial Hypertension, Psoriasis, Frontotemporal Dementia, Ischemic stroke, Pre-Eclampsia, Amyotrophic Lateral Sclerosis, Lung Cancer, Uveitis, Diabetes Mellitus, Glomerulosclerosis, Focal Segmental, Obesity, Nonalcoholic Steatohepatitis, Organ dysfunction syndrome, Rheumatoid Arthritis, Schizophrenia, Fuchs' Endothelial Dystrophy, Diabetes Mellitus, Type 1, Multiple Sclerosis, Friedreich Ataxia, Liver Diseases, Subarachnoid Hemorrhage, Acute Lung Injury, Metabolic Syndrome, Arrhythmias, Cardiac, Pulmonary Disease, Chronic Obstructive, Colonic Cancer, Breast Cancer, Radiodermatitis, Respiratory Distress Syndrome, Acute, Hypertension, Colitis, Ulcerative, Anemia, Sickle Cell, Dermatitis, Atopic, Heart failure with normal ejection fraction, Respiratory Distress Syndrome, Myocardial Infarction, Age Related Macular Degeneration, Intestinal Diseases, Diabetic Nephropathies, Chronic Pain, Metabolic dysfunction-associated steatotic liver disease, Diabetic Cardiomyopathies, Cardiomegaly, Idiopathic Pulmonary Fibrosis, Fibrosis, Heart Failure, Cystic Fibrosis, Atherosclerosis, Nephritis, Hereditary, Heart Diseases, Chronic Kidney Diseases, Sarcopenia, Beta-Thalassemia, COVID-19, Insulin Resistance, Glomerulonephritis, IGA, Status Asthmaticus, Pulmonary Fibrosis"
What molecular targets and specific diseases are associated with the invention described in WO2022140643A1?,"NR2E1; Essential Tremor, Chronic Traumatic Encephalopathy, Alzheimer Disease, Depressive Disorder, Memory Disorders, Autistic Disorder, Epilepsy, Frontotemporal Dementia, Neoplasms, Depressive Disorder, Major, Multiple System Atrophy, Schizophrenia, Diabetic Neuropathies, Metabolic Diseases, Lewy Body Disease, Amyotrophic Lateral Sclerosis, Stroke, Cognitive Dysfunction, Supranuclear Palsy, Progressive, Multiple Sclerosis, Nervous System Diseases, Cerebrovascular Disorders, Crouzon Syndrome With Acanthosis Nigricans, Angelman Syndrome"
What molecular targets and specific diseases are associated with the invention described in WO2020161217A1?,"ISBT; Cataract, Scleroderma, Systemic, Cholestatic liver disease, Xanthomatosis, Cerebrotendinous, Cholestasis, Extrahepatic, Bile Reflux, Cholestasis-edema syndrome, Norwegian type, Parenteral nutrition associated cholestasis, Alagille Syndrome, Gastrointestinal Diseases, Pancreatitis, Obesity, Arteriosclerosis, Fibrosis, Liver, Chemical and Drug Induced Liver Injury, Pruritus, Reye Syndrome, Neonatal Hemochromatosis, Intrahepatic Cholestasis of Pregnancy, Cholestasis, Cardiovascular Diseases, Acute Coronary Syndrome, Cholestasis, Intrahepatic, Alpha 1-Antitrypsin Deficiency, Hyperlipidemias, Crohn Disease, Muscular Atrophy, Multiple Sclerosis, Histiocytosis, Langerhans-Cell, Hepatitis C, Ischemia, Angina, Unstable, Biliary Atresia, Hypertension, Inflammatory Bowel Diseases, Myocardial Infarction, Glucose Intolerance, Constipation, Sitosterolemia, Metabolic dysfunction-associated steatotic liver disease, Vascular Diseases, Glucose Metabolism Disorders, Constipation - functional, Digestive System Disorders, Hypertension, Portal, Hyperglycemia, Abetalipoproteinemia, Uremic pruritus, Pregnancy, Stroke, Insulin Resistance, Hepatitis, Alcoholic, Chronic constipation, Amyloidosis, Bile Duct Neoplasms, Parkinson Disease, Dyslipidemias, Glomerular disease, Neoplasms, Hypercholesterolemia, Hyperinsulinism, Retinal Diseases, Microvascular Angina, Vascular restenosis, progressive familial intrahepatic cholestasis, Osteopetrosis, Diabetes Mellitus, Liver Cirrhosis, Irritable bowel syndrome with constipation, Bile Acid Malabsorption, Primary, Angina, Stable, Bile Acid Synthesis Defect, Congenital, 1, Nonalcoholic Steatohepatitis, Hepatitis, Drug-Induced, Cholangitis, Sclerosing, Protoporphyria, Erythropoietic, Hepatitis E, Sarcoidosis, Malabsorption Syndromes, Diabetes Mellitus, Insulin-Dependent, 2, Hepatitis, Autoimmune, Jaundice, Chronic idiopathic constipation, Iron Overload, Liver Diseases, Cholestasis, Progressive Familial Intrahepatic 1, Arrhythmias, Cardiac, Metabolic Syndrome, Hepatitis B, Ileal Diseases, North American Indian Childhood Cirrhosis, Cardiomyopathies, Bile Acid Synthesis Defect, Wounds and Injuries, Acute Fatty Liver of Pregnancy, Immunoglobulin G4-Related Disease, Choledocholithiasis, Gallstones, Caroli Disease, Opioid-Induced Constipation, Biliary stricture, Hepatitis D, Atrial Fibrillation, Primary Biliary Cholangitis, Hypertriglyceridemia, Heart Failure, Peripheral arterial occlusive disease, Atherosclerosis, Enterocolitis, Necrotizing, ACTH Deficiency, Isolated, Down Syndrome, Chronic Kidney Diseases, Kidney Diseases, Hepatocellular Carcinoma, Bile-induced gastritis, Hepatitis A, Diabetic Foot, Chylomicron Retention Disease, Fatty Liver, Hepatic Fibrosis, Congenital, Irritable Bowel Syndrome, Fatty acid deficiency, Hypobetalipoproteinemia, Familial, 1"
What molecular targets and specific diseases are associated with the invention described in WO2024222860A1?,"TAAR1; Alzheimer Disease, Vertigo, Mania, Autistic Disorder, Pain, Epilepsy, Apnea, Anxiety Disorders, Hypertension, Dementia, Premenstrual Dysphoric Disorder, Neurodegenerative Diseases, Sleep Wake Disorders, Acute schizophrenia, Paranoid Schizophrenia, Chronic schizophrenia, Behavioural disorders, Huntington Disease, Psychotic Disorders, Dyskinesias, Sleep Initiation and Maintenance Disorders, Depressive Disorder, Migraine Disorders, Hepatolenticular Degeneration, Psychomotor Agitation, Schizophrenia, Attention Deficit Disorder, Neurotic Disorders, Seizures, Multiple Sclerosis, Nervous System Diseases, Personality Disorders, Sexual Dysfunction, Fibromyalgia, Mood Disorders, Vomiting, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2018134698A1?,"MAGL; Psoriasis, Autoimmune Diseases, Spondylitis, Fascioliasis, Muscle Spasticity, Meningitis, Pulmonary Embolism, Pancreatitis, Glaucoma, Obesity, Celiac Disease, Fibrosis, Liver, Pruritus, Glioblastoma, Neoplasm Metastasis, Migraine Disorders, Hematologic Neoplasms, Hepatolenticular Degeneration, Brain Injuries, Tourette Syndrome, Pulmonary Edema, Brain Abscess, Kidney Neoplasms, Attention Deficit Disorder, Recurrent Anaplastic (Malignant) Meningioma, Cardiovascular Diseases, Nausea, Sleep Apnea Syndromes, Toothache, Prion Diseases, Ischemia, Herpesviridae Infections, Leukoencephalopathy, Progressive Multifocal, Vomiting, Gout, Ependymoma, Trigeminal Neuralgia, Tuberculosis, Epilepsy, Pneumonia, Hepatitis, Glomerulonephritis, Immune System Diseases, Anti-myelin-associated glycoprotein associated polyneuropathy, Amyloidosis, Hereditary, Transthyretin-Related, Asthma, Dysmenorrhea, Stress Disorders, Post-Traumatic, Lung Diseases, Interstitial, Sunburn, Graft Rejection, Primitive Neuroectodermal Tumors, Nicotine Dependence, Ischemia of kidney, Arachnoiditis, Colitis, Panic Disorder, Neuralgia, Lupus Erythematosus, Stroke, Neurilemmoma, Guillain-Barre Syndrome, Tendinopathy, Trypanosomiasis, African, Dermatitis, Brain Ischemia, Headache, Parkinson Disease, Cerebral Hemorrhage, Budd-Chiari Syndrome, HIV Wasting Syndrome, Pain, Mesothelioma, Central Nervous System Diseases, Cystitis, Anxiety Disorders, Ischemic stroke, Neuroinflammation, Neuroblastoma, Ocular Hypotension, Amyotrophic Lateral Sclerosis, Medulloepithelioma, Enteritis, Bursitis, Endometriosis, Neurodegenerative Diseases, Ankylosing Spondylitis, Huntington Disease, Transverse Myelitis, Musculoskeletal Diseases, Cystitis, Interstitial, Pelvic Inflammatory Disease, Acute Kidney Injury, Rheumatoid Arthritis, Demyelinating Diseases, Sarcoidosis, Medulloblastoma, Ependymoblastoma, Seizures, Tonsillitis, Tension-Type Headache, Vasculitis, Liver Diseases, Liver cyst, Inflammatory pain, Behcet Syndrome, Burns, Spinal Cord Diseases, Arrhythmias, Cardiac, Pulmonary Disease, Chronic Obstructive, Hemorrhagic stroke, Myocardial Ischemia, Low Back Pain, Hypersensitivity, Melanoma, Dysplasia, Skin Neoplasms, Hepatomegaly, Bipolar Disorder, Complex Regional Pain Syndromes, Optic Neuritis, Cerebral Sarcoma, Optic Nerve Diseases, Down Syndrome, Kidney Diseases, Lung Diseases, Spider Bites, Substance Withdrawal Syndrome, Papilloma, Fatty Liver, Tremor, Dystrophy, Macular, Cholecystitis, Asperger Syndrome, Alzheimer Disease, Eczema, Bulimia, Phlebitis, Rabies, Liver Cirrhosis, Biliary, Cachexia, Frontotemporal Dementia, Diabetic Neuropathies, Metabolic Diseases, Alagille Syndrome, Cognitive Dysfunction, Gilbert Disease, Anorexia, Hemangioma, Cranial Nerve Diseases, Dermatitis, Contact, Dyskinesias, Insect Bites and Stings, Schizophrenia, Prostatic Cancer, Acute Pain, Peripheral Nervous System Diseases, Charcot-Marie-Tooth Disease, Dystonia, Astrocytoma, Neuromyelitis Optica, Sciatica, Leukodystrophy NOS, Multiple Sclerosis, Appendicitis, postoperative cognitive dysfunction, Respiratory Distress Syndrome, Acute, Mild cognitive disorder, Hypertension, Pain, Postoperative, Rhinitis, Leukoencephalopathies, Vasospasm, Diabetic Nephropathies, Chronic Pain, Sleep Initiation and Maintenance Disorders, Cystic Fibrosis, Attention Deficit Disorder With Hyperactivity, Agoraphobia, AIDS Dementia Complex, Phobia, Specific, Abdominal Pain, Reflex Sympathetic Dystrophy, Alcoholic Neuropathy, Dyslipidemias, Neoplasms, Myelitis, Dementia, Ocular Hypertension, Sjogren's Syndrome, Lung Cancer, Opioid abuse, Eye Diseases, Liver Cirrhosis, Chromosome 7, Trisomy 7q, Acne Vulgaris, Pleural Effusion, Brain Cancer, Beriberi, Myelinolysis, Central Pontine, Chemotherapy-induced nausea and vomiting, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Phobia, Social, Cholangitis, Sclerosing, Spinal Cord Injuries, Hemochromatosis, Pharyngitis, Bronchitis, Chronic, Glioblastoma Multiforme, Cannabis withdrawal, Osteoporosis, Iron Overload, Leukemia, Obsessive-Compulsive Disorder, Creutzfeldt-Jakob Syndrome, Reperfusion Injury, Gastrointestinal Neoplasms, Cerebral Palsy, Urinary Bladder, Neurogenic, Subarachnoid Hemorrhage, Arthralgia, Bladder Cancer, Snake Bites, Wounds and Injuries, Chronic prostatitis, acute stress, Hearing Loss, Drug-induced anxiety disorder, Visceral Pain, Pain Disorder, Skin Diseases, Emphysema, Osteoarthritis, Idiopathic Pulmonary Fibrosis, Causalgia, Liver Failure, Acute, Atherosclerosis, Mucositis, Chest Pain, Urinary Tract Infections, Anemia, Hemolytic, Oligodendroglioma, Brain Injuries, Traumatic, Irritable Bowel Syndrome"
What molecular targets and specific diseases are associated with the invention described in WO2016106309A1?,"RGN; Eczema, Allograft Rejection, Pulmonary Disease, Chronic Obstructive, Psoriasis, Sinusitis, Rhinitis, Allergic, Arthritis, Job Syndrome, Mastocytosis, Conjunctivitis, Allergic, Colitis, Ulcerative, Inflammatory Bowel Diseases, Dermatitis, Atopic, Asthma, Arthritis, Psoriatic, Eosinophilic Enteropathy, Systemic Lupus Erythematosus, Dermatitis, Allergic Contact, Acne Vulgaris, Dermatitis, Contact, Food Hypersensitivity, Churg-Strauss Syndrome, Rhinitis, Allergic, Seasonal, Asthma, Exercise-Induced, Osteoarthritis, Rhinitis, Allergic, Perennial, Allergic asthma, Rheumatoid Arthritis, Acute Basophilic Leukemia, Bronchitis, Cardiovascular Diseases, Conjunctivitis, Crohn Disease, Chronic Urticaria, Multiple Sclerosis, Reperfusion Injury"
What molecular targets and specific diseases are associated with the invention described in WO2022164842A1?,"M5 receptor; Puerperal Disorders, Opioid-Related Disorders, Depressive Disorder, Schizoaffective disorder, Anxiety Disorders, Tobacco Use Disorder, Schizophrenia, Psychedelic, Alcohol-Related Disorders, Menstruation Disturbances, Bipolar I disorder, Substance-Related Disorders, Paranoid Schizophrenia, Behavioural disorders, Substance Abuse, Psychotic Disorders"
What molecular targets and specific diseases are associated with the invention described in WO2023205173A1?,"QPCTL; Alzheimer Disease, Pulmonary Arterial Hypertension, Psoriasis, Basal Cell Carcinoma, Mesothelioma, Autoimmune Diseases, Squamous Cell Carcinoma of Head and Neck, Neoplasms, Small Cell Lung Cancer, Burkitt Lymphoma, Dementia, Lung Cancer, Endometriosis, Neurodegenerative Diseases, Arthritis, Psoriatic, Ewing Sarcoma, Small Lymphocytic Lymphoma, Well Differentiated Pancreatic Endocrine Tumor, Chronic phase chronic myeloid leukemia, Churg-Strauss Syndrome, Chondrosarcoma, Nonalcoholic Steatohepatitis, Glioblastoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Rheumatoid Arthritis, Prostatic Cancer, Soft Tissue Sarcoma, Lymphoma, Adenocarcinoma, Mantle-Cell Lymphoma, Renal Cell Carcinoma, Multiple Sclerosis, Colorectal Cancer, Leukemia, Pulmonary Disease, Chronic Obstructive, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Colonic Cancer, Rhinitis, Allergic, B-Cell Lymphoma, Breast Cancer, Bladder Cancer, Inflammatory Bowel Diseases, Dermatitis, Atopic, Breast Ductal Carcinoma, Hairy Cell Leukemia, Asthma, Esophageal Carcinoma, Multiple Myeloma, Melanoma, Skin Neoplasms, Waldenstrom Macroglobulinemia, Acute Myeloid Leukemia, Idiopathic Pulmonary Fibrosis, Atherosclerosis, Osteosarcoma, Diffuse Large B-Cell Lymphoma, Stomach Cancer, Follicular Lymphoma, Ovarian Cancer, Glioma, Non-Small Cell Lung Cancer, Merkel Cell Carcinoma, Nasal Polyps, Non-Hodgkin Lymphoma, Marginal Zone B-Cell Lymphoma, Squamous Cell Carcinoma"
What molecular targets and specific diseases are associated with the invention described in WO2017129125A1?,"FXR; Hypertriglyceridemia, Fibrosis, Liver, Diabetes Mellitus, Type 2, Calculus, Ureteral, Nonalcoholic Steatohepatitis, Cholangitis, Sclerosing, Fibrosis, Atherosclerosis, Cholestatic liver disease, Hepatitis, Chronic liver disease, Biliary Atresia, Hypercholesterolemia, Gallstones, Hepatic Insufficiency, Cardiovascular Diseases, Hepatitis, Alcoholic, Hyperlipidemias, Prostatic Hyperplasia, Hyperplasia, Obesity, Metabolic dysfunction-associated steatotic liver disease, Primary Biliary Cholangitis, Arteriosclerosis"
What molecular targets and specific diseases are associated with the invention described in WO2021150885A1?,"CDKL5; Autism Spectrum Disorder, Bulimia, Neoplasms, Arthritis, Mobius Syndrome, Rett Syndrome, Coffin-Lowry Syndrome, Dementia, Cognitive Dysfunction, Lung Cancer, Diabetes Mellitus, Glaucoma, Timothy Syndrome, psychological symptoms behavior compulsive behavior addiction, Chronic phase chronic myeloid leukemia, Developmental delay, Klinefelter Syndrome, Phelan-McDermid syndrome, Schizophrenia, Tourette Syndrome, Rheumatoid Arthritis, Cardiovascular Diseases, Seizures, Potocki-Lupski Syndrome, Sleep Apnea Syndromes, Histiocytosis, Langerhans-Cell, Obsessive-Compulsive Disorder, Shock, Septic, Creutzfeldt-Jakob Syndrome, Myelodysplastic Syndromes, Periodontal Diseases, Gout, Pulmonary Disease, Chronic Obstructive, Acute Lymphoblastic Leukemia, Heart Septal Defects, Atrial, Spinocerebellar Ataxias, Prader-Willi Syndrome, Hypertension, Erythema Nodosum, Inflammatory Bowel Diseases, Spinocerebellar Degenerations, Fatigue Syndrome, Chronic, Multiple Myeloma, Stress Disorders, Post-Traumatic, Anorexia Nervosa, Williams Syndrome, Tuberous Sclerosis, Angelman Syndrome, Acute Myeloid Leukemia, Sleep Initiation and Maintenance Disorders, Memory Disorders, Depressive Disorder, Osteoarthritis, Lupus Erythematosus, Down Syndrome, Stomach Cancer, Acute Promyelocytic Leukemia, De Lange Syndrome, Non-Small Cell Lung Cancer, Dystrophy, Macular, Fragile X Syndrome"
What molecular targets and specific diseases are associated with the invention described in WO2022115620A1?,"CH24H; Alzheimer Disease, Autism Spectrum Disorder, Depressive Disorder, Epilepsy, Schizoaffective disorder, Schizophrenia, Mild cognitive disorder, Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Spasm, Developmental and epileptic encephalopathy, Paranoid Schizophrenia, Brain Infarction, Glaucoma, Behavioural disorders, Multiple Sclerosis, Huntington Disease, Brain Injuries, Traumatic, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2024140431A1?,"TRPV3; Eczema, Nociceptive Pain, Pain, Psoriasis, Arthritis, Anxiety Disorders, Diabetic Neuropathies, Retinal Diseases, Dementia, Amyotrophic Lateral Sclerosis, Enteritis, Urinary Incontinence, Cancer Pain, Diabetes Mellitus, HIV Infections, Pancreatitis, Gastrointestinal Diseases, Obesity, Huntington Disease, Acne Vulgaris, Celiac Disease, Dyskinesias, Actinic Keratosis, Rosacea, Pruritus, Migraine Disorders, Acute Pain, Peripheral Nervous System Diseases, Vulvodynia, Neuralgia, Postherpetic, Spasm, Crohn Disease, Toothache, Prostatic Hyperplasia, Cardiac pain, Fibromyalgia, Vomiting, Inflammatory pain, Pulmonary Disease, Chronic Obstructive, Arthralgia, Trigeminal Neuralgia, Inflammatory Bowel Diseases, Myocardial Ischemia, Urticaria, Pain, Postoperative, Dermatitis, Atopic, Respiration Disorders, Asthma, Alopecia, Skin Diseases, Chronic Pain, Erythema, Memory Disorders, Depressive Disorder, Osteoarthritis, Ileitis, Neuralgia, Nerve Degeneration, Duodenal Ulcer, Meniere Disease, Stroke, Tinnitus, Hyperacusis, Gastroesophageal Reflux, Dermatitis, Irritable Bowel Syndrome"
What molecular targets and specific diseases are associated with the invention described in WO2024140687A1?,"S1PR2; Diabetes Mellitus, Type 2, Liver Cancer, Coronary Artery Disease, Basal Cell Carcinoma, Central Nervous System Diseases, Testicular Neoplasms, Neoplasms, Retinopathy of Prematurity, Neuroblastoma, Pancreatic Cancer, Metabolic Diseases, Hypercholesterolemia, Hyperinsulinism, Intestinal Neoplasms, Familial Exudative Vitreoretinopathies, Lung Cancer, Hepatic Encephalopathy, Meningioma, Mediastinal Cancer, HIV Infections, Obesity, Hearing Disorders, Brain Cancer, Nonalcoholic Steatohepatitis, Glioblastoma, Prostatic Cancer, Rheumatoid Arthritis, Maxillary Sinus Neoplasms, Penile Neoplasms, Laryngeal Neoplasms, Soft Tissue Sarcoma, Kidney Neoplasms, Vulvar Neoplasms, Lymphoma, Salivary Gland Neoplasms, Pituitary Adenoma, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Osteoma, Cicatrix, Hyperlipidemias, Multiple Sclerosis, Kaposi Sarcoma, Osteoporosis, Leukemia, Cerebrovascular Disorders, Reperfusion Injury, Pulmonary Disease, Chronic Obstructive, Metabolic Syndrome, Colonic Cancer, Endometrial Carcinoma, Tongue Neoplasms, Breast Cancer, Bladder Cancer, Aortic Aneurysm, Thoracic, Neuritis, Hypertension, Inflammatory Bowel Diseases, Dermatitis, Atopic, Myocardial Infarction, Vascular Neoplasms, Esophageal Carcinoma, Hearing Loss, Multiple Myeloma, Melanoma, Nephrosis, Aortic Aneurysm, Abdominal, Skin Neoplasms, Metabolic dysfunction-associated steatotic liver disease, Uterine Cervical Cancer, Deafness, Vascular Diseases, Thyroid Cancer, Squamous Cell Neoplasms, Retinitis, Osteoarthritis, Diabetes Complications, Atherosclerosis, Osteosarcoma, Colitis, Hyperglycemia, Diffuse Large B-Cell Lymphoma, Stomach Cancer, Stroke, Rectal Cancer, Insulin Resistance, Ovarian Cancer, Glioma, Fatty Liver, Choriocarcinoma, Nasopharyngeal Carcinoma, Non-Hodgkin Lymphoma, Mouth Neoplasms, Infectious Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2016188827A1?,"KMO; Alzheimer Disease, Acute Lung Injury, Burns, Depressive Disorder, Cholecystitis, Acute, Spinocerebellar Ataxias, Acute Kidney Injury, Shock, Cardiogenic, Pneumonia, Schizophrenia, Respiratory Distress Syndrome, Acute, Wounds and Injuries, Systemic Inflammatory Response Syndrome, Chronic Kidney Diseases, Amyotrophic Lateral Sclerosis, AIDS Dementia Complex, Hepatic Encephalopathy, Intestinal Diseases, HIV Infections, Pancreatitis, Sepsis, Liver Diseases, Huntington Disease, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2022040545A1?,"GABAA receptor; Alzheimer Disease, Depression, Postpartum, Bulimia, Autism Spectrum Disorder, Central Nervous System Diseases, Cachexia, Depressive Disorder, Major, Rett Syndrome, Coma, Cognition Disorders, Dementia, Amyotrophic Lateral Sclerosis, Premenstrual Dysphoric Disorder, Neurodegenerative Diseases, Suicidal Ideation, Anorexia, Substance Abuse, Dyskinesias, Aggression, Schizophrenia, Acute Pain, Jet Lag Syndrome, Attention Deficit Disorder, Dystonia, Agitation, Seizures, Vascular Malformations, Ischemia, Obsessive-Compulsive Disorder, Chronobiology Disorders, Seasonal Affective Disorder, Autistic Disorder, Binge-Eating Disorder, Epilepsy, Schizoaffective disorder, Depressive Disorder, Treatment-Resistant, Lewy Body Disease, Substance-Related Disorders, Stress Disorders, Post-Traumatic, Pain Disorder, Chronic Pain, Crouzon Syndrome With Acanthosis Nigricans, Vascular Diseases, Status Epilepticus, Sleep Initiation and Maintenance Disorders, Bipolar Disorder, Memory Disorders, Depressive Disorder, Panic Disorder, Attention Deficit Disorder With Hyperactivity, Neuralgia, Movement Disorders, Tinnitus, Stroke, Substance Withdrawal Syndrome, Tremor, Personality Disorders, Dementia, Vascular, Fragile X Syndrome, Brain Injuries, Traumatic"
What molecular targets and specific diseases are associated with the invention described in WO2018148626A1?,"RIPK1; Nonalcoholic Steatohepatitis, Psoriasis, Heart Failure, Crohn Disease, Rheumatoid Arthritis, Inflammatory Bowel Diseases, Colitis, Ulcerative"
What molecular targets and specific diseases are associated with the invention described in WO2021191837A1?,"GABRA5; Alzheimer Disease, Memory Disorders, Brain Diseases, Depressive Disorder, Major, Schizophrenia, Mild cognitive disorder, Cognition Disorders, Down Syndrome, Neurodevelopmental Disorders, Dementia, Stroke, Cognitive Dysfunction, Neurodegenerative Diseases, Substance-Related Disorders, Neurocognitive Disorders, Pain Disorder, Mood Disorders, Brain Cancer"
What molecular targets and specific diseases are associated with the invention described in WO2023187670A1?,"MMPs; Scleroderma, Kidney Tubular Necrosis, Acute, Inflammation, Glomerulonephritis, Membranous, Polycystic Kidney Diseases, Liver Diseases, Alcoholic, Glomerulosclerosis, Focal Segmental, Hypertension, Pulmonary, Lupus Nephritis, Myocardial fibrosis, Chemical and Drug Induced Liver Injury, Nonalcoholic Steatohepatitis, Cholangitis, Sclerosing, Acute Kidney Injury, Hemochromatosis, Renal transplant rejection, Aortic Aneurysm, Naxos Disease, Cardiovascular Diseases, Nephrosis, Lipoid, Giant Cell Arteritis, Hermanski-Pudlak Syndrome, Liver Diseases, Reperfusion Injury, Hypertrophy, Acute Lung Injury, Purpura, Schoenlein-Henoch, Aortic Valve Disease, Pulmonary Disease, Chronic Obstructive, Cardiomyopathies, Heart failure with reduced ejection fraction, Respiratory Distress Syndrome, Acute, Biliary Atresia, Glomerulonephritis, Myocardial Reperfusion Injury, Myocardial Infarction, Diabetic Nephropathies, Aortic Aneurysm, Abdominal, Myocardial injury, Metabolic dysfunction-associated steatotic liver disease, Vascular Diseases, Primary Biliary Cholangitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Emphysema, Myocarditis, Cardiomegaly, Idiopathic Pulmonary Fibrosis, Fibrosis, Liver Failure, Acute, Heart Failure, AIDS-Associated Nephropathy, Kidney Diseases, Aortic Valve Stenosis, Lung Diseases, COVID-19, Glomerulonephritis, Membranoproliferative, Kidney Failure, Chronic, Fatty Liver, Fibromuscular Dysplasia, Viral Myocarditis, Sepsis, Glomerulonephritis, IGA, Contrast agents, Renal injury"
What molecular targets and specific diseases are associated with the invention described in WO2024078448A1?,"HPK1; Alopecia Areata, Scleroderma, Hashimoto Disease, Liver Cancer, Psoriasis, Autoimmune Diseases, Gastrointestinal Stromal Tumors, Purpura, Thrombocytopenic, Idiopathic, Rabies, Testicular Neoplasms, Rhabdomyosarcoma, Inflammation, Graves Disease, Adrenal Gland Neoplasms, Antiphospholipid Syndrome, Nephritis, Arthritis, Psoriatic, Connective Tissue Neoplasms, Ewing Sarcoma, Celiac Disease, Prostatic Cancer, Penile Neoplasms, Neurocytoma, Vaginal Neoplasms, Soft Tissue Sarcoma, Gallbladder Carcinoma, Kidney Neoplasms, Vulvar Neoplasms, Hemorrhagic Fever, Ebola, Postpericardiotomy Syndrome, Evans Syndrome, Myositis, Inclusion Body, Dermatomyositis, Leiomyosarcoma, Crohn Disease, Hyperlipidemias, Multiple Sclerosis, Colorectal Cancer, Polymyalgia Rheumatica, Hepatitis C, Fibromyalgia, Gout, Dengue, Ependymoma, Hemangiosarcoma, Hepatitis, Rhinitis, Head and Neck Neoplasms, Asthma, Pemphigus, Multiple Myeloma, Biliary Tract Neoplasms, Primitive Neuroectodermal Tumors, Small intestine carcinoma, Papillary Adenocarcinoma, Syringoma, Hypopharyngeal Carcinoma, Systemic Vasculitis, Muscle Neoplasms, Myocarditis, Polyarteritis Nodosa, Hemangioblastoma, Stomach Cancer, Craniopharyngioma, COVID-19, Meniere Disease, Pinealoma, Choriocarcinoma, Thyroiditis, Autoimmune, Amyloidosis, Encephalitis, Vitiligo, Pemphigoid, Bullous, Lupus Erythematosus, Discoid, Mesothelioma, Neoplasms, Congenital Heart Block, Myelitis, Polymyositis, Ophthalmia, Sympathetic, Pancreatic Cancer, Scleritis, Enteritis, Endocarditis, Subacute Bacterial, Rheumatic Fever, Lung Cancer, Endometriosis, Uveitis, Mixed Connective Tissue Disease, Diabetes Mellitus, wegener's granuloma, Neuroendocrine Tumors, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Exanthema, Transverse Myelitis, Brain Cancer, Influenza, Human, Chordoma, Cystitis, Interstitial, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Rheumatoid Arthritis, Sarcoidosis, Eye Neoplasms, Fever, Lymphoma, Salivary Gland Neoplasms, Myositis, Pemphigoid, Benign Mucous Membrane, Leukemia, Granuloma, Plasma Cell, Stiff-Person Syndrome, Sarcoma, germ cell cancers, Bacterial Infections, Hypogammaglobulinemia, Pulmonary Disease, Chronic Obstructive, Hepatitis B, Ulcer, Endometrial Carcinoma, Arteritis, Breast Cancer, Hepatitis, Viral, Human, Appendiceal Neoplasms, Bladder Cancer, Neuritis, Encephalomyelitis, Colitis, Ulcerative, Fatigue Syndrome, Chronic, Esophageal Carcinoma, Neurofibroma, Bronchial Neoplasms, Skin Diseases, Hepatitis D, Skin Neoplasms, Uterine Cervical Cancer, Systemic Lupus Erythematosus, Primary Biliary Cholangitis, Urethral Neoplasms, Severe Acute Respiratory Syndrome, Thyroid Cancer, Carcinoid Tumor, Osteoarthritis, Anemia, Pernicious, Neutropenia, Myeloproliferative Disorders, Osteosarcoma, Anaphylaxis, Sebaceous Gland Neoplasms, Anus Neoplasms, Hepatitis A, Ovarian Cancer, Acquired Immunodeficiency Syndrome, Myasthenia Gravis, Anemia, Hemolytic, Viral Myocarditis, Infectious Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2017095758A1?,"NR1H2; Niemann-Pick Diseases, Alzheimer Disease, Stroke, Cardiovascular Diseases, Depressive Disorder, Diabetes Mellitus, Age Related Macular Degeneration, Schizophrenia, Obesity, Parkinson Disease, Amyotrophic Lateral Sclerosis"
What molecular targets and specific diseases are associated with the invention described in WO2021009567A1?,"NLRP3; Alzheimer Disease, Gout, Diabetes Mellitus, Type 2, Psoriasis, Autoimmune Diseases, Central Nervous System Diseases, Colitis, Ulcerative, Inflammatory Bowel Diseases, Metabolic Diseases, Amyotrophic Lateral Sclerosis, Lung Diseases, Obstructive, Asthma, Obesity, Metabolic dysfunction-associated steatotic liver disease, Fatty Liver, Alcoholic, Nonalcoholic Steatohepatitis, Idiopathic Pulmonary Fibrosis, Fibrosis, Atherosclerosis, Rheumatoid Arthritis, Lupus Erythematosus, Lung Diseases, Cardiovascular Diseases, Stroke, Multiple Sclerosis, Liver Diseases, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2022256298A1?,"PIKFYVE; Chronic Traumatic Encephalopathy, Alzheimer Disease, Niemann-Pick Disease, Type C, Frontotemporal Dementia, Charcot-Marie-Tooth Disease, Type 4j, Depressive Disorder, Major, Mucolipidoses, Gaucher Disease, Lewy Body Disease, Amyotrophic Lateral Sclerosis, Leukoencephalopathies, Bipolar I disorder, Supranuclear Palsy, Progressive, Behavioural disorders, Lichen Nitidus, Huntington Disease, Neuronal Intranuclear Inclusion Disease, Lysosomal Storage Diseases, Bipolar Disorder, Corticobasal degeneration, Depressive Disorder, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Tay-Sachs Disease, Schizophrenia, Motor Neuron Disease, Attention Deficit Disorder With Hyperactivity, Peripheral Nervous System Diseases, Nerve Degeneration, Polymicrogyria, Guillain-Barre Syndrome, Multiple Sclerosis, Nervous System Diseases, Yunis Varon Syndrome, Mood Disorders, Parkinson Disease, Familial, Type 1, Brain Injuries, Traumatic, Brain Ischemia, Tauopathies, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2024105018A1?,"mGluR7; Inflammatory pain, Hearing Loss, Sudden, Vestibular Diseases, Pain, Central Nervous System Diseases, Schizoaffective disorder, Anxiety Disorders, Labyrinth Diseases, Pain, Postoperative, Cancer Pain, Hearing Loss, Language Development Disorders, Ototoxicity, Pain, Intractable, Paranoid Schizophrenia, Stress Disorders, Post-Traumatic, Visceral Pain, Pain Disorder, Chronic Pain, Psychotic Disorders, Otitis Media, Generalized anxiety disorder, Acute Pain, Schizophrenia, Panic Disorder, Neuralgia, Agoraphobia, Tinnitus, Functional disorder, Post-traumatic pain, Nervous System Diseases, Hearing Loss, Noise-Induced, Obsessive-Compulsive Disorder, Presbycusis, Hearing Loss, Sensorineural, Headache"
What molecular targets and specific diseases are associated with the invention described in WO2019170750A1?,"PDE4; Dental Plaque, Plaque psoriasis, Psoriasis, Neoplasms, Arthritis, Psoriatic, Arthritis, Crohn Disease, Colorectal Cancer, Colitis, Ulcerative, Inflammatory Bowel Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2024028365A1?,"GPR84; Pulmonary Disease, Chronic Obstructive, Pain, Psoriasis, Autoimmune Diseases, Neoplasms, Immunologic Deficiency Syndromes, Neuroinflammatory Diseases, Inflammatory Bowel Diseases, Colitis, Ulcerative, Asthma, Uveitis, Neurodegenerative Diseases, Chronic viral hepatitis, Systemic Lupus Erythematosus, Esophagitis, Acute Myeloid Leukemia, Nonalcoholic Steatohepatitis, Idiopathic Pulmonary Fibrosis, Pyoderma Gangrenosum, Endocrinology and Metabolic Disease, Rheumatoid Arthritis, Neuralgia, Periodontitis, Hepatocellular Carcinoma, Cardiovascular Diseases, Multiple Sclerosis, Leukemia, Gastroesophageal Reflux"
What molecular targets and specific diseases are associated with the invention described in WO2017095723A1?,"LTB4R; Diabetes Mellitus, Type 2, Metabolic Syndrome, Insulin Resistance, Nonalcoholic Steatohepatitis, Dyslipidemias, Neoplasms, Atherosclerosis, Lipid Metabolism Disorders, Hyperglycemia, Obesity, Metabolic dysfunction-associated steatotic liver disease, Hypertension"
What molecular targets and specific diseases are associated with the invention described in WO2018081294A1?,"IRAK1; Eczema, Alzheimer Disease, Alopecia Areata, Scleroderma, Hashimoto Disease, Aortitis, Altitude Sickness, Psoriasis, Liver Cirrhosis, Biliary, Linear IgA Bullous Dermatosis, Autoimmune Diseases, Purpura, Thrombocytopenic, Idiopathic, Scleroderma, Systemic, Graves Disease, Radiculopathy, Mastocytosis, Nephritis, Interstitial, Retinitis Pigmentosa, Red-Cell Aplasia, Pure, Uveitis, Posterior, Visible Lesion, Pancreatitis, Arteriosclerosis, Ichthyosis Vulgaris, liver function failure, Dermatitis, Contact, Ichthyosis, Celiac Disease, Erythema Multiforme, Cutaneous T-Cell Lymphoma, Neoplasm Metastasis, Migraine Disorders, Angioedema, Cardiovascular Diseases, Muscular Dystrophies, Dermatomyositis, Crohn Disease, Multiple Sclerosis, Kaposi Sarcoma, Hepatitis C, Eosinophilia, Myelodysplastic Syndromes, Multiple Organ Failure, Anemia, Aplastic, Glomerulonephritis, Inflammatory Bowel Diseases, Lichen Planus, Immune System Diseases, Rhinitis, Dermatitis, Atopic, Asthma, Anemia, Megaloblastic, Pemphigus, Intestinal Diseases, Diabetic Nephropathies, Sezary Syndrome, Graft Rejection, Idiopathic Interstitial Pneumonias, Thrombosis, Stomach Ulcer, Late onset asthma, Polyarteritis Nodosa, Colitis, Graves Ophthalmopathy, Gingival Hyperplasia, Lupus Erythematosus, Carcinogenesis, Meniere Disease, Guillain-Barre Syndrome, Keratoconus, Sepsis, Respiratory Diseases, Pemphigoid, Bullous, Shock, Dermatitis, Parkinson Disease, Gingivitis, Hyperthyroidism, Enterocolitis, Pseudomembranous, Alopecia, Male Pattern, Keratoconjunctivitis, Keratitis, Herpetic, Keratitis, Neoplasms, Massive Hepatic Necrosis, Polymyositis, Hemolytic-Uremic Syndrome, Scleritis, Amyotrophic Lateral Sclerosis, Lung Diseases, Obstructive, Rheumatic Fever, Sjogren's Syndrome, Lung Cancer, inflammatory dermatosis, Neurodegenerative Diseases, Uveitis, Arcus Senilis, wegener's granuloma, Eosinophilic Enteropathy, Acne Vulgaris, Virus Diseases, Brain Diseases, Cholangitis, Sclerosing, Allergic asthma, Hypoxia, Acute Kidney Injury, Rheumatoid Arthritis, Pyoderma, Sarcoidosis, Periodontitis, Acute-On-Chronic Liver Failure, Myositis, Corneal Opacity, Diabetes Mellitus, Type 1, Cicatrix, Hepatitis, Autoimmune, Vasculitis, Lung Injury, Osteoporosis, Pulmonary Emphysema, Reperfusion Injury, Behcet Syndrome, Burns, Agranulocytosis, Bacterial Infections, Liver Cirrhosis, Alcoholic, Chronic Lymphocytic Leukemia, Hepatitis B, Ulcer, Leiomyoma, Cytomegalovirus Infections, Wounds and Injuries, Encephalomyelitis, Siderosis, Colitis, Ulcerative, Myocardial Ischemia, Urticaria, Hypersensitivity, Age Related Macular Degeneration, Epidermolysis Bullosa, Systemic Lupus Erythematosus, Primary Biliary Cholangitis, Erythema, Addison Disease, Granulomatosis With Polyangiitis, Eosinophilic Fasciitis, Liver Failure, Acute, Fibrosis, Anemia, Pernicious, Atherosclerosis, end organ damage, Enterocolitis, Necrotizing, Corneal Dystrophy, Fuchs' Endothelial, 1, Autoimmune Haemolytic Anaemias, Uveomeningoencephalitic Syndrome, Proctitis, Bronchitis, Chronic Kidney Diseases, Kidney Diseases, Respiratory Hypersensitivity, Hypopigmentation, Acquired Immunodeficiency Syndrome, Vernal Keratoconjunctivitis, Myasthenia Gravis, Dermatitis, Seborrheic, Anti-Glomerular Basement Membrane Disease"
What molecular targets and specific diseases are associated with the invention described in WO2018134695A1?,"MAGL; Psoriasis, Autoimmune Diseases, Spondylitis, Fascioliasis, Muscle Spasticity, Meningitis, Pulmonary Embolism, Pancreatitis, Glaucoma, Obesity, Celiac Disease, Fibrosis, Liver, Pruritus, Neoplasm Metastasis, Glioblastoma, Migraine Disorders, Hematologic Neoplasms, Hepatolenticular Degeneration, Brain Injuries, Tourette Syndrome, Pulmonary Edema, Brain Abscess, Attention Deficit Disorder, Kidney Neoplasms, Recurrent Anaplastic (Malignant) Meningioma, Cardiovascular Diseases, Nausea, Sleep Apnea Syndromes, Toothache, Ischemia, Prion Diseases, Herpesviridae Infections, Vomiting, Leukoencephalopathy, Progressive Multifocal, Gout, Ependymoma, Epilepsy, Tuberculosis, Trigeminal Neuralgia, Pneumonia, Hepatitis, Glomerulonephritis, Immune System Diseases, Anti-myelin-associated glycoprotein associated polyneuropathy, Amyloidosis, Hereditary, Transthyretin-Related, Asthma, Dysmenorrhea, Stress Disorders, Post-Traumatic, Lung Diseases, Interstitial, Sunburn, Graft Rejection, Primitive Neuroectodermal Tumors, Nicotine Dependence, Ischemia of kidney, Arachnoiditis, Panic Disorder, Colitis, Neuralgia, Lupus Erythematosus, Stroke, Neurilemmoma, Guillain-Barre Syndrome, Tendinopathy, Brain Ischemia, Dermatitis, Trypanosomiasis, African, Headache, Parkinson Disease, Budd-Chiari Syndrome, Cerebral Hemorrhage, HIV Wasting Syndrome, Pain, Mesothelioma, Central Nervous System Diseases, Anxiety Disorders, Cystitis, Ischemic stroke, Neuroinflammation, Neuroblastoma, Ocular Hypotension, Medulloepithelioma, Amyotrophic Lateral Sclerosis, Enteritis, Bursitis, Endometriosis, Neurodegenerative Diseases, Ankylosing Spondylitis, Huntington Disease, Transverse Myelitis, Musculoskeletal Diseases, Cystitis, Interstitial, Pelvic Inflammatory Disease, Acute Kidney Injury, Rheumatoid Arthritis, Demyelinating Diseases, Sarcoidosis, Medulloblastoma, Ependymoblastoma, Seizures, Tension-Type Headache, Tonsillitis, Vasculitis, Liver Diseases, Liver cyst, Inflammatory pain, Behcet Syndrome, Spinal Cord Diseases, Burns, Pulmonary Disease, Chronic Obstructive, Arrhythmias, Cardiac, Hemorrhagic stroke, Myocardial Ischemia, Low Back Pain, Hypersensitivity, Melanoma, Dysplasia, Skin Neoplasms, Hepatomegaly, Bipolar Disorder, Complex Regional Pain Syndromes, Optic Neuritis, Cerebral Sarcoma, Optic Nerve Diseases, Down Syndrome, Kidney Diseases, Lung Diseases, Spider Bites, Substance Withdrawal Syndrome, Fatty Liver, Papilloma, Tremor, Dystrophy, Macular, Cholecystitis, Asperger Syndrome, Alzheimer Disease, Eczema, Bulimia, Phlebitis, Liver Cirrhosis, Biliary, Rabies, Frontotemporal Dementia, Cachexia, Diabetic Neuropathies, Metabolic Diseases, Alagille Syndrome, Cognitive Dysfunction, Gilbert Disease, Anorexia, Hemangioma, Cranial Nerve Diseases, Dermatitis, Contact, Dyskinesias, Insect Bites and Stings, Acute Pain, Schizophrenia, Prostatic Cancer, Peripheral Nervous System Diseases, Charcot-Marie-Tooth Disease, Dystonia, Astrocytoma, Neuromyelitis Optica, Sciatica, Leukodystrophy NOS, Multiple Sclerosis, Appendicitis, postoperative cognitive dysfunction, Respiratory Distress Syndrome, Acute, Mild cognitive disorder, Hypertension, Rhinitis, Pain, Postoperative, Leukoencephalopathies, Vasospasm, Diabetic Nephropathies, Chronic Pain, Sleep Initiation and Maintenance Disorders, Cystic Fibrosis, Attention Deficit Disorder With Hyperactivity, Agoraphobia, AIDS Dementia Complex, Phobia, Specific, Abdominal Pain, Reflex Sympathetic Dystrophy, Alcoholic Neuropathy, Dyslipidemias, Neoplasms, Myelitis, Dementia, Ocular Hypertension, Sjogren's Syndrome, Lung Cancer, Opioid abuse, Eye Diseases, Liver Cirrhosis, Chromosome 7, Trisomy 7q, Acne Vulgaris, Beriberi, Brain Cancer, Pleural Effusion, Myelinolysis, Central Pontine, Chemotherapy-induced nausea and vomiting, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Phobia, Social, Cholangitis, Sclerosing, Spinal Cord Injuries, Hemochromatosis, Pharyngitis, Bronchitis, Chronic, Glioblastoma Multiforme, Cannabis withdrawal, Iron Overload, Leukemia, Osteoporosis, Obsessive-Compulsive Disorder, Creutzfeldt-Jakob Syndrome, Reperfusion Injury, Gastrointestinal Neoplasms, Cerebral Palsy, Urinary Bladder, Neurogenic, Subarachnoid Hemorrhage, Arthralgia, Bladder Cancer, Snake Bites, Wounds and Injuries, Chronic prostatitis, acute stress, Hearing Loss, Drug-induced anxiety disorder, Visceral Pain, Pain Disorder, Skin Diseases, Emphysema, Causalgia, Osteoarthritis, Idiopathic Pulmonary Fibrosis, Liver Failure, Acute, Mucositis, Atherosclerosis, Chest Pain, Urinary Tract Infections, Anemia, Hemolytic, Oligodendroglioma, Brain Injuries, Traumatic, Irritable Bowel Syndrome"
What molecular targets and specific diseases are associated with the invention described in WO2025038949A1?,"SLC6A19; Hyperphenylalaninemia, Phenylketonurias, Diabetes Mellitus, Chronic Kidney Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2021254470A1?,"GLP-1R; Diabetes Mellitus, Type 2, Nonalcoholic Steatohepatitis, Coronary Artery Disease, Diabetes Complications, Atherosclerosis, Hyperglycemia, Hypertension, Dementia, Diabetes Mellitus, Type 1, Cardiovascular Diseases, Stroke, Diabetes Mellitus, Glucose Intolerance, Hyperlipidemias, Brain Infarction, Obesity, Metabolic dysfunction-associated steatotic liver disease, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2019204537A1?,"RIPK1; Cerebral Hemorrhage, Alzheimer Disease, Retinal Degeneration, Pulmonary Disease, Chronic Obstructive, Psoriasis, Frontotemporal Dementia, Multiple System Atrophy, Pseudobulbar Palsy, Respiratory Distress Syndrome, Acute, Systemic Inflammatory Response Syndrome, Colitis, Ulcerative, Lewy Body Disease, Amyotrophic Lateral Sclerosis, Retinitis Pigmentosa, Respiratory Distress Syndrome, Myocardial Infarction, Intestinal Diseases, Supranuclear Palsy, Progressive, Intracranial Hemorrhages, Huntington Disease, Progressive bulbar palsy, Corticobasal degeneration, Atherosclerosis, Motor Neuron Disease, Demyelinating Diseases, Peripheral Nervous System Diseases, Chronic Kidney Diseases, Stroke, Muscular Dystrophies, Crohn Disease, Spinal Muscular Atrophy, Muscular Atrophy, Multiple Sclerosis, Sepsis, Ischemia, Irritable Bowel Syndrome, Brain Injuries, Traumatic, Reperfusion Injury, Tauopathies, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2022040267A1?,"TLR9; Fibrosis, Liver, Nonalcoholic Steatohepatitis, Renal fibrosis, Idiopathic Pulmonary Fibrosis, Fibrosis, Cholangitis, Sclerosing, Fibrosis of pancreas, Diabetic Nephropathies, Metabolic dysfunction-associated steatotic liver disease, Primary Biliary Cholangitis, Gallbladder Diseases, Chronic Kidney Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2022066864A1?,"SHMT; Eczema, Scleroderma, Hashimoto Disease, Psoriasis, Autoimmune Diseases, Contracture, Neoplasms, Scleroderma, Systemic, Postmyocardial infarction syndrome, Fibrosis of pancreas, Graves Disease, Keloid, Polymyositis, Nephrogenic Fibrosing Dermopathy, Inflammatory Bowel Diseases, Colitis, Ulcerative, Bursitis, Retroperitoneal Fibrosis, Graft Rejection, Systemic Lupus Erythematosus, Metabolic dysfunction-associated steatotic liver disease, Mediastinal Fibrosis, Primary Biliary Cholangitis, Primary Myelofibrosis, Myocardial fibrosis, Fibrosis, Liver, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Solid tumor, Idiopathic Pulmonary Fibrosis, Fibrosis, Hematologic Neoplasms, arthrofibrosis, Rheumatoid Arthritis, Sarcoidosis, Penile Induration, Diabetes Mellitus, Type 1, Cicatrix, Renal fibrosis, Dermatomyositis, Guillain-Barre Syndrome, Crohn Disease, Myasthenia Gravis, Multiple Sclerosis, Vasculitis, Myelofibrosis, Pulmonary Fibrosis"
What molecular targets and specific diseases are associated with the invention described in WO2021123145A1?,"σ receptor; Alzheimer Disease, Premature aging syndrome, Depressive Disorder, Memory Disorders, Autism Spectrum Disorder, Central Nervous System Diseases, Amnesia, Amyotrophic Lateral Sclerosis, Mental Retardation, X-Linked, Cognitive Dysfunction, Neurodegenerative Diseases, Multiple Sclerosis, Huntington Disease, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2023275366A1?,"NLRP3; Gout, Pulmonary Disease, Chronic Obstructive, Coronary Artery Disease, Autoimmune Diseases, Cardiomyopathies, Colitis, Ulcerative, Inflammatory Bowel Diseases, Neonatal-Onset Multisystem Inflammatory Disease, Asthma, inflammatory dermatosis, Myocardial Infarction, Diabetic Nephropathies, Metabolic dysfunction-associated steatotic liver disease, Systemic Lupus Erythematosus, Acne Vulgaris, Cryopyrin-Associated Periodic Syndromes, Celiac Disease, Chemical and Drug Induced Liver Injury, Nonalcoholic Steatohepatitis, Idiopathic Pulmonary Fibrosis, Cardiomegaly, Chondrocalcinosis, Autoinflammatory disease, Acute Kidney Injury, Muckle-Wells Syndrome, Rheumatoid Arthritis, Familial cold urticaria, Chronic Kidney Diseases, Hidradenitis Suppurativa, Kidney Diseases, Cardiovascular Diseases, Chronic lung disease, Multiple Sclerosis, Liver Diseases, Vitiligo, Respiratory Diseases, Hepatitis C, Chronic, Reperfusion Injury"
What molecular targets and specific diseases are associated with the invention described in WO2023196720A2?,"LRRK2; Young onset Parkinson disease, Alzheimer Disease, Essential Tremor, Alzheimer Disease 8, Athetosis, Diabetes Mellitus, Type 2, Parkinson Disease 10, Spinocerebellar Ataxias, Optic Atrophy, Frontotemporal Dementia, Gaucher Disease, Multiple System Atrophy, Lewy Body Disease, Inflammatory Bowel Diseases, Dementia, Amyotrophic Lateral Sclerosis, Parkinsonian Disorders, Sphingolipidoses, Mitochondrial Complex I Deficiency, Supranuclear Palsy, Progressive, Parkinson Disease, Postencephalitic, Agnosia, REM Sleep Behavior Disorder, Kufor-Rakeb Syndrome, Klippel-Feil Syndrome, Parkinson Disease, Secondary, Pick Disease of the Brain, Amyotrophic Lateral Sclerosis 1, Rheumatoid Arthritis, 3-Methylglutaconic Aciduria, Gerstmann-Straussler-Scheinker Disease, Parkinson Disease 3, Auditory Neuropathy, Movement Disorders, Dystonia, Gaucher Disease, Type 1, Aphasia, Tremor, Crohn Disease, Ulnar Nerve Compression Syndromes, Nervous System Diseases, Parkinson Disease, Familial, Type 1, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2024182689A1?,"LRRK2; Alzheimer Disease, Purpura, Thrombocytopenic, Idiopathic, Neoplasms, Breast Cancer, Ischemic stroke, Neuroinflammation, Papillary Renal Cell Carcinoma, Low grade glioma, Amyotrophic Lateral Sclerosis, Sjogren's Syndrome, Lung Cancer, Red-Cell Aplasia, Pure, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Lichen Nitidus, Thyroid Cancer, Acute Myeloid Leukemia, Leprosy, Spinal Cord Injuries, Rheumatoid Arthritis, Prostatic Cancer, Kidney Neoplasms, Autoimmune Haemolytic Anaemias, Lymphoma, Primary Parkinson's disease, AIDS Dementia Complex, Evans Syndrome, Myositis, Diabetes Mellitus, Type 1, Skin Diseases, Vesiculobullous, Crohn Disease, Vasculitis, Multiple Sclerosis, Leukemia, Brain Injuries, Traumatic, Tauopathies"
What molecular targets and specific diseases are associated with the invention described in WO2018010856A1?,"EIF2AK1; Metabolic Syndrome, Diabetes Mellitus, Type 2, Insulin Resistance, Nonalcoholic Steatohepatitis, Dyslipidemias, Fatty Liver, Atherosclerosis, Heart Diseases, Metabolic dysfunction-associated steatotic liver disease, Obesity, Hypertension"
What molecular targets and specific diseases are associated with the invention described in WO2022020738A1?,"SCAP; Insulin Resistance, Nonalcoholic Steatohepatitis, Neoplasms, Liver Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2024183710A1?,"KIF18A; Scleroderma, Psoriasis, Mesothelioma, Autoimmune Diseases, Testicular Neoplasms, Neoplasms, Rhabdomyosarcoma, Papillary thyroid cancer, Small Cell Lung Cancer, Polymyositis, Neuroblastoma, Pancreatic Cancer, Autoimmune Lymphoproliferative Syndrome, Sjogren's Syndrome, Mixed Connective Tissue Disease, Urogenital Neoplasms, Plasmacytoma, Brain Cancer, Chondrosarcoma, Lip Neoplasms, Prostatic Cancer, Rheumatoid Arthritis, Laryngeal Neoplasms, Gallbladder Carcinoma, Kidney Neoplasms, Lymphoma, Salivary Gland Neoplasms, Uterine Corpus Cancer, Seminoma, Dermatomyositis, Crohn Disease, Multiple Sclerosis, Leukemia, Liposarcoma, Chronic Myelogenous Leukemia, Thyroid Cancer, Medullary, Hereditary Nonpolyposis?Colorectal Cancer, Sarcoma, Adenoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Endometrial Carcinoma, Colonic Cancer, Tongue Neoplasms, Breast Cancer, Bladder Cancer, Encephalomyelitis, Inflammatory Bowel Diseases, Colitis, Ulcerative, Head and Neck Neoplasms, Dermatitis, Atopic, Esophageal Carcinoma, Bronchial Neoplasms, Multiple Myeloma, Melanoma, Teratocarcinoma, Systemic Lupus Erythematosus, Uterine Cervical Cancer, Hypopharyngeal Carcinoma, Muscle Neoplasms, Osteosarcoma, Stomach Cancer, Hepatocellular Carcinoma, Adenomatous Polyps, Rectal Cancer, Ovarian Cancer, Retinoblastoma, Choriocarcinoma, Non-Small Cell Lung Cancer, Myasthenia Gravis, Fibrosarcoma"
What molecular targets and specific diseases are associated with the invention described in WO2017034872A1?,"CB1R; Alzheimer Disease, Diabetes, Gestational, Diabetes Mellitus, Type 2, Nonalcoholic Steatohepatitis, Fibrosis, Dyslipidemias, Arthritis, Atherosclerosis, Neuralgia, Hypertension, Metabolic Diseases, Inflammatory Bowel Diseases, Leprosy, Lepromatous, Diabetes Mellitus, Type 1, Insulin Resistance, Prediabetic State, Glucose Intolerance, Diabetes Mellitus, Multiple Sclerosis, Latent Autoimmune Diabetes in Adults, Osteoporosis, Obesity, Brain Injuries, Traumatic"
What molecular targets and specific diseases are associated with the invention described in WO2022147694A1?,"UCP1; Diabetes Mellitus, Type 2, Nonalcoholic Steatohepatitis, Diabetes Mellitus, Liver Diseases, Obesity, Metabolic dysfunction-associated steatotic liver disease, Metabolic Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2024249929A2?,"NLRP3; Influenza A virus infection, Alzheimer Disease, Gout, airway disease, Arthritis, Inflammation, Hashimoto's Encephalitis, Hypertension, Inflammatory Bowel Diseases, Asthma, Neurodegenerative Diseases, Myocardial Infarction, Hyperoxaluria, Metabolic dysfunction-associated steatotic liver disease, Dermatitis, Allergic Contact, Cryopyrin-Associated Periodic Syndromes, Silicosis, Nonalcoholic Steatohepatitis, Atherosclerosis, Rheumatoid Arthritis, Graft vs Host Disease, Stroke, Diabetes Mellitus, Type 1, Insulin Resistance, Multiple Sclerosis, Brain Injuries, Traumatic, Myelodysplastic Syndromes"
What molecular targets and specific diseases are associated with the invention described in WO2019002571A1?,"mGluR5; Functional disorder, Cognitive Dysfunction, Phelan-McDermid syndrome, Schizophrenia, Nervous System Diseases, Rett Syndrome, Fragile X Syndrome, Dementia, Tuberous Sclerosis, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2022204150A1?,"TAAR1; Bipolar Disorder, Depressive Disorder, Autistic Disorder, Central Nervous System Diseases, Schizophrenia, Social Behavior Disorders, Attention Deficit Disorder With Hyperactivity, Panic Disorder, Cognitive Dysfunction, Stress Disorders, Post-Traumatic, Nervous System Diseases, Obsessive-Compulsive Disorder, psychological symptoms behavior compulsive behavior addiction, Psychotic Disorders"
What molecular targets and specific diseases are associated with the invention described in WO2021143762A1?,"PCSK9; Arterial Occlusive Diseases, Homozygous familial hypercholesterolemia, Arrhythmias, Cardiac, Diabetes Mellitus, Type 2, Endocarditis, Carotid Artery Diseases, Dyslipidemias, Cardiomyopathies, Cerebral Arteriosclerosis, Diabetic Neuropathies, Coronary Disease, Hypertension, Hypercholesterolemia, Myocardial Ischemia, Hyperphosphatemia, Myocardial Infarction, Glucose Intolerance, HIV Infections, Intermittent Claudication, Diabetic Nephropathies, Metabolic dysfunction-associated steatotic liver disease, Angina, Stable, Hypertriglyceridemia, Hyperlipoproteinemias, Nonalcoholic Steatohepatitis, Heart Failure, Atherosclerosis, Chronic Kidney Diseases, Peripheral Arterial Disease, Cardiovascular Diseases, Stroke, Insulin Resistance, Acute Coronary Syndrome, Hyperlipidemias, Cerebrovascular Disorders, Acute myocardial infarction"
What molecular targets and specific diseases are associated with the invention described in WO2016105525A2?,"EGFR; Alzheimer Disease, Eczema, Allograft Rejection, Liver Cancer, Psoriasis, Autoimmune Diseases, Cachexia, Arthritis, Inflammation, Systemic Inflammatory Response Syndrome, Nephritis, Meningitis, Basal Cell Neoplasms, HIV Infections, Arteriosclerosis, Solid tumor, Glioblastoma, Lip Neoplasms, Prostatic Cancer, Peripheral Nervous System Diseases, Kidney Neoplasms, Cardiovascular Diseases, Renal Cell Carcinoma, Crohn Disease, Multiple Sclerosis, Colorectal Cancer, Ischemia, Shock, Septic, Chronic Myelogenous Leukemia, Carcinoma, Sarcoidosis, Pulmonary, Pneumonia, Hypertension, Inflammatory Bowel Diseases, Bone Cancer, Asthma, Myocardial Infarction, Multiple Myeloma, Small intestine carcinoma, Thrombosis, Silicosis, Stomach Ulcer, Neuralgia, Arthritis, Gouty, Lupus Erythematosus, Stomach Cancer, Acute Promyelocytic Leukemia, Stroke, Sepsis, Brain Ischemia, Dermatitis, Parkinson Disease, Pain, Basal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Central Nervous System Diseases, Neoplasms, Neuroinflammation, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Amyotrophic Lateral Sclerosis, Lung Cancer, Neurodegenerative Diseases, Juvenile Idiopathic Arthritis, Huntington Disease, Brain Cancer, Influenza, Human, Spinal Cord Injuries, Malaria, Rheumatoid Arthritis, Fever, Lymphoma, Adenocarcinoma, Chronic lung disease, Osteoporosis, Leukemia, Liver Diseases, Opportunistic Infections, Reperfusion Injury, Gastrointestinal Neoplasms, Bacterial Infections, Gastrointestinal dysfunction, Pulmonary Disease, Chronic Obstructive, Colonic Cancer, Ulcer, B-Cell Lymphoma, Cardiomyopathies, Postmyocardial infarction syndrome, Breast Cancer, Bladder Cancer, Hemorrhagic stroke, Colitis, Ulcerative, Esophageal Carcinoma, Hypersensitivity, Skin Diseases, Skin Neoplasms, Uterine Cervical Cancer, Bone Resorption, AIDS-Related Complex, Acute Myeloid Leukemia, Osteoarthritis, Respiratory Distress Syndrome, Adult, Heart Failure, end organ damage, Myalgia, Graft vs Host Disease, Hepatocellular Carcinoma, Lung Diseases, Ovarian Cancer, Acquired Immunodeficiency Syndrome, Glioma, Mouth Neoplasms, Gastritis, Irritable Bowel Syndrome, Infectious Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2024151519A2?,"PPARγ; Metabolic Syndrome, Neoplasms, Breast Cancer, Bladder Cancer, Bone Diseases, Developmental, Pancreatic Cancer, Metabolic Diseases, Bone Diseases, Metabolic, Bone Cancer, Esophageal Carcinoma, Diabetes Mellitus, Multiple Myeloma, Obesity, Weight Gain, Nonalcoholic Steatohepatitis, Cardiomegaly, Hematologic Neoplasms, Heart Failure, Atherosclerosis, Edema, Prostatic Cancer, Osteitis Deformans, Weight Loss, Hyperparathyroidism, Colorectal Cancer, Osteoporosis, Bone Diseases, Dermatophilosis"
What molecular targets and specific diseases are associated with the invention described in WO2022253997A1?,"ISBT; Polycystic Kidney, Autosomal Dominant, Cataract, Scleroderma, Systemic, Cholestatic liver disease, Xanthomatosis, Cerebrotendinous, Cholestasis, Extrahepatic, Bile Reflux, Cholestasis-edema syndrome, Norwegian type, Parenteral nutrition associated cholestasis, Alagille Syndrome, Pancreatitis, Gastrointestinal Diseases, Obesity, Arteriosclerosis, Fibrosis, Liver, Chemical and Drug Induced Liver Injury, Pruritus, Polycystic Liver Disease, Neonatal Hemochromatosis, Intrahepatic Cholestasis of Pregnancy, Cholestasis, Cardiovascular Diseases, Acute Coronary Syndrome, Cholestasis, Intrahepatic, Alpha 1-Antitrypsin Deficiency, Hyperlipidemias, Crohn Disease, Multiple Sclerosis, Muscular Atrophy, Histiocytosis, Langerhans-Cell, Hepatitis C, Barrett Esophagus, Ischemia, Angina, Unstable, Biliary Atresia, Hypertension, Inflammatory Bowel Diseases, Polycystic Kidney, Autosomal Recessive, Myocardial Infarction, Glucose Intolerance, Constipation, Sitosterolemia, Metabolic dysfunction-associated steatotic liver disease, Vascular Diseases, Glucose Metabolism Disorders, Constipation - functional, Digestive System Disorders, Cystic Fibrosis, Hypertension, Portal, Hyperglycemia, Abetalipoproteinemia, Pregnancy, Stroke, Insulin Resistance, Hepatitis, Alcoholic, Chronic constipation, Amyloidosis, Bile Duct Neoplasms, Parkinson Disease, Dyslipidemias, Neoplasms, Glomerular disease, Hypercholesterolemia, Retinal Diseases, Hyperinsulinism, Microvascular Angina, Vascular restenosis, progressive familial intrahepatic cholestasis, Osteopetrosis, Diabetes Mellitus, Polycystic Kidney Diseases, Liver Cirrhosis, Irritable bowel syndrome with constipation, Bile Acid Malabsorption, Primary, Fatty acid oxidation disorder, Angina, Stable, Bile Acid Synthesis Defect, Congenital, 1, Nonalcoholic Steatohepatitis, Hepatitis, Drug-Induced, Complication, Cholangitis, Sclerosing, Protoporphyria, Erythropoietic, Hepatitis E, Sarcoidosis, Diabetes Mellitus, Insulin-Dependent, 2, Hepatitis, Autoimmune, Jaundice, Chronic idiopathic constipation, Liver Diseases, Iron Overload, Cholestasis, Progressive Familial Intrahepatic 1, Arrhythmias, Cardiac, Metabolic Syndrome, Hepatitis B, Ileal Diseases, Cardiomyopathies, Renal Insufficiency, Bile Acid Synthesis Defect, Wounds and Injuries, Acute Fatty Liver of Pregnancy, Immunoglobulin G4-Related Disease, Choledocholithiasis, Gallstones, Caroli Disease, Biliary stricture, Opioid-Induced Constipation, Hepatitis D, Atrial Fibrillation, Primary Biliary Cholangitis, Hypertriglyceridemia, Fibrosis, Heart Failure, Postcholecystectomy Syndrome, Cholelithiasis, Atherosclerosis, Peripheral arterial occlusive disease, Enterocolitis, Necrotizing, ACTH Deficiency, Isolated, Down Syndrome, Chronic Kidney Diseases, Diabetic Foot, Hepatocellular Carcinoma, Kidney Diseases, Bile-induced gastritis, Hepatitis A, Chylomicron Retention Disease, Fatty Liver, Hepatic Fibrosis, Congenital, Irritable Bowel Syndrome, Zellweger Syndrome, Hypobetalipoproteinemia, Familial, 1"
What molecular targets and specific diseases are associated with the invention described in WO2022031994A1?,"GLP-1R; Alzheimer Disease, Peripheral Vascular Diseases, Cataract, Diabetes Mellitus, Type 2, Coronary Artery Disease, Psoriasis, Dyslipidemias, Arthritis, Hypertrophy, Left Ventricular, Short Bowel Syndrome, Ischemic stroke, Diabetic Neuropathies, Skin and Connective Tissue Diseases, Hyperinsulinism, Microvascular Angina, Vascular restenosis, Cognitive Dysfunction, Diabetes Mellitus, Foot Ulcer, Hypertension, Pulmonary, Obesity, psychological symptoms behavior compulsive behavior addiction, Nonalcoholic Steatohepatitis, Schizophrenia, Diabetic Retinopathy, Peripheral Arterial Disease, Diabetes Mellitus, Type 1, Cardiovascular Diseases, Angina Pectoris, Sleep Apnea Syndromes, Crohn Disease, Hyperlipidemias, Osteoporosis, Hyperlipoproteinemia Type II, Glomerulosclerosis (disorder), Gout, Metabolic Syndrome, Hemorrhagic stroke, Endothelial dysfunction, Hypertension, Colitis, Ulcerative, Inflammatory Bowel Diseases, Hyperuricemia, Myocardial Infarction, Glucose Intolerance, Intermittent Claudication, Diabetic Nephropathies, Premenstrual Syndrome, Metabolic dysfunction-associated steatotic liver disease, Weight Gain, Ketosis, Thrombosis, Diabetes, Gestational, Fibrosis, Heart Failure, Atherosclerosis, Colitis, Hyperglycemia, Erectile Dysfunction, Hepatocellular Carcinoma, Kidney Diseases, Functional disorder, Stroke, Insulin Resistance, Ischemic Attack, Transient, Prediabetic State, Polycystic Ovary Syndrome, Kidney Failure, Chronic, Dystrophy, Macular, Coronary Restenosis, Acidosis, Brain Injuries, Traumatic, Irritable Bowel Syndrome, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2015130445A1?,"CB1R; Alzheimer Disease, Diabetes, Gestational, Diabetes Mellitus, Type 2, Nonalcoholic Steatohepatitis, Fibrosis, Dyslipidemias, Arthritis, Atherosclerosis, Neuralgia, Hypertension, Inflammatory Bowel Diseases, Metabolic Diseases, Diabetes Mellitus, Type 1, Insulin Resistance, Prediabetic State, Glucose Intolerance, Multiple Sclerosis, Latent Autoimmune Diabetes in Adults, Osteoporosis, Obesity, Brain Injuries, Traumatic"
What molecular targets and specific diseases are associated with the invention described in WO2021174205A1?,"GABAA receptor; Arthropathy, Progressive Pseudorheumatoid, of Childhood, Essential Tremor, Alzheimer Disease, Sleep Initiation and Maintenance Disorders, Pain, Memory Disorders, Autism Spectrum Disorder, Depressive Disorder, Epilepsy, Depressive Disorder, Major, Anxiety Disorders, Depressive Disorder, Treatment-Resistant, Movement Disorders, Dementia, Tinnitus, Substance Withdrawal Syndrome, Stress Disorders, Post-Traumatic, Personality Disorders, Substance Abuse, Mood Disorders, Vascular Diseases, Fragile X Syndrome, Brain Injuries, Traumatic"
What molecular targets and specific diseases are associated with the invention described in WO2023014908A1?,"LPAR1; Scleroderma, Fibrosis, Liver, Demyelinating Autoimmune Diseases, CNS, Nonalcoholic Steatohepatitis, Glioblastoma, Idiopathic Pulmonary Fibrosis, Fibrosis, Neoplasms, Demyelinating Diseases, Peripheral Nervous System Diseases, Neurodegenerative Diseases, Multiple Sclerosis, Encephalitis, Pulmonary Fibrosis, Brain Cancer"
What molecular targets and specific diseases are associated with the invention described in WO2024059524A1?,"MALT1; Hodgkin's Lymphoma, Scleroderma, Eczema, Alopecia Areata, Hashimoto Disease, Liver Cancer, Psoriasis, Sinusitis, Autoimmune Diseases, Purpura, Thrombocytopenic, Idiopathic, Neoplasms, Arthritis, Job Syndrome, Burkitt Lymphoma, Conjunctivitis, Allergic, Nervous System Neoplasms, Pancreatic Cancer, Metabolic Diseases, Lung Cancer, Endometriosis, Uveitis, Acute Disease, Arthritis, Psoriatic, Chronic Disease, Thrombotic Thrombocytopenic Purpura, Acquired, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Celiac Disease, Rosacea, Acute Graft Versus Host Disease, Prostatic Cancer, Rheumatoid Arthritis, Nasal infection, Arthritis, Reactive, Nephrotic Syndrome, Lymphoma, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Chronic graft-versus-host disease, Crohn Disease, Multiple Sclerosis, Colorectal Cancer, Mediastinal large B-cell lymphoma, Leukemia, Cerebrovascular Disorders, Pulmonary Disease, Chronic Obstructive, Rhinitis, Allergic, B-Cell Lymphoma, Breast Cancer, Inflammatory Bowel Diseases, Colitis, Ulcerative, Dermatitis, Atopic, Leprosy, Lepromatous, Asthma, Sezary Syndrome, Skin Neoplasms, Aortic Aneurysm, Abdominal, Systemic Lupus Erythematosus, Uterine Cervical Cancer, Crouzon Syndrome With Acanthosis Nigricans, Emphysema, Osteoarthritis, Idiopathic Pulmonary Fibrosis, Respiratory Distress Syndrome, Adult, Diffuse Large B-Cell Lymphoma, Lupus Erythematosus, Bronchitis, Stomach Cancer, Carrington Syndrome, COVID-19, Fasciitis, Acquired Immunodeficiency Syndrome, Myasthenia Gravis, Vitiligo, Non-Hodgkin Lymphoma, Marginal Zone B-Cell Lymphoma, Dermatitis, Bile Duct Neoplasms"
What molecular targets and specific diseases are associated with the invention described in WO2018130869A1?,"GABAA receptor; Alzheimer Disease, Intellectual Disability, Bipolar Disorder, Autistic Disorder, Autism Spectrum Disorder, Central Nervous System Diseases, Neoplasms, Schizophrenia, Rett Syndrome, Mild cognitive disorder, Medulloblastoma, Dementia, Amyotrophic Lateral Sclerosis, Cognitive Dysfunction, Amnesia, Anterograde, Stress Disorders, Post-Traumatic, Substance Abuse, Fragile X Syndrome, Brain Cancer, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2018218042A1?,"ASK1; Alzheimer Disease, Scleroderma, Diabetes Mellitus, Type 2, Psoriasis, Autoimmune Diseases, Neoplasms, Ischemic stroke, Graves Disease, Xanthomatosis, Cerebrotendinous, Pyelonephritis, Transplant glomerulopathy, Metabolic Diseases, Nephritis, Interstitial, Amyotrophic Lateral Sclerosis, Parenteral nutrition associated cholestasis, Sjogren's Syndrome, Neurodegenerative Diseases, Chronic glomerulonephritis, Diabetes Mellitus, Thyroiditis, Chronic, Polycystic Kidney Diseases, Liver Diseases, Alcoholic, Glomerulosclerosis, Focal Segmental, Obesity, Arteriosclerosis, Huntington Disease, Nonalcoholic Steatohepatitis, Cholangitis, Sclerosing, Hypoxia, Rheumatoid Arthritis, Hemochromatosis, Intrahepatic Cholestasis of Pregnancy, Sarcoidosis, Naxos Disease, Cardiovascular Diseases, Seizures, Nephrosclerosis, Hepatitis, Autoimmune, Alpha 1-Antitrypsin Deficiency, Crohn Disease, Multiple Sclerosis, Osteoporosis, Autoimmune cytopenias, Bone Diseases, Ischemia, Reperfusion Injury, Epilepsy, Hepatitis, Glomerulonephritis, Inflammatory Bowel Diseases, Colitis, Ulcerative, Choledocholithiasis, Myocardial Ischemia, Dermatitis, Atopic, Acute hepatopathy, Neurotoxicity Syndromes, Myocardial Infarction, Multiple Myeloma, Diabetic Nephropathies, Chronic viral hepatitis, Metabolic dysfunction-associated steatotic liver disease, Systemic Lupus Erythematosus, Crouzon Syndrome With Acanthosis Nigricans, Primary Biliary Cholangitis, Thrombocytopenia, Cardiomegaly, Osteoarthritis, Heart Failure, Atherosclerosis, Chronic liver disease, Autoimmune Haemolytic Anaemias, Chronic Kidney Diseases, Graft vs Host Disease, Kidney Diseases, Stroke, Insulin Resistance, Renal fibrosis, Fatty Liver, Myasthenia Gravis, Hyperplasia, Respiratory Diseases, Hepatic Fibrosis, Congenital, Brain Injuries, Traumatic, Gastritis, Brain Ischemia, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2015121660A1?,"p38 MAPK; Pulmonary Disease, Chronic Obstructive, Sinusitis, Rhinitis, Allergic, Neoplasms, Kerato conjunctivitis sicca, Conjunctivitis, Allergic, Inflammatory Bowel Diseases, Colitis, Ulcerative, Rhinitis, Asthma, Uveitis, Diabetes Mellitus, Glaucoma, Keratoplasty rejection, Celiac Disease, Virus Diseases, Emphysema, Osteoarthritis, Diabetic macular oedema, Idiopathic Pulmonary Fibrosis, Heart Failure, Cystic Fibrosis, Rheumatoid Arthritis, Diabetic Retinopathy, Sarcoidosis, Childhood asthma, Graft vs Host Disease, Bronchitis, Chronic, Conjunctivitis, Retinal Vein Occlusion, Crohn Disease, Macular Edema, Eosinophilic Esophagitis, Wet age-related macular degeneration"
What molecular targets and specific diseases are associated with the invention described in WO2024146906A1?,"caspase 2; Alzheimer Disease, Influenza A virus infection, Gout, Bacterial Infections, Metabolic Syndrome, Linear atrophy, Dyslipidemias, Mild cognitive disorder, Metabolic Diseases, Lewy Body Disease, Myocardial Ischemia, Retinal Diseases, Amyotrophic Lateral Sclerosis, Myocardial Infarction, Diabetes Mellitus, Glaucoma, Eye Diseases, Optic Neuropathy, Ischemic, Metabolic dysfunction-associated steatotic liver disease, Obesity, Huntington Disease, Hypoxia-Ischemia, Brain, Ischemia of kidney, Rhabdoviridae Infections, Nonalcoholic Steatohepatitis, Chondrocalcinosis, Cholangitis, Sclerosing, Fibrosis, Atherosclerosis, Brain Injuries, Hepatocellular Carcinoma, Stroke, Creutzfeldt-Jakob Syndrome, Brain Injuries, Traumatic, Brain Ischemia, Eye Injuries, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2024140970A1?,"RIPK1; Alzheimer Disease, Peripheral Vascular Diseases, Retinal Degeneration, Pulmonary Disease, Chronic Obstructive, Psoriasis, Sclerosteosis, Autoimmune Diseases, Neoplasms, Frontotemporal Dementia, Inflammation, Respiratory Distress Syndrome, Acute, Colitis, Ulcerative, Inflammatory Bowel Diseases, Systemic Inflammatory Response Syndrome, Retinitis Pigmentosa, Amyotrophic Lateral Sclerosis, Enteritis, Myocardial Infarction, Neurodegenerative Diseases, Pancreatitis, Intermittent Claudication, Chronic nephritis, Nonalcoholic Steatohepatitis, Idiopathic Pulmonary Fibrosis, Osteoarthritis, Atherosclerosis, Rheumatoid Arthritis, Lupus Erythematosus, Graft vs Host Disease, Stroke, Crohn Disease, Multiple Sclerosis, Sepsis, Lung Injury, Acute Ischemic Stroke, Irritable Bowel Syndrome, Brain Injuries, Traumatic, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2022036177A1?,"M4 receptor; Brain Diseases, Excessive Daytime Sleepiness, MPTP Poisoning, Schizophrenia, Chorea, Attention Deficit Disorder With Hyperactivity, Movement Disorders, Dystonia, Cognitive Dysfunction, Neurodegenerative Diseases, Supranuclear Palsy, Progressive, Crouzon Syndrome With Acanthosis Nigricans, Dyskinesias, Cerebral Palsy"
What molecular targets and specific diseases are associated with the invention described in WO2021238588A1?,"AMPA receptor; Alzheimer Disease, Bipolar Disorder, Depressive Disorder, Schizophrenia, Parkinson Disease"
What molecular targets and specific diseases are associated with the invention described in WO2023010078A1?,"M4 receptor; Alzheimer Disease, Excessive Daytime Sleepiness, Schizophrenia, Chorea, Multiple System Atrophy, Attention Deficit Disorder With Hyperactivity, Lewy Body Disease, Dystonia, Cognitive Dysfunction, Parkinsonian Disorders, Tremor, Supranuclear Palsy, Progressive, Crouzon Syndrome With Acanthosis Nigricans, Huntington Disease, Dyskinesias, Cerebral Palsy"
What molecular targets and specific diseases are associated with the invention described in WO2021257660A1?,"UCP1; Nonalcoholic Steatohepatitis, Diabetes Mellitus, Obesity, Metabolic Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2020093008A1?,"TAU; Chronic Traumatic Encephalopathy, Depressive Disorder, Schizophrenia, Nervous System Diseases, Dementia, Vascular, Brain Injuries, Traumatic, Down Syndrome, Amyotrophic Lateral Sclerosis"
What molecular targets and specific diseases are associated with the invention described in WO2015121444A1?,"p38 MAPK; Pulmonary Disease, Chronic Obstructive, Sinusitis, Rhinitis, Allergic, Neoplasms, Kerato conjunctivitis sicca, Conjunctivitis, Allergic, Colitis, Ulcerative, Inflammatory Bowel Diseases, Rhinitis, Asthma, Uveitis, Diabetes Mellitus, Glaucoma, Keratoplasty rejection, Virus Diseases, Celiac Disease, Emphysema, Osteoarthritis, Idiopathic Pulmonary Fibrosis, Diabetic macular oedema, Heart Failure, Cystic Fibrosis, Rheumatoid Arthritis, Diabetic Retinopathy, Sarcoidosis, Childhood asthma, Graft vs Host Disease, Bronchitis, Chronic, Retinal Vein Occlusion, Conjunctivitis, Crohn Disease, Macular Edema, Eosinophilic Esophagitis, Wet age-related macular degeneration"
What molecular targets and specific diseases are associated with the invention described in WO2023139536A1?,"PARP7; Eczema, Scleroderma, Alzheimer Disease, Hashimoto Disease, Psoriasis, Purpura, Thrombocytopenic, Idiopathic, Autoimmune Diseases, Arthritis, Inflammation, Rhabdomyosarcoma, Graves Disease, Nervous System Neoplasms, Metabolic Diseases, Antiphospholipid Syndrome, Meningitis, Follicular Adenocarcinoma, Hematologic Neoplasms, Prostatic Cancer, Kidney Neoplasms, Astrocytoma, End Stage Liver Disease, Dermatomyositis, Crohn Disease, Multiple Sclerosis, Kaposi Sarcoma, Colorectal Cancer, Adrenal Gland Diseases, Barrett Esophagus, Bone Diseases, Myelodysplastic Syndromes, Trachoma, Tuberculosis, Rhinitis, Allergic, Hepatitis, Immune System Diseases, Inflammatory Bowel Diseases, Glomerulonephritis, Head and Neck Neoplasms, Dermatitis, Atopic, Asthma, Hairy Cell Leukemia, Graft Rejection, Endophthalmitis, Thrombosis, Cystic Fibrosis, Colitis, Lupus Erythematosus, Stomach Cancer, Acute Promyelocytic Leukemia, AIDS Dementia Complex, Neurilemmoma, Vaginitis, Respiratory Diseases, Vitiligo, Non-Hodgkin Lymphoma, Dermatophilosis, Dermatitis, Fibrosarcoma, Squamous Cell Carcinoma, Parkinson Disease, Gingivitis, Hodgkin's Lymphoma, Dermatitis Herpetiformis, Mesenchymal Cell Neoplasm, Neoplasms, Small Cell Lung Cancer, Lipid Metabolism Disorders, Polymyositis, Burkitt Lymphoma, Ophthalmia, Sympathetic, Conjunctivitis, Allergic, Orchitis, Neuroblastoma, Pancreatic Cancer, Hypercholesterolemia, Amyotrophic Lateral Sclerosis, Pre-Eclampsia, Sjogren's Syndrome, Lung Cancer, Uveitis, Central Nervous System Neoplasms, Ankylosing Spondylitis, Huntington Disease, Oophoritis, Onchocerciasis, Cystitis, Interstitial, Complication, Spinal Cord Injuries, Rheumatoid Arthritis, Periodontitis, Myositis, Diabetes Mellitus, Type 1, Seminoma, Hepatitis, Autoimmune, Giant Cell Arteritis, Gallbladder Neoplasms, Vasculitis, Nervous System Diseases, Osteoporosis, Leukemia, Thyroiditis, Behcet Syndrome, Pulmonary Disease, Chronic Obstructive, Acute Lymphoblastic Leukemia, Colonic Cancer, Endometrial Carcinoma, Cardiomyopathies, B-Cell Lymphoma, Hashimoto's Encephalitis, Encephalomyelitis, Colitis, Ulcerative, Myocardial Ischemia, Male Breast Neoplasms, Esophageal Carcinoma, Philadelphia chromosome positive chronic myelogenous leukemia, Corneal Dystrophies, Hereditary, Nephrosis, Melanoma, Skin Neoplasms, Teratocarcinoma, Systemic Lupus Erythematosus, Uterine Cervical Cancer, Primary Biliary Cholangitis, Thyroid Cancer, Acute Myeloid Leukemia, Leprosy, Granulomatosis With Polyangiitis, T-Cell Lymphoma, Osteoarthritis, Respiratory Distress Syndrome, Adult, Anemia, Pernicious, Atherosclerosis, Ileitis, Osteosarcoma, Heart Diseases, Autoimmune Haemolytic Anaemias, Graft vs Host Disease, Ovarian Cancer, Glioma, Myasthenia Gravis, Osteolysis, Urologic Neoplasms, Pulmonary Fibrosis"
What molecular targets and specific diseases are associated with the invention described in WO2024193689A1?,"TYK2; Scleroderma, Psoriasis, Autoimmune Diseases, Arthritis, Psoriatic, Crohn Disease, Rheumatoid Arthritis, Multiple Sclerosis, Lupus Nephritis, Vitiligo, Systemic Lupus Erythematosus, Colitis, Ulcerative, Dermatitis, Atopic"
What molecular targets and specific diseases are associated with the invention described in WO2017148518A1?,"VAP-1; Kidney Diseases, Androgen-Insensitivity Syndrome, Nonalcoholic Steatohepatitis, Retinal Diseases"
What molecular targets and specific diseases are associated with the invention described in WO2018217946A1?,"LRRK2; Alzheimer Disease, Acute Myeloid Leukemia, Leprosy, Hematologic Neoplasms, Neoplasms, Breast Cancer, Prostatic Cancer, Rheumatoid Arthritis, Kidney Neoplasms, Colitis, Ulcerative, Inflammatory Bowel Diseases, Dementia, Amyotrophic Lateral Sclerosis, Lung Cancer, Neurodegenerative Diseases, Multiple Myeloma, Crohn Disease, Ankylosing Spondylitis, Parkinson Disease, Dyskinesias"
